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The function of the vascular endothelium is to maintain vascular homeostasis, by providing 
an anti-thrombotic, anti-inflammatory and vasodilatory interface between circulating blood 
and the vessel wall, meanwhile facilitating the selective passage of blood components such 
as signaling molecules and immune cells. Dysfunction of the vascular endothelium is 
implicated in a number of pathological states including atherosclerosis and hypertension, 
and is thought to precede atherogenesis by a number of years. Vascular endothelial growth 
factor A (VEGF) is a crucial mitogenic signaling molecule, not only essential for 
embryonic development, but also in the adult for regulating both physiological and 
pathological angiogenesis. Previous studies by our laboratory have demonstrated that 
VEGF-A activates AMP-activated protein kinase (AMPK), the downstream component of 
a signaling cascade important in the regulation of whole body and cellular energy status. 
Furthermore, studies in our laboratory have indicated that AMPK is essential for VEGF-A-
stimulated vascular endothelial cell proliferation. AMPK activation typically stimulates 
anabolic processes and inhibits catabolic processes including cell proliferation, with the 
ultimate aim of redressing energy imbalance, and as such is an attractive therapeutic target 
for the treatment of obesity, metabolic syndromes, and type 2 diabetes. Metabolic diseases 
are associated with adverse cardiovascular outcomes and AMPK activation is reported to 
have beneficial effects on the vascular endothelium. The mechanism by which VEGF-A 
stimulates AMPK, and the functional consequences of VEGF-A-stimulated AMPK 
activation remain uncertain. 
The present study therefore aimed to identify the specific mechanism(s) by which VEGF-A 
regulates the activity of AMPK in endothelial cells, and how this might differ from the 
activation of AMPK by other agents. Furthermore, the role of AMPK in the pro-
proliferative actions of VEGF-A was further examined. Human aortic and umbilical vein 
endothelial cells were therefore used as a model system to characterise the specific 
effect(s) of VEGF-A stimulation on AMPK activation. 
The present study reports that AMPK α1 containing AMPK complexes account for the vast 
majority of both basal and VEGF-A-stimulated AMPK activity. Furthermore, AMPK α1 is 
localized to the endoplasmic reticulum when sub-confluent, but translocated to the Golgi 
apparatus when cells are cultured to confluence. AMPK α2 appears to be associated with a 
structural cellular component, but neither α1 nor α2 complexes appear to translocate in 
response to VEGF-A stimulation. The present study confirms previous reports that when 
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measured using the MTS cell proliferation assay, AMPK is required for VEGF-A-
stimulated endothelial cell proliferation. However, parallel experiments measuring cell 
proliferation using the Real-Time Cell Analyzer xCELLigence system, do not agree with 
these previous reports, suggesting that AMPK may in fact be required for an aspect of 
mitochondrial metabolism which is enhanced by VEGF-A. Studies into the mitochondrial 
activity of endothelial cells have proved inconclusive at this time, but further studies into 
this are warranted. 
During previous studies in our laboratory, it was suggested that VEGF-A-stimulated 
AMPK activation may be mediated via the diacylglycerol (DAG)-sensitive transient 
receptor potential cation channel (TRPCs -3, -6 or -7) family of ion channels. The present 
study can neither confirm, nor exclude the expression of TRPCs in vascular endothelial 
cells, nor rule out their involvement in VEGF-A-stimulated AMPK activation; more 
specific investigative tools are required in order to characterise their involvement. 
Furthermore, nicotinic acid adenine dinucleotide phosphate (NAADP)-stimulated Ca
2+
 
release from acidic intracellular organelles is not required for AMPK activation by VEGF-
A. 
Despite what is known about the mechanisms by which AMPK is activated, far less is 
known concerning the downregulation of AMPK activity, as observed in human and 
animal models of metabolic disease. Phosphorylation of AMPK α1 Ser485 (α2 Ser491) has 
recently been characterised as a mechanism by which the activity of AMPK is negatively 
regulated. We report here for the first time that VEGF-A stimulates AMPK α1 Ser485 
phosphorylation independently of the previously reported AMPK α1 Ser485 kinases Akt 
(protein kinase B) and ERK1/2 (extracellular signal-regulated kinase 1/2). Furthermore, 
inhibition of protein kinase C (PKC), the activity of which is reported to be elevated in 
metabolic disease, attenuates VEGF-A- and phorbol 12-myristate 13-acetate (PMA)-
stimulated AMPK α1 Ser485 phosphorylation, and increases basal AMPK activity. In 
contrast to this, PKC activation reduces AMPK activity in human vascular endothelial 
cells. Attempts to identify the PKC isoform responsible for inhibiting AMPK activity 
suggest that it is one (or more) of the Ca
2+
-regulated DAG-sensitive isoforms of PKC, 
however cross regulation of PKC isoform expression has limited the present study. 
Furthermore, AMPK α1 Ser485 phosphorylation was inversely correlated with human 
muscle insulin sensitivity. As such, enhanced AMPK α1 Ser485 phosphorylation, 
potentially mediated by increased PKC activation may help explain some of the reduced 
AMPK activity observed in metabolic disease. 
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SKF96365  1-[2-(4-Methoxyphenyl)-2-[3-(4-methoxyphenyl)propoxy]ethyl-1H-imidazole  
   hydrochloride 
SOC   store-operated channels 
Ssp1   sporulation-specific gene 1, the yeast homologue of CaMKK 
Ssp2   sporulation-specific gene 2 
STO-609  7-Oxo-7H-benzimidazo[2,1-a]benz[de]isoquinoline-3-carboxylic acid acetate 
STRAD   STE20-related kinase adapter protein alpha 
TE   Tris-EDTA 
TEMED   N,N,N′,N′-tetramethylethylenediamine 
xvii 
TGF-β   transforming growth factor β 
TNFα   tumor necrosis factor α 
TPC    two-pore channel 
Tris base  tris-(hydroxymethyl)-amonoethane 
TRPC   transient receptor potential cation channel 
TRPP   transient receptor potential channel (polycystin) 
TRPV   transient receptor potential channel (vanilloid) 
TSad   T cell–specific adapter 
TZD   thiazolidinediones 
U-73122  1-[6-[[(17β)-3-Methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-
   dione 
ULK-1   Unc-51–like kinase 
VCAM1   vascular cell adhesion molecule 1 
VEGF   vascular endothelial growth factor 
VEGF-R   VEGF receptor 
Veh   vehicle 
vHL   Von Hippel–Lindau tumour suppressor 
VSMC   vascular smooth muscle cell 
WT   wild type 
ZMP   AICAR; 5-aminoimidazole-4-carboxamide-1-β-D-furanosyl 5’monophosphate 
1 
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1.1 Cell signalling 
1.1.1 Phosphorylation & protein kinases 
The ability of cells to perceive and respond appropriately to external stimuli is central to 
survival; cell signalling is the communication mechanism by which cells perceive and 
respond to their environment. Signalling molecules such as peptides, hormones, steroids, 
lipids and dissolved gases act in autocrine, paracrine and endocrine manners facilitating the 
coordinated behaviour of individual cells, larger organs and whole organisms. In the 
simplest linear form, cells detect an external stimulus, transmit the signal internally and 
then effect the appropriate biological response. Cell signalling pathways are however not 
linear, but rather form complex signalling networks which process, encode, integrate and 
amplify signals, such that a single stimuli has the capacity to affect a diverse range of 
responses. Protein kinases and phosphatases, which catalyse the protein phosphorylation 
and de-phosphorylation respectively, of serine, threonine and tyrosine residues within their 
substrates, are a major component of signalling cascades. The modification of proteins by 
phosphorylation has the capacity to induce reversible conformational change, alters 
subcellular localisation, half-life and interaction with other proteins, with the effect of 
regulating the biological activity of the protein and its substrates. 
1.1.2 The discovery of AMPK  
In 1973, two groups independently observed the inhibition of HMG-CoA reductase 
(HMGCR) and acetyl-CoA carboxylase (ACC) by an, as yet uncharacterised soluble 
protein kinase, effects which were found to be stimulated by AMP and inhibited by ATP 
(Beg et al. 1973, Carlson and Kim 1973). It wasn’t until 1987 that these effects were 
reported to be the function of the same enzyme (Carling et al. 1987). In line with the 
precedent set by the cyclic-AMP dependent protein kinase (PKA), the new kinase was later 
named AMP-activated protein kinase or AMPK, after its allosteric activator (Munday et al. 
1988). AMPK has since been characterised as the downstream component of a protein 
kinase signalling cascade, which plays a central role in the regulation of whole-body and 
cellular energy status serving to redress energy imbalance under times of metabolic stress. 
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1.2 AMPK 
1.2.1 Overview 
AMPK is activated by an increase in the ratio of AMP (or ADP) to ATP caused by 
metabolic stress due to either increased ATP consumption e.g. exercise in muscle, or the 
inhibition of ATP production e.g. nutrient or oxygen deprivation. AMPK is a 
heterotrimeric complex, consisting of a catalytic (α) and regulatory (β and γ) subunits. The 
γ subunit contains domains responsible for sensing cellular adenine nucleotide levels, 
whereas amongst other functions the β subunit acts as a scaffold stabilising the interaction 
between the α and γ subunits. AMPK can be allosterically activated by the binding of AMP 
to the γ subunit, however maximal activation of AMPK is achieved by phosphorylation of 
Thr172 on the α subunit by the upstream AMPK-kinases liver kinase B1 (LKB1) in 
complex with STE20-related adaptor (STRAD) and the adaptor protein MO25, or 
Ca
2+
/calmodulin-dependent protein kinase kinase-β (CaMKKβ) (Figure 1-1). Activated 
AMPK acts to redress energy imbalance in the short-term by inhibiting ATP consuming 
processes and stimulating ATP production, but also has long-term effects on gene and 
protein expression. AMPK is highly conserved, such that orthologues have been identified 
in almost every eukaryote for which a genome sequence has been completed (Hardie 
2011), highlighting the importance of this regulatory mechanism in different species. 
Figure 1-1: Summary of the mechanism of AMPK activation 
AMPK is a heterotrimeric complex consisting of a catalytic (α) and regulatory (β and γ) subunits. AMPK is 
activated allosterically by the binding of AMP to the γ subunit, or by phosphorylation of Thr172 within the 
activation loop of the α subunit, catalysed by LKB1 complexed with STRAD and MO25, or in response to 
elevated intracellular Ca
2+
 by CaMKKβ. AMPK is dephosphorylated by phosphatases reverting AMPK to the 
inactive form. (Redrawn from Viollet et al. 2009). 
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1.2.2 AMPK subunit structure 
AMPK is a heterotrimeric complex, consisting of a catalytic (α) and non-catalytic, 
regulatory (β and γ) subunits (Figure 1-2). Each subunit has a distinct role in the activity or 
stability of the AMPK complex, and are coded for by seven distinct genes (α1-PRKAA1, 
α2-PRKAA2, β1-PRKAB1, β2-PRKAB2, γ1-PRKAG1, γ2-PRKAG2 and γ3-PRKAG3). 
Twelve different heterotrimeric complex combinations are therefore theoretically possible 
however alternative splicing of the different genes further increases this variation (Kahn et 
al. 2005). 
Figure 1-2: AMPK protein domain structure 
The mammalian AMPK α, β and γ1, γ2, γ3 proteins are shown. The α subunit contains a conserved 
phosphorylation (P) site at Thr172 within the kinase domain and a central auto-inhibitory sequence (AIS). 
The β subunit contains a glycogen binding domain (GBD) and C-terminal domain (CTD) necessary for 
complex formation with α and γ. The γ subunits have variable N-terminal domains (NTD) and four conserved 
cystathione-β-synthase (CBS) motifs. These act in pairs to form Bateman domains, which act as adenine 
nucleotide binding sites. (Redrawn from Hardie, 2007). 
1.2.2.1  Alpha (α) subunit 
The catalytic α subunits (α1 and α2) are highly conserved within their catalytic core (~90 
% identical) but diverge substantially outwith this conserved region (61 % shared identity) 
(Stapleton et al. 1996). The N-terminal catalytic serine/threonine kinase domain contains a 
conserved threonine at position 172; phosphorylation of which is essential for full 
activation of AMPK (Woods et al. 1994). The remainder of AMPK α consists of an auto-
inhibitory sequence (AIS) which negatively regulates AMPK activity via interaction with 
α (1/2) 
β (1/2) 
γ1 
γ2 
γ3 
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the catalytic α kinase domain (L. Chen et al. 2009), and C-terminal domain which is 
required for AMPK complex assembly (Crute et al. 1998). Although Thr172 is the major 
activating phosphorylation site on AMPK α, other phosphorylated residues have been 
identified including α1 Ser485 (α2 Ser491) and Thr258, although these are not involved in 
the activation of AMPK (Woods et al. 2003b). 
AMPK α1 is widely expressed, however α2 is reported to be the predominant isoform 
expressed in cardiac and striated muscle, specific expression patterns are however likely to 
vary markedly between species. Northern blot analysis by Stapleton and co-workers 
determined the presence of AMPK α2 mRNA in rat skeletal muscle, with lesser amounts 
found in liver, heart and kidney, whereas low levels of AMPK α1 mRNA was found in all 
the tissues examined in this particular study (heart, brain, spleen, lungs, liver, kidney and 
testis) (Stapleton et al. 1996). These findings were supported by immunoblot analysis, 
again demonstrating abundant AMPK α2 expression in heart, liver and skeletal muscle 
whereas AMPK α1 protein was again found to be widely expressed (Stapleton et al. 1996). 
Later studies using immunohistochemical methods measured the expression of AMPK α1 
and α2 in human tissue biopsies from various tissues (heart, striated muscle, stomach, 
pancreas, kidney, liver, gut, breast, lung) (Quentin et al. 2011). This study however had the 
advantage of being able to determine AMPK expression patterns within the discreet cell 
populations that make up most organs e.g. identify differential α isoform expression 
patterns in the islets of Langerhans and pancreatic acini cells. 
1.2.2.2  Beta (β) subunit 
The β subunit facilitates the assembly of the AMPK complex, by stabilising the interaction 
between the α and γ subunits. The β subunit contains a glycogen-binding domain (GBD). 
Binding of the oligosaccharide component of glycogen to AMPK acts to inhibit its activity 
(McBride et al. 2009). Therefore glycogen binding to the β subunit provides another 
mechanism by which AMPK can sense and regulate energy homeostasis. The C-terminal 
domain of AMPK β is necessary for AMPK α/β/γ complex formation (Hudson et al. 2003). 
AMPK β is also reported to contain N-terminal myristoylation sites which may regulate the 
subcellular distribution of the AMPK complex (Mitchelhill et al. 1997). 
1.2.2.3  Gamma (γ) subunit 
The γ subunits are characterised by the presence of four cystathione-β-synthase (CBS) 
motifs. These occur in tandem pairs forming structures called Bateman domains, the site of 
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nucleotide binding thereby controlling the allosteric activity of the AMPK complex 
(Bateman 1997). Crystallisation studies revealed that three of the four mammalian CBS 
motifs facilitate nucleotide binding; two sites readily exchange AMP, ADP or ATP, 
whereas the third site is occupied by a non-exchangeable molecule of AMP (Xiao et al. 
2007). The importance of the γ subunit is highlighted by the observation that the sensitivity 
of an AMPK complex to regulation by AMP is dependent upon the γ isoform present 
(Cheung et al. 2000). 
1.2.3 Regulation of AMPK activity by AMP/ADP 
When the reaction catalysed by adenylate kinase (2 ADP ↔ ATP + AMP) is assumed to be 
maintained at or near equilibrium, the AMP:ATP ratio will vary by the approximate square 
of the ADP:ATP ratio (e.g. [AMP]/[ATP] ≈ ([ADP]/[ATP])2) making the former a more 
sensitive indicator of cellular energy status (Hardie et al. 1998). Binding of AMP or ADP 
to the γ subunit allosterically activates AMPK, and promotes the phosphorylation of 
Thr172 by upstream kinases. Furthermore, allosteric activation renders AMPK a poorer 
substrate for protein phosphatases (e.g. PP2C) effectively inhibiting Thr172 de-
phosphorylation (Sanders et al. 2007b). In contrast, ATP binding to the γ subunit 
competitively antagonises AMP/ADP-mediated allosteric activation of AMPK and further 
Thr172 phosphorylation. It has been suggested that ADP rather than AMP is the principal 
nucleotide regulating the activation of AMPK (Xiao et al. 2011). The cellular ADP and 
ATP concentrations are far greater than AMP such that ADP:ATP may be a more 
physiologically relevant stimulus for AMPK activation. Contrary to this, AMP was later 
reported to be a more potent inhibitor of Thr172 de-phosphorylation than ADP (Gowans et 
al. 2013). Furthermore, allosteric activation of AMPK by AMP was sufficient to stimulate 
ACC phosphorylation in the absence of Thr172 phosphorylation suggesting that the 
allosteric activation of AMPK by AMP also contributes significantly to overall AMPK 
activity (Gowans et al. 2013). 
1.2.4 Phosphorylation of AMPK at Thr172 
Despite being named because of its allosteric activation by AMP, the effect of AMP on 
AMPK activity is relatively modest (<5-fold increase) (Carling et al. 1987) compared to 
the effect of Thr172 phosphorylation (>100-fold increase) (Suter et al. 2006). Thr172 
phosphorylation is essential for the full activation of AMPK, as mutation of Thr172 to 
alanine abolishes AMPK activity (Crute et al. 1998). AMPK can be rapidly 
dephosphorylated upon cessation of the activating stimulus, however the identity of the 
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protein phosphatases that dephosphorylate Thr172 in different tissues in vivo remains 
elusive. 
1.2.5 AMPK Thr172 kinases 
The identity of the kinase(s) mediating Thr172 phosphorylation remained elusive for many 
years and it was studies in yeast that ultimately led to their identification. Two groups 
independently reported that Tos3 and Sak1, along with a further closely related kinase 
Elm1 phosphorylated and activated Snf1, the yeast homologue of AMPK (Hong et al. 
2003, Sutherland et al. 2003). The closest related mammalian kinases to these yeast Snf1-
kinases are the Ca
2+
/calmodulin-dependent kinase-kinase (CaMKK) family and the tumour 
suppressor liver kinase B1 (LKB1). 
1.2.5.1  LKB1 
LKB1 much like AMPK, exists as a heterotrimeric complex, formed with MO25 and 
STRAD. It was debated for some time as to whether or not AMP directly stimulated LKB1 
activity, however two independent groups published reports arguing against direct AMP-
stimulated LKB1 activation (Hawley et al. 2003, Woods et al. 2003a). Currently, LKB1 is 
largely thought to be constitutively active and elevated levels of AMP allosterically 
increase AMPK activity while inhibiting the de-phosphorylation of Thr172 by protein 
phosphatases such as PP2C (Suter et al. 2006, Sanders et al. 2007b). 
1.2.5.2  CaMKKβ 
Despite LKB1 being identified as the major AMPK-kinase, several lines of evidence 
reported that AMPK could be activated in cells lacking LKB1 expression. In HeLa cells, 
which naturally lack LKB1 expression, AMPK activity was retained, and furthermore 
Thr172 phosphorylation was observed (Hawley et al. 2005), suggesting the presence of an 
AMPK-kinase other than LKB1. Three independent studies subsequently reported that 
CaMKKβ is an AMPK-kinase (Hawley et al. 2005, Hurley et al. 2005, Woods et al. 2005).  
CaMKKβ consists of unique N- and C-terminal domains separated by a Ser/Thr kinase 
domain and a regulatory domain, composed of overlapping auto-inhibitory and CaM-
binding regions. CaMKKβ has autonomous activity for Ca2+/calmodulin-dependent-kinase 
I (CaMKI) and Ca
2+
/calmodulin-dependent-kinase IV (CaMKIV), with phosphorylation of 
Ser129, -133 and 137 within an N-terminal region reported to be important regulator of 
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CaMKKβ’s autonomous activity (Tokumitsu et al. 2001). Furthermore, relieving auto-
inhibition is reported to promote the auto-phosphorylation of Thr482, further contributing 
to the regulation of CaMKKβ’s autonomous activity (Tokumitsu et al. 2011). Other 
substrates including AMPK however, require Ca
2+
/CaM-mediated activation of CaMKKβ 
for kinase activity (Hurley et al. 2005) and CaMKKβ-AMPK interactions are reported to 
occur between the kinase domains of both proteins (Green et al. 2011). CaMKKβ is 
expressed in numerous tissue culture models including murine pre-adipocytes, embryonic 
fibroblasts and isolated hepatocytes, as well as human umbilical vein endothelial cells 
(Anderson et al. 2012, Lin et al. 2011, Stahmann et al. 2006). CaMKKβ is also present in 
many areas of the brain and nervous system, and to a lesser extent in testis, spleen and lung 
(Anderson et al. 1998, Ohmstede et al. 1989). When Ca
2+ 
levels fall, Thr172 is rapidly 
dephosphorylated by protein phosphatases, such as PP2C, accounting for the transient 
nature of AMPK activity after CaMKKβ-mediated activation (Carling et al. 2008). 
1.2.6 Phosphorylation of AMPK at Ser485/491 
Despite the well-characterised mechanisms of activating-Thr172 phosphorylation, far less 
is known concerning the phosphorylation of AMPK at other residues, including α1 Ser485 
(Ser485 is the murine designation and equivalent to human α1 Ser487) and α2 491. AMPK 
Ser485/491 phosphorylation is reported to be associated with reduced AMPK activity 
(Horman et al. 2006, Soltys et al. 2006, Berggreen et al. 2009, Ning et al. 2011) and can 
therefore be thought of as an inhibitory event. Initial studies reported that insulin or IGF-1-
stimulated Akt (protein kinase B) activation reduced AMPK activity due to Akt-mediated 
Ser485 phosphorylation, in heart (Horman et al. 2006), cardiac myocytes (Soltys et al. 
2006), adipocytes (Berggreen et al. 2009) and vascular smooth muscle (Ning et al. 2011). 
During the current study AMPK α2 Ser491 was reported to be a poor Akt substrate and is 
rather more likely to be modified by auto-phosphorylation (Hawley et al. 2014). More 
recently however, insulin/IGF-1 and Akt-independent mechanisms of Ser485 
phosphorylation have been reported. LPS stimulated AMPK α1 Ser485 phosphorylation in 
RAW264.7 cells, in a manner sensitive to IKK but not Akt inhibition (Park et al. 2014). 
Furthermore, inhibitors of the mitogen/extracellular signal-regulated kinase (MEK1/2)- 
extracellular-signal-regulated kinases (ERK1/2) pathway are reported to inhibit cytokine 
(CCL21)-stimulated AMPK α1 Ser485 phosphorylation in human dendritic cells, 
independently of Akt (Lopez-Cotarelo et al. 2015). 
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1.2.7 Effects of AMPK activation 
Activation of AMPK exerts short-term effects via the rapid phosphorylation of specific 
substrates, and long-term effects via gene and protein expression. The pleiotropic effects of 
AMPK activation aim to redress energy imbalance by stimulating catabolic processes to 
generate ATP (e.g. fatty acid uptake and oxidation, glucose uptake and glycolysis, and 
mitochondrial biogenesis) and inhibiting anabolic/ATP consuming processes (e.g. the 
synthesis of fatty acids, triglycerides, cholesterol and glycogen, gluconeogenesis and 
protein synthesis), effects which can be observed in a diverse range of tissues, including 
liver, skeletal muscle, adipose, heart, brain and the vasculature (Figure 1-3). 
1.2.7.1  Lipid metabolism 
Under times of metabolic stress, AMPK activation seeks to stimulate energy availability by 
stimulating fatty acid oxidation. AMPK phosphorylates and inhibits ACC, the key 
regulated enzyme catalysing the conversion of acetyl-CoA to malonyl-CoA. Decreased 
malonyl-CoA synthesis relieves the inhibitory effect of malonyl-CoA on carnitine 
palmitoyl transferase stimulating fatty acid (FA) transport into mitochondria where they 
are subsequently oxidised to yield ATP (McGarry 1995). Furthermore, AMPK activation is 
reported to stimulate the expression of the fatty acid transporters FAT/CD36 and FABPpm 
in cardiomyocytes and Langendorff perfused hearts (Chabowski et al. 2006), in addition to 
previous reports that AMPK increased their trafficking to the plasma membrane 
(Chabowski et al. 2005). These effects have the combined effect of increasing fatty acid 
transport and subsequent oxidation.  
HMGCR is a key enzyme regulating the synthesis of cholesterol. AMPK was first 
identified as the enzyme that phosphorylated HMGCR (Beg et al. 1973, Carling et al. 
1987), resulting in its inhibition. AMPK-mediated inhibition of HMGCR decreases 
mevalonate synthesis, and the synthesis of its downstream products, including cholesterol. 
More recently statins (HMGCR inhibitors) have also been shown to activate AMPK (Sun 
et al. 2006), and it has been suggested that the vaso- and cardio-protective effects of statins 
may act at least in part via AMPK. 
1.2.7.2  Glucose metabolism 
AMPK is an important regulator of glucose metabolism, influencing glucose transport, 
glycolysis, gluconeogenesis and glycogen synthesis. Glucose uptake into muscle and 
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adipose is facilitated by the recruitment of glucose transporters such as GLUT4 from 
intracellular vesicles to the plasma membrane. AMPK is reported to increase GLUT4 
expression, and regulate insulin-stimulated trafficking of GLUT4 to the plasma membrane 
(Holmes et al. 1999, Buhl et al. 2001). AMPK is also reported to phosphorylate 
phosphofructokinase-2 (PFK-2) in ischemic cardiac muscle (Marsin et al. 2001). PFK-2 is 
a key enzyme catalysing the conversion of fructose-6-phosphate to fructose-2,6-
bisphosphate, which itself stimulates PFK-1, further accelerating glycolysis. AMPK 
activation is further reported to suppress hepatic gluconeogenesis in an AMPK-dependent 
manner by downregulating PEPCK and G6Pase (Foretz et al. 2005), key gluconeogenic 
enzymes. Furthermore, AMPK is reported to phosphorylate and inhibit glycogen synthase 
at Ser7, and stimulate glycogen phosphorylase (Inoue and Yamauchi 2006) thereby 
promoting the breakdown of glycogen and supressing its synthesis. 
1.2.7.3  Protein synthesis and cell growth  
The mammalian target of rapamycin (mTOR) is a key regulator of organismal growth and 
homeostasis. mTOR combines with different proteins to form two complexes (mTORC1 
and mTORC2) which have distinct mechanisms of regulation and downstream signalling. 
AMPK regulates the activity of mTORC1 by directly phosphorylating Raptor, stimulating 
its binding to 14-3-3, thereby preventing the association of Raptor with mTOR. 
Furthermore, AMPK phosphorylates the negative regulator of mTORC1, TSC2 (Inoki et 
al. 2006), which stimulates the conversion of Rheb to its inactive (GDP-bound) state. 
Inactive Rheb is therefore no longer able to stimulate the kinase activity of mTORC1. 
Inhibition of mTORC1 reduces the phosphorylation a number of downstream translation 
initiators thereby inhibiting protein synthesis. 
1.2.7.4  Mitochondrial biogenesis 
Mitochondrial biogenesis is stimulated in response to a numerous signals during times of 
metabolic stress, or in response to environmental stimuli. The transcription factor 
peroxisome proliferator-activated receptor γ co-activator 1α (PGC-1α) is activated by 
AMPK, which stimulates the transcription of a number of mitochondrial genes (Lin et al. 
2005). PGC-1α is reported to be downregulated in PRKAA2-/- mice (Um et al. 2010), 
whereas AMPK activation using AICAR is reported to upregulate the mRNA expression of 
NFR-1 and mtTFA stimulating mitochondrial biogenesis in HUVEC (Kukidome et al. 
2006). 
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1.2.7.5  Vascular homeostasis (NO synthesis) 
eNOS plays a critical role in maintaining vascular homeostasis via the synthesis of NO. 
AMPK (Thr172) and eNOS (Ser633) phosphorylation are reported to be stimulated by 
shear stress, atorvastatin and adiponectin, and eNOS phosphorylation was prevented by 
prior inhibition or genetic ablation of AMPK (Z. Chen et al. 2009). Furthermore, the aorta 
of PRKAA2
-/-
 mice showed attenuated atorvastatin-induced eNOS phosphorylation (Z. 
Chen et al. 2009). 
1.2.7.6  Ischemic preconditioning 
Sukhodub and colleagues report that AMPK activation is crucial for ischemic pre-
conditioning, as the cardio-protective effect of preconditioning is lost in dominant-negative 
PRKAA2 transgenic mice (Sukhodub et al. 2007). AMPK α2 appears to be essential for 
preconditioning-stimulated recruitment of the KATP channel to the sarcolemmal membrane, 
decreasing the sarcolemmal action potential, and preventing Ca
2+
 overload and cell death 
(Sukhodub et al. 2007). 
1.2.7.7  Autophagy 
Under conditions of glucose deprivation, AMPK promotes autophagy to ensure cell 
viability, and is reported to achieve this by stimulating the activity of the mammalian 
autophagy initiating kinase 1 (Ulk1) (Kim et al. 2011). When glucose is abundant, 
mTORC1 is reported to phosphorylate Ulk1 on Ser757 preventing its association with 
AMPK. However, when glucose supplies are diminished, AMPK is activated which 
inhibits mTORC1 activity via the phosphorylation of TSC2 and Raptor. Ulk1 Ser757 
phosphorylation is no longer sustained, and the de-phosphorylation of Ser757 permits the 
interaction of AMPK with Ulk1. AMPK subsequently phosphorylates Ulk1 at Ser317 and 
Ser777, thus initiating autophagy (Kim et al. 2011). 
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Figure 1-3: Effects of AMPK activation  
AMPK targets and regulates a diverse range of proteins and processes, including fatty acid and glucose 
metabolism, cholesterol biosynthesis, the generation of ROS and vasoactive mediators, and regulating cell 
growth and protein synthesis. Targets which are positively regulated by AMPK are indicated by arrows, and 
those negatively regulated are indicated by a dashed/blunt ended line and the processes which they regulate 
are indicated around the periphery. ACC - acetyl-CoA carboxylase; eEF2 - eukaryotic elongation factor-2; 
eNOS - endothelial NO synthase; ERRα - oestrogen-related receptor α; FABPpm - fatty acid binding protein; 
FAT/CD36 - fatty acid transporter; GLUT4 - glucose transporter 4; HMGCR - 3-hydroxy 3-methylglutaryl 
CoA reductase; mTOR - mammalian target of rapamycin; PCG-1α -transcriptional coactivator peroxisome 
proliferator-activated receptor-γ coactivator 1α; PFK2 - phosphofructokinase-2; ULK-1 - Unc-51–like 
kinase; ROS - reactive oxygen species; NADPH - nicotinamide adenine dinucleotide phosphate. (Redrawn 
with modifications from Harada et al. 2012). 
H. R. Heathcote (2016)  Chapter 1 – Introduction 13 
1.2.8 Pharmacological activation of AMPK 
A number of compounds are used experimentally to activate AMPK including plant 
derived compounds and drugs currently used in the treatment of type 2 diabetes (Figure 
1-4). 
Figure 1-4: Pharmacological activation of AMPK 
AMPK is activated by phosphorylation of Thr172 within the catalytic α subunit catalysed by LKB1 or 
CaMKKβ, or allosterically by sensing changes in cellular energy. Elevated levels of AMP or ADP (relative 
to ATP) bind to the γ subunit inhibiting the activity of AMPK phosphatases (P-ase). The antidiabetic drugs 
metformin and rosiglitazone, and the plant derived compounds resveratrol, berberine and galgeine activate 
AMPK by increasing the ratio of AMP or ADP to ATP. The adenosine analogue AICAR is phosphorylated 
to ZMP mimicking the effect of AMP without altering adenine nucleotide ratios. Furthermore, A769662 and 
salicylate activate AMPK via binding directly to the β1 subunit. Increases in intracellular calcium stimulate 
CaMKKβ-mediated AMPK activation, independently of adenine nucleotide levels. (Redrawn from Bijland et 
al. 2013). 
1.2.8.1  Metformin 
The biguanide drug metformin is now the first-line agent for the treatment of type 2 
diabetes and was first reported to activate AMPK in hepatocytes (Zhou et al. 2001), 
although the extent to which AMPK activation contributes to its clinical effect remains 
disputed. The major action of metformin is the suppression of hepatic gluconeogenesis, 
however it is thought to activate AMPK via inhibition of NADH dehydrogenase 
(mitochondrial complex I) (El-Mir et al. 2000, Owen et al. 2000) thereby altering cellular 
nucleotide levels, although nucleotide-independent mechanisms have also been suggested 
(Hawley et al. 2002). 
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1.2.8.2  AICAR 
AICAR is an adenosine analogue which is transported into cells via adenosine transporters 
and subsequently phosphorylated to the AMP mimetic ZMP (5-aminoimidazole-4-
carboxamide-1-β-D-furanosyl 5’monophosphate). In the laboratory setting, AICAR is 
widely used in studies of glucose and lipid metabolism, and insulin signalling. AICAR has 
been shown to stimulate adiponectin secretion and inhibit pro-inflammatory signalling 
(Lihn et al. 2004). AICAR is also reported to reverse various aspects of dysfunctional 
metabolism in animal models, but unfortunately has a short half-life, requires intravenous 
infusion and caused bradycardia and hypoglycaemia (Wong et al. 2009), making it a less 
than ideal therapeutic compound. 
1.2.8.3  A769662 and salicylate 
A769662 is a member of the thienopyridine family and directly activates AMPK (Sanders 
et al. 2007a). A769662 stimulates the allosteric activation of AMPK and inhibits its de-
phosphorylation, mimicking the effect of, but independent of AMP binding (Goransson et 
al. 2007). A769662-stimulated activation of AMPK is dependent upon interaction with the 
glycogen binding domain of the β1 subunit, and residues in the γ subunit which are not 
involved in AMP binding. For reasons yet to be fully understood, A769662 activates only 
complexes containing the β1 subunit and not β2 (Scott et al. 2008). Treating ob/ob mice 
with A769662 is reported to reduce plasma glucose and weight gain, and significantly 
decrease plasma and liver triacylglycerol levels (Cool et al. 2006), indicating that targeting 
AMPK using small molecules is a feasible therapeutic strategy for metabolic disease. 
Salicylate is a derivative of aspirin and salsalate administered orally, which at 
concentrations used therapeutically stimulates ACC phosphorylation and suppresses de 
novo lipogenesis, effects that were further enhanced by dual therapy with metformin 
(O'Brien et al. 2015 ). Salicylate directly activates AMPK by binding at the same site as 
A769662 on the β1 subunit. Furthermore, salicylate stimulates hepatic ACC 
phosphorylation and fatty acid oxidation in PRKAB1
WT
 mice, an effect that is lost in 
PRKAB1
-/- 
mice, indicating that salicylate has AMPK-dependent effects in vivo (Hawley et 
al. 2012). 
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1.2.8.4  Thiazolidinediones (troglitazone, rosiglitazone, pioglitazone) 
Thiazolidinediones (TZDs) are insulin-sensitising agents and their mechanism of action is 
thought to be mainly mediated via peroxisome proliferator-activated receptor γ (PPARγ)-
mediated gene transcription in adipocytes (Lehmann et al. 1995). TZDs stimulate 
adipogenesis, reduce plasma free fatty acids and mediate the release of adiponectin and 
other adipokines (Kubota et al. 2006 ). PPARγ and adipocyte-independent actions of TZDs 
have also been reported, including the rapid activation of AMPK by troglitazone in both 
isolated skeletal muscle and mammalian tissues in vivo (gastrocnemius and soleus muscles, 
liver, and epididymal fat) (LeBrasseur et al. 2006). In this particular study AMPK 
activation was found to correlate with changes in adenine nucleotide levels (increased 
AMP:ATP), glucose uptake and fatty acid oxidation in skeletal muscle (LeBrasseur et al. 
2006). 
1.2.9 The vascular endothelium 
The vascular endothelium acts as the interface between circulating blood and the 
underlying vessel wall. The endothelium comprises a single layer of flattened endothelial 
cells which line the entire vascular network, from largest arteries to the smallest capillaries. 
The vascular endothelium was previously thought of as a layer of inert cells, facilitating 
the selective passage of water and electrolytes. More recently however the distinct and 
unique functions of the vascular endothelium have become apparent. The vascular 
endothelium is now understood to act in both sensory and effector capacities, inhibiting 
thrombosis, facilitating the interaction of platelets and immune cells with the endothelium, 
regulating vascular tone and initiating angiogenesis. 
Where the integrity of the endothelium is compromised, thrombin promotes fibrin 
formation and platelet aggregation. In the intact endothelium, thrombin interacts with 
thrombomodulin, subsequently activating protein C, which inhibits coagulation by 
stimulating the degradation of key clotting enzymes and neutralising fibrinolytic inhibitors 
(Popovic et al. 2011). A healthy vascular endothelium has the ability to balance pro-
thrombotic and anti-thrombotic actions in accordance with local conditions for example, 
when haemostasis is required to restore vascular integrity after injury. 
Vascular endothelial cells express a number of adhesion molecules, including integrins and 
adhesion molecules such as ICAM-1 and VCAM-1, which along with circulating soluble 
factors (cytokines) and components of the extracellular matrix, facilitate endothelial-
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leukocyte interactions (Davies et al. 1993), e.g. fibrinogen mediates the interaction 
between endothelial ICAM-1 and Mac-1 which is expressed on the cell surface of 
leukocytes (Altieri et al. 1995). 
Endothelial cells also produce a number of vasoactive factors: endothelium derived nitric 
oxide and prostacyclins induce vascular relaxation and inhibit platelet activation. 
Furthermore endothelial cells can produce vasoconstrictive factors e.g. endothelin, 
thromboxane A2, Angiotensin II and superoxide to regulate appropriate vascular tone 
(Cohen 1995). 
Angiogenesis, the formation of new blood vessels from a pre-existing vascular network, 
requires the coordinated proliferation and migration of a number of cell types including 
endothelial cells, smooth muscle cells and pericytes. This process is exquisitely dependent 
upon signals being exchanged between these cells. Vascular endothelial growth factor 
(VEGF) provided the first example of a mitogen specific for the vascular endothelium 
(Leung et al. 1989). VEGF-A initiates angiogenesis whereas other endothelial factors for 
example angiopoietin and ephrin are required for subsequent remodelling and the 
maturation of the newly formed vessels. The vascular endothelium is therefore highly 
dynamic, acting as an anti-thrombotic surface facilitating the free passage of plasma and 
blood constituents, regulating the adhesion of inflammatory cells, regulating vascular tone 
and initiating angiogenesis, with the net effect of maintaining vascular homeostasis. 
1.2.10 Endothelial dysfunction 
Endothelial dysfunction is an imbalance in the function of the vascular endothelium 
characterised by a shift towards enhanced vessel constriction, cell proliferation, thrombosis 
and chronic inflammation (Endemann and Schiffrin 2004). Vascular dysfunction is 
associated with numerous pathological states including metabolic syndrome, diabetes, 
heart failure, chronic kidney disease and hypertension. Endothelial dysfunction impairs the 
ability of the endothelium to regulate thrombosis, immune responses, fluid balance and 
vascular tone. 
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1.2.11 AMPK activation in the vascular endothelium 
The diverse effects of AMPK activation in the vasculature (Figure 1-5), make it an 
attractive therapeutic target in the treatment of vascular disease, especially those related to 
dysfunctional metabolism (Motoshima et al. 2006, Kodiha and Stochaj 2011, García-Prieto 
et al. 2015).  
Figure 1-5: The multiple effects of AMPK activation on the vascular endothelium 
AMPK activation acts via multiple mechanisms to improve endothelial function, stimulating eNOS activity 
and NO bioavailability, ameliorating lipotoxicity by inhibiting lipid accumulation and suppressing pro-
inflammatory signalling and the generation of reactive oxygen species (ROS). (Adapted from Shirwany and 
Zou, 2010). 
Highlighting the importance of LKB1 in the vasculature is a study reporting that 
endothelial specific knockout of LKB1 in mice (STK11
endo-/-
) results in significantly 
decreased eNOS activity, impaired endothelial function and acetylcholine-induced vessel 
relaxation (Zhang et al. 2014). Furthermore, the STK11
endo-/- 
mice develop hypertension 
and ventricular hypertrophy. Administration of a constitutively active AMPK recombinant 
adenoviral vector however, alleviated endothelial dysfunction and lowered blood pressure 
in these animals (Zhang et al. 2014). In human endothelial cells, thrombin is reported to 
activate AMPK via increased intracellular Ca
2+
 and CaMKKβ activation, in the absence of 
detectable changes of AMP and crucially, independently of LKB1 inhibition (Stahmann et 
al. 2006). 
Vascular endothelial cells express both isoforms of the AMPK α subunit, but it is thought 
that α1 expression is higher than α2 (Schulz et al. 2005, Goirand et al. 2007, Zou et al. 
2004). Less is known about vascular smooth muscle, however reports indicate that AMPK 
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α1 is the predominant catalytic isoform, with very little AMPK α2 activity detected in 
smooth muscle of porcine carotid arteries (Rubin et al. 2005). 
AMPK activators used clinically have been shown to ameliorate endothelial dysfunction. 
Metformin is reported to have cardio-protective effects independent of its anti-
hyperglycaemic actions, including activating eNOS increasing NO bioactivity, and 
stimulating fatty acid oxidation (Calvert et al. 2008 , Saeedi et al. 2008). Furthermore, 
rosiglitazone and pioglitazone are reported to have additional anti-atherosclerotic, anti-
inflammatory and other beneficial effects on endothelial function (Wong et al. 2009). 
1.2.11.1  eNOS and NO bioavailability 
The endothelium regulates vascular tone via the synthesis and secretion of vasoactive 
substances with nitric oxide (NO), synthesised from L-arginine by endothelial NO synthase 
(eNOS) being one of the most important. eNOS expression is reduced via TNFα-stimulated 
inhibition of the eNOS promoter and by destabilising eNOS mRNA (Neumann et al. 2004, 
Kleinbongard et al. 2010). Furthermore, superoxide rapidly reacts with NO to produce 
peroxynitrite, and ROS contribute to eNOS uncoupling leading to increased superoxide 
generation and decreased NO production. AMPK activates eNOS by phosphorylating 
Ser1177 (Morrow et al. 2003) and Ser633 (Z. Chen et al. 2009), and by promoting its 
association with Hsp90 (Davis et al. 2006, Wang et al. 2009). A number of factors have 
been reported to stimulate eNOS activity in an AMPK-dependent manner including 
VEGF-A (Reihill et al. 2011), PPARγ agonists (Boyle et al. 2008), leptin (Procopio et al. 
2009), adiponectin (Chen et al. 2003), and AICAR and metformin (Davis et al. 2006). 
Evidence has also emerged reporting that NO activates AMPK, via a CaMKK-dependent 
mechanism providing evidence for a positive feedback loop (Zhang et al. 2008). 
1.2.11.2  Lipid metabolism 
The statin class of HMGCR inhibitors exhibit cardio-protective effects beyond cholesterol 
reduction (Nissen et al. 2006), and furthermore are reported to activate AMPK (Sun et al. 
2006). Excess fatty acids promote the de novo synthesis of diacylglycerol (DAG) which 
activates certain isoforms of protein kinase C (PKC). PKC activation stimulates NAPDH-
oxidase, and pro-inflammatory intermediates, and reduces eNOS activity and insulin 
sensitivity, exacerbating endothelial dysfunction (Geraldes and King 2010). Another 
consequence of AMPK activation is reported to be increased endothelial cholesterol efflux 
via upregulated expression of the cholesterol efflux pump ATP-binding cassette G1 
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(ABCG1). AICAR treatment in hypercholesterolaemic mice inhibited atherosclerotic 
lesion progression which was associated with elevated ABCG1 expression (Li et al. 2010). 
AMPK activation is therefore able to regulate the energy demands of endothelial cells 
while protecting against endothelial lipotoxicity due to elevated levels of FAs. 
1.2.11.3  Anti-inflammatory effects 
Chronic inflammation and the recruitment and infiltration of immune cells are early steps 
in the development of CVD. Cytokines such as TNFα and IL-1β increase nuclear-factor κB 
(NF-κB)-mediated transcription of pro-inflammatory intermediates such as monocyte 
chemoattractant protein 1 (MCP-1) and interleukin 6 (IL-6) as well as adhesion molecules 
such as ICAM-1 and VCAM-1, thereby facilitating the recruitment and migration of 
inflammatory cells. In HUVECs, AMPK activation is reported to reduce inflammatory cell 
adhesion and migration (Ewart et al. 2008). Furthermore, berberine treatment inhibited the 
expression of the adhesion molecules ICAM-1 and VCAM-1 in HUVEC, suppressing 
monocyte (THP1) adhesion (Wang et al. 2009). 
1.2.11.4  Inhibition of reactive oxygen species 
Redox balance is perturbed by increased oxidative stress and/or a reduction in anti-oxidant 
capacity; a major source of ROS in the vasculature is the NADPH oxidase system. 
Superoxide synthesised by NADPH oxidase is a major contributing factor to atherogenesis, 
removing bioavailable NO and by forming damaging species such as peroxinitrite. AMPK 
activation by rosiglitazone has been reported to reduce the generation of ROS stimulated 
by hyperglycaemia (Ceolotto et al. 2007). Mitochondrial-derived ROS however, generated 
in response to hypoxia, are reported to activate AMPK (Emerling et al. 2009),  and 
stimulate the transcription of genes involved in antioxidant defences e.g. catalase, 
thioredoxin and manganese superoxide dismutase suggesting a positive role for sub-
pathological levels of ROS in an ‘early warning system’. Furthermore, maintaining redox 
balance has knock on effects on NO availability and reduced adhesion molecule 
expression, ameliorating vascular inflammation. 
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1.3 Vascular Endothelial Growth Factor Signalling 
Vascular endothelial growth factors are secreted mitogens which are highly specific for the 
vascular endothelium (Leung et al. 1989). The different VEGF isoforms signal to cells by 
selectively binding to three receptor tyrosine kinases (VEGF-Rs). VEGF-A is required for 
physiological angiogenesis being essential for normal development, while also having been 
implicated in a wide range of pathological states including atherogenesis, diabetic 
vasculopathies, neoangiogenesis and tumour metastasis, in addition to inflammatory 
diseases such as rheumatoid arthritis. Manipulation of VEGF signalling is therefore an 
attractive therapeutic strategy for pathologies involving aberrant angiogenesis. 
1.3.1 VEGF 
There are five isoforms of VEGF coded for by distinct genes in humans: VEGF-A, -B, -C, 
-D and placenta growth factor (PlGF), with splice variants and post-translational 
modifications adding further variation. Further VEGF-related proteins were later 
identified, encoded by viruses (VEGF-E) (Ogawa et al. 1998) or found in the venom of 
some snakes (VEGF-F) (Yamazaki et al. 2003). 
1.3.1.1  VEGF-A 
The human gene for VEGF-A (hereafter referred to as VEGF) is organised into eight exons 
separated by seven introns, and is localised to chromosome 6p21.3 (Vincenti et al. 1996). 
Alternative splicing of the pre-mRNA transcript results in several distinct variants (Figure 
1-6). VEGF165 lacks the residues coded for by exon 6, but is the most biologically potent 
and abundant of the variants found in humans (Houck et al. 1991). VEGF-A165 is also the 
isoform and variant used in the present study unless otherwise stated. The other VEGF 
splice variants are characterised by the presence or absence of exons 6 and 7, and the 
affinity and subsequent activity of specific VEGF splice variants is somewhat dependent 
upon the ability to bind to VEGF-receptor cofactors such as neuropilin and heparin 
sulphate proteoglycans (Cébe Suarez et al. 2006). VEGF is essential for vasculogenesis in 
the developing embryo, as demonstrated by the observation that the loss of a single allele 
in VEGF-A
+/- 
mice is embryonically lethal at day E11-12 due to defective vascular 
development (Carmeliet et al. 1996, Ferrara et al. 1996). 
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Figure 1-6: Exon structure of VEGF-A mRNA splice variants in human.  
The VEGF-A gene comprises eight exons (1-8) and alternative mRNA splicing leads to the formation of 
multiple VEGF isoforms which vary in their amino acid number. VEGF165 is the predominant variant found 
in humans. (Redrawn with modifications from Cross et al. 2003). 
1.3.1.2  VEGF-B 
VEGF-B is widely expressed but is particularly abundant in the heart, skeletal muscle and 
pancreas (Olofsson et al. 1996a).  Human VEGF-B is found in two variants, VEGF-B167 
and VEGF-B186, which bind and activate VEGF-R1 (Olofsson et al. 1996b). Unlike VEGF-
A
+/- 
or 
-/-
 knock out mice, VEGF-B
-/-
 mice are viable and fertile, and are reported to display 
only subtle cardiac phenotypes. VEGF-B
-/- 
mice are reported to have smaller hearts, 
dysfunctional coronary vasculature and demonstrate impaired recovery after ischemic 
insult (Bellomo et al. 2000), suggesting a role for VEGF-B in vascular maintenance and 
the response to stress, rather than in development. 
1.3.1.3  VEGF-C, -D and PlGF 
VEGF-C primarily binds to and activates VEGF receptor 3 but can also activate VEGF- 
receptor 2 as a secondary target (Leppänen et al. 2010). While the primary function of 
VEGF-C is promoting the survival, growth and migration of lymphatic endothelial cells 
during development and lymphangiogenesis, VEGF-C is also a mitogenic stimulus for 
cultured vascular endothelial cells (Tammela et al. 2008). VEGF-C is synthesised in a 
‘pro-protein’ form and is required to undergo sequential proteolytic processing at the C- 
and N-termini, catalysed by pro-protein convertases and ADAMTS3/plasmin respectively 
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to generate the mature, active form of VEGF-C (Siegfried et al. 2003, McColl et al. 2003, 
Jeltsch et al. 2014). The affinity of VEGF-C for VEGF receptor 3 increases with sequential 
cleavage, but only the fully cleaved/mature protein demonstrates significant affinity for its 
secondary receptor VEGF receptor 2 (Joukov et al. 1997). VEGF-D is structurally and 
functionally very similar to VEGF-C, and likewise requires complex proteolytic 
maturation, however far less is known about the function of VEGF-D. VEGF-D deficiency 
(VEGF-D
null 
mice) does not affect embryonic or post-natal lymphangiogenesis, but VEGF-
D contributes to peritumoral lymphangiogenesis  and lymph node metastasis, suggesting 
that VEGF-D may contribute to lymphatic metastasis but is dispensable for normal 
lymphatic development (Baldwin et al. 2005, Koch et al. 2009). 
PlGF is expressed in the early embryonic trophoblast and placenta during all stages of 
gestation (Clark et al. 1998) and has vasodilatory effects in human and rat resistance 
arteries (Osol et al. 2008). Alternative mRNA splicing generates multiple variants: 
PlGF131, -152, -204 and -224, and both serum and placental levels of PlGF are reported to be 
reduced in early and late-onset preeclampsia while levels of the soluble form of VEGF 
receptor 1 (sVEGF-R1) are reported to be elevated (Maynard et al. 2003). PlGF levels are 
therefore considered a useful biomarker for identifying patients at high risk of developing 
placental dysfunction and pre-eclampsia (Chappell et al. 2013). 
1.3.2 Regulation of VEGF production 
Hypoxia and a number of cytokines and growth factors stimulate VEGF expression. 
Hypoxia-induced VEGF expression is mediated largely via a hypoxia response element 
(HRE) acting as a transcription enhancer upstream of the VEGF gene (Levy et al. 1995, 
Liu et al. 1995). The HRE contains a binding motif for the hypoxia inducible factor (HIF-
1) which under normoxic conditions is highly O2-labile, therefore only under hypoxic 
conditions does HIF-1 accumulate sufficiently to influence gene transcription. The product 
of the von Hippel-Lindau (vHL) tumour suppressor gene is reported to negatively regulate 
HIF-1 activity as part of a ubiquitin-ligase complex which targets HIF-1 for degradation by 
the proteasome; oxygen promotes the hydroxylation of HIF-1, a requirement for 
association with vHL (Maxwell et al. 1999). Hypoxia also enhances the DNA binding 
ability of HIF-1, and increases the half-life of VEGF mRNA via association with the RNA 
binding protein HuR. Together these have the combined effect of stabilising HIF-1 and 
increasing transcription of the VEGF gene. Furthermore adenosine released by hypoxic 
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cells upregulates VEGF expression via binding to the adenosine A2 receptor and activating 
the PKA pathway (Takagi et al. 1996). 
Many cytokines and growth factors upregulate VEGF mRNA expression or induce its 
release including the epidermal (EGF) (Goldman et al. 1993), transforming (TGF-β) (Brogi 
et al. 1994, Pertovaara et al. 1994), fibroblast (FGF) (Seghezzi et al. 1998), insulin-like-1 
(IGF-1) (Goad et al. 1996) and platelet-derived (PDGF) (Brogi et al. 1994) growth factors. 
Inflammatory cytokines such as TGF-β and IL-1 upregulate VEGF expression in a number 
of cell types, including synovial fibroblasts (Berse et al. 1999), consistent with the 
hypothesis that VEGF is a mediator of inflammatory disorders, whereas the anti-
inflammatory cytokine IL-10, and IL-13 are reported to inhibit VEGF release (Matsumoto 
et al. 1997). 
1.3.2.1  Regulation of VEGF production by AMPK 
Whilst we and others have reported that VEGF activates AMPK (Reihill et al. 2007, 
Stahmann et al. 2010), there are now numerous reports suggesting that AMPK positively 
regulates VEGF synthesis. Lee and co-workers report that in a range of human cancer cell 
lines (DU145 prostate cancer, HeLa cervical carcinoma, HepG2 hepatocellular carcinoma 
and MCF7 breast adenocarcinoma), AMPK activity is required for hypoxia induced HIF-1 
transcriptional activity and therefore expression of hypoxia responsive genes, including 
VEGF (Lee et al. 2003). The same group later reported that glucose deprivation increases 
VEGF mRNA stability via AMPK in DU145 cells (Yun et al. 2005), and furthermore that 
the carcinogenic metals cobalt, vanadate and arsenite activate AMPK, stimulating VEGF 
expression, but via HIF-1 dependent and independent mechanisms depending upon the 
carcinogenic metal the DU145 cells were exposed to (Lee et al. 2006). Mizrachy-Schwartz 
also report that in primary keratinocytes transformed with the human papillomavirus 
(HPV), AMPK inhibition reduced the levels of c-Myc, HIF-1α, and VEGF in transformed 
cells cultured to ‘late-passages’ and in cells exposed to benzo[a]pyrene (a carcinogen that 
is present in cigarette smoke) (Mizrachy-Schwartz et al. 2007). 
This effect is however not limited to cell models of cancer; Ouchi and colleagues 
demonstrated that in both cultured C2C12 myotubes and a mouse model of hind-limb 
ischemia AICAR stimulates increased VEGF expression via AMPK and p38 MAPK, by 
increasing the stability of VEGF mRNA (Ouchi et al. 2005). Furthermore, in osteoblast-
like MC3T3-E1 cells, Kato and colleagues report that AMPK positively regulates FGF-2- 
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stimulated VEGF secretion via ERK1/2 and/or SAPK/JNK (Kato et al. 2010). Mizutani 
and co-workers further report that AMPK positively regulates TGF-β-stimulated VEGF 
synthesis via MEK1/2 and ERK1/2 in the same osteoblast-like MC3T3-E1 cell line, as well 
as normal human osteoblasts (NHOst) (Mizutani et al. 2012). Finally, Ahluwalia and co-
workers report that in myocardial microvascular endothelial cells, AICAR stimulates 
VEGF production and angiogenesis via AMPK, and identified MAPK/ERK1/2 as a likely 
mechanism for mediating this (Ahluwalia and Tarnawski 2011). Together, these studies 
suggest that AMPK also regulates VEGF expression levels, suggesting that a positive 
feedback mechanism could theoretically exist, whereby AMPK stimulates VEGF 
production and VEGF activates AMPK. 
1.3.3 VEGF receptors 
The different isoforms of VEGF transmit signals into cells via selectively binding to one of 
three receptors (VEGF-Rs) (Figure 1-7). The VEGF-Rs consist of an extracellular ligand 
binding domain organised into seven immunoglobulin-like loops, a single trans-membrane 
domain, a tyrosine kinase domain interrupted by a 70 amino-acid insert, and a C-terminal 
tail. Binding of VEGF to its receptor induces receptor dimerization, accompanied by 
activation of receptor kinase activity leading to receptor auto-phosphorylation. Receptor 
phosphorylation recruits interacting proteins which activate a variety of signalling 
pathways regulating cell proliferation, migration and survival (Stuttfeld and Ballmer-Hofer 
2009). 
 
  
Figure 1-7: Interactions between the VEGF family members and their receptors 
The VEGF ligand family includes VEGF -A, -B, -C, -D, -E and placenta growth factor (PlGF), which bind in a specific manner to the three VEGF receptors VEGF-R1, -2 and -3. 
VEGF-A and -B, in addition to PlGF bind to VEGF-R1, whereas VEGF-A, -C, -D and -E are ligands for VEGF-R2. VEGF-R3, whose expression is limited to the lymphatic system, is 
a receptor for VEGFs -C and –D (Matsumoto and Mugishima 2006). 
 
Monocytes/macrophages Vascular endothelium Lymphatic endothelium 
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1.3.3.1  VEGF-R1 
VEGF-R1 (Flt1) is activated in response to VEGF-A, VEGF-B and PlGF binding. VEGF-
R1 is widely expressed in endothelial cells in both the embryo during development and 
postnatally. Furthermore, VEGF-R1 expression is found in a range of non-endothelial cells 
including monocytes and macrophages, vascular smooth muscle cells and tumour cells 
(Barleon et al. 1996, Ishida et al. 2001, Fan et al. 2005). VEGF-R1 expression is regulated 
by hypoxia via a hypoxia-inducible enhancer element within the FLT1 promoter. 
Alternative splicing of FLT1 results in a soluble version of the receptor (sVEGF-R1) 
consisting of the six N-terminal extracellular Ig-like loops. 
VEGF-R1 binds VEGF-A with a higher affinity than VEGF-R2 (Kd = 16 pM vs 760 pM) 
however VEGF-R1 tyrosine-kinase activity is only weakly stimulated by ligand binding 
(Waltenberger et al. 1994). It has been argued that VEGF-R1 negatively regulates VEGF 
signalling via VEGF-R2: VEGF-R1 (or indeed sVEGF-R1) is proposed to sequester VEGF 
preventing its interaction with VEGF-R2, or form VEGF-R1/R2 heterodimers resulting in 
assembly of less active signalling complexes (Cudmore et al. 2012). Supporting this role in 
negative regulation was the finding that FLT1
-/-
 mice die between E8.5 and E9 due to 
endothelial cell overgrowth and disorganisation of the vascular network (Fong et al. 1995) 
whereas mice expressing tyrosine kinase activity-deficient VEGF-R1 are viable (Hiratsuka 
et al. 1998), although display impaired immune responses. The presence of the receptor 
and not its activity is therefore essential for normal development. 
1.3.3.2  VEGF-R3 
VEGF-R3 (Flt4) is synthesised as a precursor protein prior to maturation by proteolytic 
cleavage. VEGF-R3 exists as two alternative splice variants in humans, long and short 
variants (Pajusola et al. 1993), with the long variant the predominant isoform. VEGF-R3 
expression in mice is initiated at day E8.5 and is a critical regulator of both the developing 
vasculature and lymphatic system. FLT4 knockout in mice is lethal at day E10.5, due to 
cardiovascular failure and impaired organisation of the vasculature preceding the 
development of the lymphatic system (Dumont et al. 1998). A naturally-occurring A to G 
substitution mutation, corresponding to a histidine to arginine (H1035R) substitution in the 
catalytic loop of VEGF-R3 results in a loss of VEGF-R3 auto-phosphorylation and 
tyrosine kinase activity (Irrthum et al. 2000). The resulting reduction in VEGF-R3 activity 
is associated with congenital lymphoedema, highlighting the importance of VEGF-R3 in 
maintaining lymphendothelial function in adults. 
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1.3.3.3  VEGF-R2 
VEGF-R2 (KDR) expression is predominant in vascular endothelial cells and their 
embryonic precursors, with the highest levels of expression observed during 
vasculogenesis and angiogenesis (Matsumoto and Claesson-Welsh 2001). The receptor 
was also found to be expressed in a range of non-endothelial cells, including pancreatic 
duct cells, retinal progenitor cells, megakaryocytes and haemopoietic stem cells (Katoh et 
al. 1995). VEGF-R2 expression is upregulated during physiological processes such as the 
female reproductive cycle, and pathological processes including tumour neovascularisation 
(McMahon 2000). KDR
-/-
 mice die at E8.5 from impaired vascular development, a 
phenotype similar to that of VEGF-A
-/-
 mice. Furthermore, mice with a KDR
Y1173F
 knock-in 
mutation die between E8.5 and E8.9 (Shalaby et al. 1995, Sakurai et al. 2005) highlighting 
the importance of VEGF-R2 tyrosine kinase activity in embryogenesis. 
Although both VEGF-R1 and -R2 are expressed in the vascular endothelium, the 
angiogenic effects of VEGF are thought to be mainly mediated via VEGF-R2 (Matsumoto 
and Mugishima 2006). Several tyrosine residues on VEGF-R2 have been identified as 
being key in mediating VEGFs angiogenic effects, specifically Tyr951 in the insert 
domain, Tyr1054 and Tyr1059 in the kinase domain and Tyr1175 and Tyr1214 in the C-
terminal domain (Cross et al. 2003). A summary of the signalling cascades downstream of 
VEGF-R2 is presented in Figure 1-8. 
 
  
Figure 1-8: VEGF-R2 signalling mediates cell proliferation, migration and survival via numerous signalling effectors 
Binding of VEGF to its receptor stimulates the receptor tyrosine kinase activity stimulating multiple signalling pathways. (Adapted from Olsson et al. 2006, and Koch et al. 2011). 
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Phosphorylated Tyr951 acts as a binding site for the adaptor protein TSAD (T-cell specific 
adaptor molecule) and activation of the tyrosine kinase Src mediating vascular 
permeability via further interaction with VE-cadherin (Matsumoto et al. 2005). Tyr1054 
and Tyr1059 are critical for the receptor’s kinase activity, acting as positive regulators by 
promoting the auto-phosphorylation of other Tyr residues including Tyr1175 (Dougher and 
Terman 1999). Phosphorylation of Tyr1175 provides a binding site for PLCγ, inducing 
Ca
2+ 
release from intracellular stores (via IP3 production) and diacylglycerol (DAG) 
synthesis. These in turn can activate PKC, which further induces activation of the Raf-
MEK-ERK pathway promoting cell proliferation (Takahashi et al. 2001). DAG may also 
act on non-selective cation channels in the plasma membrane such as the transient receptor 
potential (TRP) family C (specifically TRPCs 3, 6 and 7), and it has previously been 
reported that functional TRPC6 is required for VEGF-stimulated angiogenesis (Hamdollah 
Zadeh et al. 2008). Tyr1175 also acts as a binding site for the adaptor protein Shb which 
further mediates PI3K (phosphoinositide 3-kinase) signalling. PI3K activates Akt/PKB 
which phosphorylates and therefore inhibits the pro-apoptotic proteins BAD and caspase 9, 
promoting cell survival (Gerber et al. 1998). Akt/PKB also activates eNOS, stimulating 
NO production (Fulton et al. 1999). Further to this, PI3K-mediated activation of Rac has 
also been implicated in vascular permeability and cell motility. Following the recruitment 
of Nck and Fyn to phospho-Tyr1214, p21-activated protein kinase-2 (PAK2) is activated 
and subsequently Cdc42 and p38 MAPK, mediating vascular permeability (Lamalice et al. 
2004). Further downstream of phospho-Tyr1214, Hsp27 has been implicated in actin 
remodelling and cell migration in a MAPKAPK2 (mitogen-activated protein kinase-
activated protein kinase 2)-dependent manner (Olsson et al. 2006, Koch et al. 2011). 
1.3.3.3.1 Akt 
Akt is a serine/threonine kinase with a key role in multiple cellular processes including cell 
survival, proliferation and glucose metabolism. The two isoforms of Akt, Akt 1 and 2 are 
implicated in inhibiting apoptosis and stimulating cell proliferation with the net effect of 
enhancing cell survival, and in the insulin receptor-signalling pathway respectively. The 
role of Akt3 is however less clear (Martini et al. 2014). Akt is activated by PI3K-mediated 
PIP2 phosphorylation (to generate PIP3), in response to receptor (G-protein or RTK) 
activation. Akt can then be activated via phosphorylation by PDK1 (phosphoinositide-
dependent kinase-1) at Thr308, and mTORC2 (mTOR complex 2) at Ser473, however 
PI3K-independent mechanisms have also been reported (Martini et al. 2014). The de-
phosphorylation of Akt Thr308 by PP2A and Ser473 by PHLPP1/2 antagonise Akt 
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activation, as does the activity of PTEN (phosphatase and tensin homolog) which catalyses 
the de-phosphorylation of PIP3, essentially the reverse reaction catalysed by PI3K (Song et 
al. 2012). Akt inhibits pro-apoptotic caspase and BAD proteins, and stimulates the 
transcription of pro-survival genes via NF-κB (Manning and Cantley 2007). Furthermore, 
Akt activation is reported to overcome cell cycle arrest, such that changes in Akt activity 
are one of the most frequently reported alterations in human cancer (Martini et al. 2014). 
1.3.3.3.2 ERK1/2 
ERK1 and ERK2 are highly homologous protein kinases (83 % amino acid identity) 
sharing many if not all functions, and are widely expressed in most mammalian tissues. 
ERK1/2 is activated in response to growth factors e.g. VEGF and PDGF, insulin, and also 
by ligands for GPCRs (Raman et al. 2007). Furthermore, ERK1/2 can be activated by shear 
stress, osmotic stress and disorganisation of the microtubule network (Chen et al. 2001). 
As with other mitogen activated protein kinase (MAPK) cascades, the ERK1/2 signalling 
cascade consists of three tiers, the MAPK-kinase kinases A-Raf, B-Raf and Raf-1, the 
MAPK kinases MEK1 and MEK2, and the MAPKs ERK1 and ERK2. ERK1/2 is activated 
by dual threonine-tyrosine phosphorylation (Thr202/Tyr204 and Thr185/Tyr187 of ERK1 
and 2 respectively) and their activity can be negatively regulated further by dual-specificity 
phosphatases e.g. MPK3 and 4, and PAC1 (phosphatase of activated cells 1) (Ward et al. 
1994, Dickinson and Keyse 2006). Activated ERK1/2 regulates growth factor responsive 
targets in the cytosol, such as the mitogen- and stress-activated protein kinases (MSKs) 
which phosphorylate and activate AP-1 (activator protein 1). ERK1/2 can also be 
translocated to the nucleus where it phosphorylates a number of transcription factors and 
accessory proteins e.g. Elk1, Sap1/2 and c-Myc (Mebratu and Tesfaigzi 2009). ERK1/2 
therefore participates in a large variety of processes including cell adhesion, cell cycle 
progression, cell migration, cell survival, differentiation, metabolism, proliferation and 
transcription. Aberrant signalling of the Ras-Raf-MEK1/2-ERK1/2 cascade is observed in 
a high proportion of cancers, such that inhibitors of Raf and MEK1/2 have been 
investigated as potential therapeutic agents for human cancers (Friday and Adjei 2008). 
1.3.3.3.3 Protein kinase C (PKC) 
The PKC family of protein kinases play important roles in several signal transduction 
cascades, including VEGF. Fifteen isozymes have been identified in humans, and they can 
be classified according to their domain structure and second messenger requirements 
(Figure 1-9) (Parker and Murray-Rust 2004). The classical or conventional PKCs (α, β1/2 
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and γ) require Ca2+, DAG and phospholipid for activation, whereas the novel PKCs (δ, ε, η 
and θ) require DAG but not Ca2+. As such both the classical and novel PKC isoforms can 
be activated by phospholipase-C signal transduction cascades. On the other hand, given the 
absence of Ca
2+
 and DAG/phorbol ester binding domains, atypical PKCs (ζ and ι/λ) require 
neither Ca
2+
 nor DAG for activation (Soetikno et al. 2012). Elevated levels of DAG and 
PKC activity are reported in various vascular tissues in models of over-nutrition/diabetes 
including retina (Shiba et al. 1993), aorta and heart (Inoguchi et al. 1992), renal glomeruli 
(Craven and DeRubertis 1989), and liver and skeletal muscle (Itani et al. 2000). 
Furthermore, several studies have reported that PKC inhibition using the compound 
LY333531 is efficacious in treating abnormalities in the retinal and renal vasculature in 
both animal models of diabetes and human patients (Adis 2007) making PKC inhibition an 
attractive therapeutic strategy. 
Figure 1-9: PKC domain structure 
The domain structures of classical, novel, and atypical protein kinase Cs (PKC). All PKCs have a pseudo-
substrate domain (green) in addition to which, the conventional and novel PKCs contain a C1 domain which 
facilitates binding to diacylglycerol (DAG) and phorbol 12-myristate 13-acetate (PMA). The C2 domain 
confers Ca
2+
 sensitivity to the conventional subfamily of PKCs but not to the novel. The atypical PKCs are 
not activated by Ca
2+
 or DAG, but their activation depends on phosphatidylserine and cis-unsaturated fatty 
acids. (Redrawn from Soetikno et al. 2012). 
Protein kinase D-1 (PKD1 in mice, PKC μ in humans), is related to the atypical family of 
PKC proteins (Valverde et al. 1994, Johannes et al. 1994) with two further proteins PKD2 
and PKD3 subsequently identified as sharing significant homology with PKD1. PKD1 is 
activated by a diverse range of stimuli including hormones, chemokines, GPCR agonists, 
bioactive lipids and growth factors, and is reported to regulate a diverse range of biological 
responses including cell proliferation and differentiation, membrane trafficking, immune 
regulation, angiogenesis and cancer (Rozengurt 2011). PKD1 is reported to be activated in 
response to growth factors in a PKC-dependent manner, as PKC inhibition in 3T3 cells and 
MEFs prevented serum-induced PKD activation (Zugaza et al. 1996). 
conventional  (α,β,γ) 
novel (δ, ε, η and θ) 
atypical (ζ and ι/λ) 
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PKD1 activation is dependent upon PKC-dependent trans-phosphorylation of Ser744 and 
Ser748 in the kinase domain activation loop (Iglesias et al. 1998) and once activated, 
PKD1 subsequently undergo auto-phosphorylation at Ser916, within its C-terminal domain 
(Matthews et al. 1999), the measurement of which is used as a surrogate marker of PKD1 
activity. PKD1 shares significant catalytic domain homology with myosin light chain 
kinase and the CAMKs, such that the three isoforms of PKD1 are classified as belonging to 
the CAMK family of protein kinases, and distinct from the ‘AGC’ kinases (PKA, PKG and 
PKC) (Hanks 2003). 
1.3.4 VEGF activates AMPK 
Previous reports from our laboratory indicated that physiologically relevant concentrations 
of VEGF (10 ng/mL) activated AMPK in HAEC (Reihill et al. 2007). AMPK was also 
shown to contribute to VEGF-stimulated eNOS Ser1177 phosphorylation and NO 
production via a PI3K/Akt-independent, PLC/CaMKK/AMPK-dependent signalling axis 
(Reihill et al. 2007). AMPK was later shown to be required for VEGF-stimulated HAEC 
proliferation and migration, whereas AMPK activation by other compounds (AICAR, 
A769662) or expression of constitutively active AMPK (Ad.AMPK-CA) in the absence of 
VEGF inhibited HAEC proliferation (Reihill et al. 2011). Furthermore, VEGF-stimulated 
HAEC chemokinesis was inhibited by CaMKK inhibition or infection with Ad.AMPK-DN 
whereas enhanced chemokinesis was mimicked by infection with Ad.AMPK-CA, even in 
the absence of VEGF (Reihill et al. 2011). It remains possible that this is a mechanism by 
which endothelial cells actively seek nutrients under conditions of nutrient 
deprivation/AMPK activation. Furthermore, expression of kinase-inactive AMPK in 
HUVEC under hypoxic conditions is reported to inhibit VEGF-stimulated migration and 
tube formation (Nagata et al. 2003). Stahmann and colleagues also report that AMPK 
contributes to angiogenesis in vitro and in vivo (Stahmann et al. 2010). VEGF-stimulated 
tube formation was inhibited in microvascular lung endothelial cells from PRKAA1
-/- 
mice 
compared to wild type mice, and similarly VEGF-stimulated sprout formation was 
inhibited by down-regulation of AMPK expression in HUVEC by siRNA (Stahmann et al. 
2010). Furthermore in PRKAA1
W/T
 mice, VEGF stimulated a 4-fold increase in the 
vascularisation of Matrigel plugs, an effect that was not present in PRKAA1
-/- 
mice 
(Stahmann et al. 2010), highlighting the requirement of AMPK in VEGF-stimulated 
angiogenic processes in vivo. 
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1.4 Overall hypothesis and experimental aims 
Despite previous reports, the mechanism by which VEGF stimulates AMPK activation has 
not been fully characterised, nor have the effects of VEGF on subsequent AMPK 
signalling been determined. This thesis sought to test the hypothesis that AMPK activation 
underlies the physiological consequences of VEGF in human endothelial cells. 
Specifically, the following experimental research questions were addressed: 
 To what extent does VEGF influence the activity of a particular catalytic isoform 
containing AMPK complex, and does VEGF effect the subcellular localisation of 
AMPK in order to facilitate the functional proliferative actions of VEGF? This was 
examined in cultured human endothelial cells stimulated with exogenous 
recombinant VEGF by immunoprecipitation kinase assays with specific subunit 
isoform-specific antibodies, confocal immunofluorescence microscopy and analysis 
of endothelial cell proliferation. 
 Do transient receptor potential cation channels (TRPCs) mediate the VEGF-
stimulated extracellular Ca
2+
 influx, and CaMKK activation which has previously 
been reported to be required for VEGF-stimulated AMPK activation (Reihill et al. 
2007)? This was examined using pharmacological agents to down- or upregulate 
TRPC activity in VEGF-stimulated cultured endothelial cells. 
 Does VEGF influence inhibitory phosphorylation of AMPK α1/2 Ser485/491? This 
was examined using specific antibodies to phosphorylated AMPK in cultured 
endothelial cells stimulated with VEGF, and the mechanisms by which VEGF 
influenced Ser485/491 phosphorylation were assessed using pharmacological and 
genetic strategies, to up- and down-regulate the activity of VEGF-stimulated 
signalling pathway proteins. 
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2.1 Materials 
2.1.1 General reagents 
Abcam, Cambridge, UK 
A769662, BAPTA-AM 
Acros Organics 
Brij-35 
BDH Laboratory Supplies, Poole, UK 
Coomassie brilliant blue G-250, tetra-sodium pyrophosphate (Na4P2O7) 
Beckman Coulter, Pasadena, CA, USA 
Ultra-Clear™ ultracentrifuge tubes 
Biafin Gmb & Co, Kassel, Germany 
Akt (human recombinant) 
Biotium, Hayward, CA, USA 
RedDot™2 
Cambridge Bioscience, Cambridge, UK 
E-Plate 96 
EMD Chemicals Inc. (Calbiochem) San Diego, CA, USA 
LY333531, OAG, PD184352, PMA 
Fisher Scientific UK Ltd, Loughborough, Leicestershire, UK 
APS (ammonium persulphate), Corning™ tissue culture T75/T150 flasks and 12/6 well 
plates, DMSO (dimethylsulphoxide), ethidium bromide, Tris base (Tris-(hydroxymethyl)-
amonoethane) 
Formedium, Hustanton, Norfolk, UK 
Bacterial agar, tryptone, yeast extract powder 
GE Healthcare, Little Chalford, Buckinghamshire, UK 
Protein G Sepharose 4 Fast Flow 
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Thermo Fisher Scientific (including Life Technologies, Applied Bio Systems, GIBCO, 
and Invitrogen), Carlsbad, CA, USA 
Blasticidin, dNTPs (dATP, dCTP, dGTP, dDTP), Dulbecco’s modified Eagles media 
(DMEM), Eagle's Minimum Essential Medium (EMEM), foetal calf serum (FCS; EU 
origin), L-glutamine, Lipofectamine® 2000 Reagent, Medium 199, Minimum Essential 
Medium (MEM), MitroTracker® Mitochondrion-Selective Probes, newborn calf serum 
(NCS), Non-Essential Amino Acids Solution (100X), One Shot chemically competent 
E.coli, Opti-MEM® reduced serum media, Penicillin-Streptomycin (10,000 U/mL), S.O.C. 
medium, Taq DNA Polymerase, TaqMan® Gene Expression Assay (FAM labelled 
probes), TaqMan® Universal Master Mix II no UNG, trypsin-EDTA, sodium pyruvate, 
zeocin 
LI-COR BioSciences, Lincoln, NE, USA 
LI-COR Odyssey Blocking Buffer 
Melford Laboratories Ltd, Chelsworth, Ipswitch, Suffolk, UK 
DTT (dithiothreitol) 
Merck Millipore Chemicals Ltd, Nottingham, UK 
Compound C, TRPC3 Channel Inhibitor Pyr3, ML-9 hydrochloride, Akt inhibitor VIII 
(isozyme-selective Akti1/2) 
National Diagnostics (UK) Ltd, Hessle, East Riding of Yorkshire, UK 
Ecoscint A 
New England Biolabs, Ipswich, MA, USA 
Gel loading dye (6 X), Low molecular weight DNA marker (100 bp), Pre-stained protein 
marker (broad range 6-175 kDa) 
Pall Life Sciences Pensacola, FL, USA 
Nitrocellulose transfer membrane (0.45 μm pore size)  
Perkin Elmer, Beaconsfield, Buckinghamshire, UK 
[γ-32P] ATP 
Pierce, Perbio Science UK Ltd, Tettenhall, Cheshire, UK 
10,000 MWCO Slide-A-Lyzer 
Premier International Foods, Cheshire, UK 
Dried skimmed milk 
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Promega Corporation, Madison, WI, USA 
CIAP (calf intestinal alkaline phosphatase), M-MLV Reverse Transcriptase, Oligo(dT), 
PKC (Protein Kinase C) from rat brain 
Roche Diagnostics Ltd, Burgess Hill, UK 
Agarose MP 
Severn Biotech Ltd, Kidderminster, Hereford, UK 
Acrylamide:bisacrylamide (37.5:1; 30 % (w/v) acrylamide) 
Seahorse Bioscience, North Billierica, MA, USA 
XF24 Cell Culture Microplates, XF24 Flux Pak, XF Assay Medium, XF Calibrant Solution 
Sigma-Aldrich Ltd, Gillingham, Dorset, UK 
AMP (adenosine monophosphate), ATP (adenosine triphosphate), BSA (bovine serum 
albumin) benzamidine, D-mannitol, EDTA, EGTA, hyperforin (dicyclohexylammonium) 
salt, kanamycin, paraformaldehyde, PMSF (phenylmethylsulphonyl fluoride), Ponceau S, 
porcine insulin, SBTI (soyabean trypsin inhibitor), TEMED, Triton X-100, Tween-20, 
VEGF (Vascular Endothelial Growth Factor - recombinant human), reverse transcription 
PCR primers, wortmannin 
Thermo Scientific, Waltham, MA, USA 
ImmunoMount™ 
R&D Systems, Inc. (Tocris Bioscience), Minneapolis, MN, USA  
STO-609 acetate, trans-Ned 19, GF109203X, CRT0066101 
Toronto Research Chemicals Inc, Ontario, Canada 
AICAR 
VWR International Ltd., Lutterworth, Leicestershire, UK  
Falcon branded cell culture plastics (96/24/12/6 well plates and 10 cm diameter dishes), 
HEPES 
Pepceuticals Ltd, Leicester, UK 
SAMS peptide 
Qiagen, Venlo, Netherlands 
HiPerFect® Transfection Reagent, siRNA 
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2.1.2 Kits 
Cell Biolabs, San Diego, CA, USA 
QuickTiter™ Adenovirus Titer Immunoassay Kit 
Promega Corporation, Madison, WI, USA 
CellTiter 96® Aqueous One Solution Cell Proliferation Assay, Wizard® Plus SV 
Minipreps DNA Purification System   
Qiagen, Venlo, Netherlands 
RNeasy Mini Kit 
Seahorse Bioscience, North Billierica, MA, USA 
XF Cell Mito Stress Test Kit 
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2.1.3 Specialist equipment 
ACEA Biosciences, San Diego, CA, USA 
RTCA SP Station, Analyzer and Control Unit (RTCA xCELLigence system) 
Beckman Coulter™, Pasadena, CA, USA 
Optima™ XL-80K ultracentrifuge, SW40 rotor, multipurpose scintillation counter LS 
6500, Allegra® X-12 centrifuge 
Bio-Rad Laboratories, Hemel Hempstead, UK 
Protein gel casting and Western blotting equipment (Mini-Protean III), Gel Doc imaging 
system, Mini-Sub Cell GT Gel System 
BMG Labtech, Ortenberg, Germany 
FLUORstar OPTIMA Microplate Reader 
Carl Ziess Ltd., Cambridge, UK  
LSM Exciter laser scanning microscope 
LI-COR BioSciences, Lincoln, NE, USA 
LI-COR Odyssey® Sa Infrared Imaging System  
Seahorse Bioscience, North Billierica, MA, USA 
XF24 Extracellular Flux Analyzer 
Techne, Bibby Scientific Ltd, Staffordshire, UK 
Progene FPR0G050 thermocycler 
Thermo Scientific, Waltham, MA, USA 
Nanodrop spectrophotometer 
WPA, Cambridge UK 
S2000 spectrophotometer 
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2.1.4 Cells and specialist media 
ATCC, Manassas, Virginia, USA 
3T3-L1 fibroblasts , HEK-293 and HeLa 
Promocell, Heidleberg, Germany 
Human aortic endothelial cells, human umbilical vein endothelial cells, MV2 endothelial 
cell growth media (with supplement) 
HeLa cells stably expressing LKB1 were kindly provided by Prof. D. Alessi (University of 
Dundee, UK) and have been described previously (Sapkota et al. 2002). 
Table 2-1: Cell lines used and their conditions of culture 
 
Cell type Culture media and supplements  Additional information 
3T3-L1 MEFs 
(mouse 
embryonic 
fibroblasts) 
DMEM with 10 % (v/v) newborn calf 
serum, 100 U/mL penicillin and 100 
μg/mL streptomycin 
Maintained between passage 2 and 12, 
Cultured at 37 °C, 10 % (v/v) CO2 
HAEC             
(human aortic 
endothelial cells) 
MV2 with MV2 supplement mix 
Primary cells from single donors,                    
Maintained until passage 6,                        
Cultured at 37 °C, 5 % (v/v) CO2 
HEK-293          
(human 
embryonic 
kidney) 
DMEM with 10 % (v/v) foetal calf serum 
and 2 mM glutamine 
Cultured at 37 °C, 5 % (v/v) CO2 
HeLa 
DMEM with 10 % (v/v) foetal calf serum 
and 2 mM glutamine 
Cultured at 37 °C, 5 % (v/v) CO2 
HeLa
LKB1-KD /WT
 
EMEM with 10 % (v/v) foetal calf serum, 
2 mM glutamine, 100 U/mL penicillin, 
100 μg/mL streptomycin, 2 mM non-
essential amino acids, 5 μg/mL blasticidin 
and 100 μg/mL zeocin 
Cultured at 37 °C, 5 % (v/v) CO2 
HUVEC             
(human umbilical 
vein endothelial 
cells) 
MV2, with supplement mix 
Primary endothelial cells pooled from 6 
donors,                                              
Maintained until passage 6,                   
Cultured at 37 °C, 5 % (v/v) CO2 
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2.1.5  Antisera 
2.1.5.1  Antibodies for immunoblotting 
Unless otherwise stated, all antibodies for immunoblotting were prepared in 50 % (v/v)   
LI-COR Odyssey Blocking Buffer, 50 % (v/v) PBS-T 
Table 2-2: Primary antibodies used for immunoblotting 
Epitope (Clone) 
Host 
Species 
Dilution Source (Cat #) 
Akt (pan) Mouse 1:2000 Cell Signalling Technology (#2920) 
AMPK α1  Sheep 1 µg/mL 
A kind gift from Prof. D.G. Hardie, The 
University of Dundee, UK  
(Woods et al. 1996) 
AMPK α1   Mouse 1:1000 Abcam (ab110036) 
AMPK α2 Sheep 1 µg/mL 
A kind gift from Prof. D.G. Hardie, The 
University of Dundee, UK  
(Woods et al. 1996) 
AMPK α2 Rabbit 1:1000 Cell Signalling Technology (#2537) 
c-Myc (9E10) Mouse 1:500 Santa Cruz Biotechnology (sc-40) 
GAPDH Mouse 1:80,000 Ambion, Cambridgeshire, UK (#4300) 
GFP Rabbit 1:3000 Abcam (ab290) 
JNK Rabbit 1:1000 Cell Signalling Technology (#9252) 
OXPHOS Antibody Cocktail Rodent 1:250 Abcam (ab110413) 
p38 MAPK Rabbit 1:1000 Cell Signalling Technology (#9212) 
p44/42 MAPK (Erk1/2) Rabbit 1:1000 Cell Signalling Technology (#9102) 
Phospho-Acetyl-CoA 
Carboxylase (Ser79) 
Rabbit 1:1000 Cell Signalling Technology (#3661) 
Phospho-Akt (Ser473)(193H12) Rabbit 1:1000 Cell Signalling Technology (#4058) 
Phospho-Akt (Thr308) Rabbit 1:1000 Cell Signalling Technology (#9275) 
Phospho-AMPK α 
(Thr172)(40H9) 
Rabbit 1:1000 Cell Signalling Technology (#2535) 
Phospho-AMPK α1 
(Ser485)(45F5) 
Rabbit 1:1000 Cell Signalling Technology (#2537) 
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Phospho-AMPK α1(Ser485) 
/AMPK α2(Ser491) 
Rabbit 1:1000 Cell Signalling Technology (#4185) 
Phospho-JNK (Thr183/Tyr185) Mouse 1:1000 Cell Signalling Technology (#9255) 
Phospho-MARCKS (Ser152/156) Rabbit 1:1000 Cell Signalling Technology (#2741) 
Phospho-p38 MAPK 
(Thr180/Tyr182) (28B10) 
Mouse 1:1000 Cell Signalling Technology (#9216) 
Phospho-p44/42 MAPK (Erk1/2) 
(Thr202/Tyr204) E10 
Mouse 1:2000 Cell Signalling Technology (#9106) 
Phospho-PKD/PKCμ (Ser916) Rabbit 1:1000 Cell Signalling Technology (#2051) 
PKC (A-9) Mouse 1:500 Santa Cruz Biotechnology Inc. (sc-17804) 
PKC (H-300) Rabbit 1:500 Santa Cruz Biotechnology Inc. (sc-10800) 
PKCα (alpha) Rabbit 1:1000 Cell Signalling Technology (#2056) 
PKCβI (beta 1) Rabbit 1:500 Santa Cruz Biotechnology Inc. (sc-209) 
PKCβII (F7) (beta 2) Mouse 1:500 Santa Cruz Biotechnology Inc. (sc-13149) 
PKCδ (delta) Rabbit 1:1000 Cell Signalling Technology (#9616) 
PKCε (epsilon) Mouse 1:1000 BD Transduction Laboratories (#610085) 
PKCζ (zeta) Rabbit 1:1000 Cell Signalling Technology (#9368) 
PKCη (eta) Rabbit 1:500 Santa Cruz Biotechnology Inc. (sc-215) 
PKCθ (theta) Mouse 1:500 BD Transduction Laboratories (#610089) 
PKCλ (lambda) Mouse 1:500 BD Transduction Laboratories (#610207) 
PKD1/PKCμ (mu) Rabbit 1:1000 Cell Signalling Technology (#2052) 
TRPC3 Rabbit 1:1000 Abnova (PAB13224) 
TRPC6 Goat 1:5000 Abnova (PAB18696) 
TRPC7 (extracellular) Rabbit 1:200 Alamone Labs (ACC-066)  
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Table 2-3: Secondary detection agents used for immunoblotting 
Conjugate Epitope Host species Dilution Source 
IRDye® 
800CW 
Goat IgG Donkey 1:5000 
LI-COR Biosciences, Lincoln, NE, 
USA (#92632214) 
IRDye® 
800CW 
Mouse IgG Donkey 1:5000 
LI-COR Biosciences, Lincoln, NE, 
USA (#926-32210) 
IRDye® 
800CW 
Rabbit IgG Donkey 1:5000 
LI-COR Biosciences, Lincoln, NE, 
USA (#926-32213) 
IRDye® 
680LT 
Rabbit IgG Donkey 1:5000 
LI-COR Biosciences, Lincoln, NE, 
USA (#926-68023) 
Alexa Fluor® 
680 
Sheep IgG Donkey 1:5000 
Life Technologies Ltd, Paisley, UK 
(#A21102) 
 
2.1.5.2  Antibodies for immunofluorescence 
Table 2-4: Primary antibodies used for immunofluorescence 
Epitope 
(Clone) 
Host species Dilution Source (Cat #) 
AMPK α1    
(aa. 344-358) 
Sheep 1 µg/mL 
A kind gift from Prof. D.G. Hardie,                             
The University of Dundee, UK (Woods et al. 1996) 
AMPK α1   
(aa. 357-524) 
Mouse 1:750 Abcam (ab110036) 
AMPK α2    
(aa. 352-366) 
Sheep 1 µg/mL 
A kind gift from Prof. D.G. Hardie,                             
The University of Dundee, UK (Woods et al. 1996) 
AMPK α2 Sheep 1:100 
A kind gift from Prof. D.G. Hardie,                                           
The University of Dundee, UK 
c-Myc (9E10) Mouse 1:300 Santa Cruz Biotechnology (sc-40) 
GM130 Mouse  1:200 BD Transduction Laboratories (#610823) 
Hsp47 Mouse 1:200 
A kind gift from Dr Tom Van Agtmael,                        
The University of Glasgow 
PDI Rabbit 1:200 
A kind gift from Prof. Neil Bullied,                              
The University of Glasgow 
tubulin 
[YL1/2] 
Rat 1:100 Abcam (ab6160) 
H. R. Heathcote (2016)  Chapter 2 – Materials and Methods 44 
 Table 2-5: Secondary detection agents for immunofluorescence 
 
2.1.6 Plasmids 
Table 2-6: Plasmid DNA 
Epitope Host Species Conjugate Dilution Source (Cat#) 
Mouse IgG 
(H+L) 
Donkey  Alexa Fluor® 488 1:100 Invitrogen (A-21202) 
Rabbit IgG 
(H+L) 
Goat Alexa Fluor® 488 1:100 Invitrogen (A-11008) 
Rabbit IgG 
(H+L) 
Donkey  Alexa Fluor® 488 1:100 Invitrogen (A-21206) 
Rat IgG 
(H+L) 
Donkey Alexa Fluor® 488 1:400 Invitrogen (A-21208) 
Sheep IgG 
(H+L) 
Donkey Alexa Fluor® 488 1:100 Invitrogen (A-11015) 
Sheep IgG 
(H+L) 
Donkey Alexa Fluor® 568 1:100 Invitrogen (A-21099) 
Insert (species) 
Vector                  
(antibiotic resistance) 
Source 
PKCα (bovine) 
pBΔG (kanamycin) 
 
A kind gift from Prof. T.M. Palmer,                                              
The University of Bradford, UK (Palmer and Stiles 1999) 
 
PKCβ1 (human) 
PKCβ2 (human) 
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2.1.7 Reverse transcriptase PCR primers 
Table 2-7: Custom primers designed for reverse transcriptase-PCR  
Target Direction Sequence 5’ to 3’  
Primer length  
(bp) 
Product 
length (bp) 
TRPC1 FWD TTCTGTGGATTATTGGGATGA  21 
505 
TRPC1 REV CAGAACAAAGCAAAGCAGGTG 21 
TRPC3 FWD ATGCTGCTTTTACCACTGTAG  21 
372 
TRPC3 REV TCCTTCTGCATTTGGGAAA 19 
TRPC4 FWD GGCGGACTTCAGGACTACAT 20 
499 
TRPC4 REV GCTGTGCTTTGACATTGGTC 20 
TRPC5 FWD CTCTCAAGAAACTGGGTCTCCTATTC 26 
325 
TRPC5 REV GTTTCAAATACATCCTCTGAGGAGTC 26 
TRPC6 FWD GGCAAAACAAATGAAGCC 18 
509 
TRPC6 REV CCCAACCTGTTTTTTGTCAA 20 
TRPC7 FWD TCAACAACTCAGCGA 15 
187 
TRPC7 REV TTCGTGTCCTAGAGGAG 17 
18S FWD AAACGGCTACCACATCCAAG 20 
250 
18S REV CGCTCCCAAGATCCAACTAC 20 
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2.1.8 Standard solutions 
Unless otherwise stated, all solutions were made in distilled water (dH2O). 
2YT  
1.6 % (w/v) tryptone, 1 % (w/v) yeast extract, 0.5 % (w/v) NaCl 
2YT was autoclaved before use. 
2YT-agar 
1.6 % (w/v) tryptone, 1 % (w/v) yeast extract, 0.5 % (w/v) NaCl, 1 % (w/v) agar 
2YT-agar was autoclaved and allowed to cool before the appropriate antibiotic was added 
and poured into petri-dishes. 
Bradford’s reagent 
35 mg/L Coomassie brilliant blue, 5 % (v/v) ethanol, 5.1 % (v/v) ortho-phosphoric acid 
Bradford’s reagent was filtered and stored in the dark 
Cell lysis buffer 
50 mM Tris-HCl (pH 7.4 at 4 °C), 50 mM NaF, 1 mM Na4P2O7, 1 mM EDTA, 1 mM 
EGTA, 1 % (v/v) Triton-X 100, 250 mM mannitol, 1 mM DTT, 1 mM Na3VO4, 0.1 mM 
benzamidine, 0.1 mM PMSF, 5 µg/mL SBTI.  
Prior to use, cell lysis buffer was stored on ice. 
HEPES-Brij DTT (HBD) buffer 
50 mM HEPES-NaOH (pH 7.4 at 4 °C), 1 mM DTT, 0.02 % (v/v) Brij-35 
HEPES-Brij DTT (HBD) buffer (high salt) 
50 mM HEPES-NaOH, (pH 7.4 at 4 °C), 1 mM DTT, 0.02 % (v/v) Brij-35, 850 mM NaCl 
HEPES-EDTA-SUCROSE (HES) 
20 mM HEPES-NaOH (pH 7.4), 1 mM EDTA, 250 mM sucrose 
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Immunoprecipitation (IP) buffer 
50 mM Tris-HCl (pH 7.4 at 4 °C), 150 mM NaCl, 50 mM NaF, 5 mM Na4P2O7, 1 mM 
EDTA, 1 mM EGTA, 1 % (v/v) Triton-X 100, 1 % (v/v) glycerol, 1 mM DTT, 1 mM 
Na3VO4, 0.1 mM benzamidine, 0.1 mM PMSF, 5 µg/mL SBTI.  
Prior to use, IP buffer was stored on ice. 
Krebs-Ringer-HEPES (KRH) buffer 
20 mM HEPES-NaOH (pH 7.4), 119 mM NaCl, 5 mM NaHCO3, 5 mM glucose, 4.8 mM 
KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 1.2 mM NaH2PO4 
KRH (Ca
2+
 free) 
20 mM HEPES-NaOH (pH 7.4), 119 mM NaCl, 5 mM NaHCO3, 5 mM glucose, 4.8 mM 
KCl, 1.2 mM MgSO4, 1.2 mM NaH2PO4, 1 mM EGTA 
KRH (high K
+
)  
20 mM HEPES-NaOH (pH 7.4), 59.5 mM NaCl, 5 mM NaHCO3, 5 mM glucose, 64.3 mM 
KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 1.2 mM NaH2PO4 
Phosphate-buffered saline (PBS) 
85 mM NaCl, 1.7 mM KCl, 5 mM Na2HPO4, 0.9 mM KH2PO4  
Phosphate-buffered saline-Tween 20 (PBS-T) 
85 mM NaCl, 1.7 mM KCl, 5 mM Na2HPO4, 0.9 mM KH2PO4, 0.1 % (v/v) Tween 20 
Ponceau S stain 
0.2 % (w/v) Ponceau S, 1 % (v/v) acetic acid 
SDS-PAGE resolving gel 
6-15 % (v/v) acrylamide/0.163-0.408 % (v/v) bisacrylamide in 125 mM Tris-HCl (pH 6.8), 
0.1 % (w/v) SDS, 0.1 % (w/v) APS and 0.05 % (v/v) TEMED 
SDS-PAGE running buffer 
190 mM glycine, 62 mM Tris base, 0.1 % (w/v) SDS 
SDS-PAGE sample buffer (4X) 
200 mM Tris-HCl (pH 6.8), 8 % (w/v) SDS, 40 % (v/v) glycerol, 0.4 % (w/v) 
bromophenol blue. 200 mM DTT was added fresh on the day of use. 
 
H. R. Heathcote (2016)  Chapter 2 – Materials and Methods 48 
SDS-PAGE stacking gel 
5 % (v/v) acrylamide/0.136 % (v/v) bisacrylamide in 125 mM Tris-HCl (pH 6.8), 0.1 % 
(w/v) SDS, 0.1 % (w/v) APS and 0.05 % (v/v) TEMED 
TAE buffer (50X) 
40 mM Tris-acetate (pH 8.2), 1 mM EDTA  
Tris-EDTA (TE buffer) 
10 mM Tris-HCl, (pH 8.0), 1 mM EDTA 
Transfer buffer 
25 mM Tris base, 192 mM glycine, 20 % (v/v) ethanol 
H. R. Heathcote (2016)  Chapter 2 – Materials and Methods 49 
2.2 Methods 
2.2.1 Cell culture 
2.2.1.1  Plastic ware 
All cultured cells were maintained in Corning T25, T75 or T150 vented flasks. For 
experimental conditions, all endothelial cells (aortic endothelial cells and umbilical vein 
endothelial cells) were cultured in Falcon 6 and 12-well plates, or Falcon 10 cm diameter 
dishes. For experimental conditions, all other cell lines (HEK-293 cells, HeLa, 3T3-L1 
fibroblasts, MEFs) were cultured in Corning 6, 12 and 24-well plates, or 10 cm diameter 
dishes. 
2.2.1.1  Recovery and culture of cryopreserved cells 
Cryopreserved cells were removed from liquid nitrogen and rapidly thawed, before being 
added to media pre-warmed and equilibrated to 37 °C and 5-10 % (v/v) CO2. Cells were 
incubated overnight, or until the cells had adhered before the media was replaced. 
Thereafter, cell culture media was replaced every 48 hours or until cells were passaged as 
described in 2.2.1.2. 
2.2.1.2  Passaging of cells 
All cells were routinely subdivided 1/5 – 1/10 when 80-90 % confluent. Cell culture media 
was aspirated and the cells were washed with pre-warmed sterile PBS. Cells were detached 
by the addition of trypsin-EDTA (0.05 % (v/v)) and incubated at 37 °C with 5-10 % (v/v) 
CO2 until cells fully detached when agitated by sharp tapping of the flask. The trypsin was 
neutralised by the addition of at least an equal volume of complete cell culture media and 
the cell suspension was divided as required, or cells were pelleted by centrifugation at 150 
x g for 5 min. The pelleted cells were then suspended and counted using a haemocytometer 
before further dilution and division as required. 
2.2.1.3  Determination of endothelial cell phenotype 
To determine whether cultured endothelial cells were maintaining their phenotype over 
sequential passages, HAEC from several batches and passages were assessed for the 
expression of endothelial cell marker CD31 (PECAM1), by immunostaining. 
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Cells were cultured on coverslips coated with type-I collagen, prior to fixing with ice cold 
methanol for 10 min. After washing, coverslips were attached to glass slides using 
petroleum jelly, and were circled using a Dako PAP pen to form a water tight seal. 
Coverslips were rinsed in PBS, and blocked with 3 % (v/v) goat serum in PBS. Coverslips 
were then incubated in anti-CD31 antibody, diluted 1:40 in PBS with 1 % (w/v) BSA, for 1 
hour at room temperature on an orbital shaker. After further washes in PBS, coverslips 
were incubated for 30 min with biotinylated goat anti-mouse IgG diluted 1:20 in PBS with 
1 % (w/v) BSA. After thorough washing in PBS, the coverslips were incubated for a 
further 30 min in ExtrAvidin Peroxidase diluted 1:20 in PBS with 1 % (w/v) BSA. 
Coverslips were further washed and incubated for 10 min in AEC substrate. After washing 
with distilled water, the coverslips were incubated in haematoxylin for 1 min, prior to a 
further rinse with distilled water. The coverslips were gently removed, and mounted on 
fresh slides using Aquamount and left to set overnight. Stained preparations were imaged 
using a Zeiss Axiophot microscope, and images captured using a JVC camera with 
AverCAP video card, in a Viglen computer.  
Positive cells were identified by reddish-brown staining in the cytoplasm, whereas nuclei 
were observed as blueish-purple (Figure 2-1). Control cells were stained in the absence of 
primary antibody. 
Figure 2-1 
Figure 2-1: Immunostaining of HAEC with anti-CD31 antibody and haematoxylin 
Immunostaining was carried out by Dr Ian Montgomery as described in 2.2.1.3. Cells positive for CD31 
staining appear reddish-brown, whereas the nuclei appear blueish-purple. 
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2.2.1.4  Cryopreservation of cells 
Confluent T75 flasks of cells were trypsinised as described in 2.2.1.2 and cells pelleted by 
centrifugation at 150 x g for 5 min. The cell pellet was suspended in 2 mLs of complete 
cell culture media with the addition of 10 % (v/v) DMSO. Cells were stored overnight at    
-80 °C, in a Mr. Frosty™ freezing container buffered with isopropyl alcohol, to achieve a 
freezing rate of -1 °C/min. Cells were transferred to a liquid nitrogen storage facility the 
next day. 
2.2.2 Propagation and purification of recombinant adenoviral vectors 
2.2.2.1  Recombinant AMPK adenoviral vector 
Recombinant adenoviral vector encoding Myc tagged dominant negative AMPK α1 (full 
length AMPK α1 containing a D157A mutation; Ad.AMPK-DN) and GFP (Ad.GFP) have 
been described previously (Woods et al. 2000), and were a generous gift from Dr F. 
Foufelle, Centre Biomédical des Cordeliers, Paris. 
2.2.2.2  HEK-293 cell culture and propagation of adenoviral vectors 
HEK-293 cells were cultured and passaged as described in 2.2, and were expanded with 
subsequent passages. For the propagation of recombinant adenoviral vectors, 25 x T150 
flasks were seeded with HEK-293s and cultured until approximately 80 % confluent. 
A pellet of cells infected with adenoviral vector was prepared by infecting five T75 flasks 
of HEK-293 cells with 2 µL each of pure recombinant virus which were cultured until 
attachment failed. The cells were pelleted at 600 x g for 15 min and the supernatant 
aspirated. The cell pellets were re-suspended in a final volume of 10 mL PBS, and the cells 
were lysed by the addition of an equal volume of Arklone P (trichlorotrifluorethane), and 
mixed thoroughly by inverting the tube for 10 seconds. The lysed cells were centrifuged 
for 15 min (600 x g) and the upper phase (containing the virus) was decanted into a fresh 
tube. A further 10 mL of PBS was added to the Arklone P, which was mixed and 
centrifuged as before - the upper phase was then added to that collected from the initial 
centrifugation, and the Arklone P layer discarded. The clarified virus was then diluted in 
sufficient serum free media to allow for the addition of ~10 mLs to each of 25 T150 flasks 
of HEK-293 cells. Three hours after the addition of the diluted virus, a further 14 mLs of 
complete media was added to each flask and cells were cultured at 37 °C (5 % (v/v) CO2). 
When attachment failed (typically 48 hours after infection), the cells were collected by 
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centrifugation at 600 x g for 15 min. The cell pellets were then pooled, and re-suspended in 
10 mL sterile PBS before being stored at -80 °C. 
2.2.2.3  Purification of recombinant adenoviral vector 
The re-suspended cell pellet prepared in 2.2.2.2 was thawed on ice, and the recombinant 
adenoviral vector extracted twice with Arklone P as described in 2.2.2.2. Sterile caesium 
chloride (CsCl) was prepared in Tris-EDTA buffer (5 mM Tris-HCl (pH 7.8), 1 mM 
EDTA) to a final density of 1.33 g/mL, and 2.5 mL added to a sterile centrifuge tube. This 
was under-laid with 1.5 mL CsCl at a density of 1.45 g/mL. The virus suspension was 
layered on top and centrifuged at 100,000 x g using an SW40 rotor in an Optima™ XL-
80K ultracentrifuge, at 8 °C for 90 min. The centrifuge tube was punctured just below the 
opaque virus layer with a sterile 21G needle and the virus was aspirated into a 2.5 mL 
syringe. This was transferred to a 10 micron Slide-A-Lyzer cassette and dialysed against 
TE buffer at 4 °C, overnight. The next day, the virus was dialysed for a further 2 hours 
against fresh TE buffer, with the addition of 10 % (v/v) glycerol. The purified virus was 
then removed from the cassette, the titre assessed as described in 2.2.2.4, and the virus was 
stored at -80 °C. 
2.2.2.4  Determination of recombinant adenovirus titre 
To determine the recombinant adenoviral vector titre, a QuickTitre™ Adenovirus Titre 
Immunoassay kit was used as per the manufacturer’s instructions. Where solutions were 
supplied by the manufacturer with unspecified concentrations (e.g. 10 X), they were 
prepared and diluted to the working concentration (1 X) as instructed by the manufacturer. 
Briefly, HEK-293 cells were seeded into a 24-well tissue culture plate (2.5 x10
5
 cells/well) 
and cultured for 1 hour at 37 °C, with 5 % (v/v) CO2. 10-fold serial dilutions of virus from 
2.2.2.3 were prepared in complete MEM, and 100 µL of diluted virus was added to each 
well. This was performed in duplicate. Infected cells were cultured for 48 hours. Culture 
medium was carefully aspirated and the cells fixed by the addition of 0.5 mL/well of ice 
cold methanol, taking care not to dislodge adhered cells. The plate was incubated at -20 °C 
for 20 min. Cells were then washed three times with PBS, before the addition of 1 % (w/v) 
BSA in PBS for 1 hour at room temperature. Anti-Hexon antibody (diluted to 1 X 
concentration) was added and incubated for 1 hour at room temperature on an orbital 
shaker, before a further three washes with PBS. 1 X HRP-conjugated secondary antibody 
was added and incubated for a further hour at room temperature on an orbital shaker. Cells 
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were then washed five times with PBS before 1 X diaminobenzidine (DAB) was added to 
each well for 10 min at room temperature. 
The DAB solution was aspirated and the cells washed twice with PBS. 1 mL of PBS was 
added to each well, and positive (brown) cells for five separate fields, per well, were 
counted using a light microscope fitted with a 10 X objective lens. Recombinant adenoviral 
vector titre was determined as plaque forming units/mL (pfu/mL). 
2.2.2.5  Transduction of cells with pure recombinant adenoviral vector for lysate 
preparation 
When approximately 50-70 % confluent, endothelial cells were washed twice with serum 
free Medium 199. Virus was diluted in serum free Medium 199 to the appropriate titre and 
1 mL typically added to each well of a 6-well plate. After the addition of the virus, cells 
were cultured at 37 °C, 5 % (v/v) CO2 for three hours, before the addition of a further 1 mL 
of complete MV2. Cells were then cultured for at least 20 hours before being treated as 
described in 2.2.7.1. 
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2.2.3  siRNA transfection 
Volumes given are per well for cells cultured in a 6-well plate. 
HUVECs were cultured as described (2.2) until 80 % confluent. The appropriate amount of 
siRNA was diluted in 150 μL OptiMEM™ media and mixed by pipetting up and down 
multiple times. 12 μL of HiPerFect® Transfection Reagent was added and the tubes were 
vortexed briefly. siRNA-transfection reagent complexes were allowed to form by 
incubating for 15 min at room temperature. Cells were washed with 1 mL/well 
OptiMEM™ before 750 μL of OptiMEM™ was added per well. siRNA complexes were 
added dropwise to the wells, and cells were cultured at 37 °C, 5 % (v/v) CO2. Three hours 
after the addition of siRNA, a further 1.5 mLs of complete MV2 was added, and cells were 
cultured for a further 48 hours at 37 °C in 5 % (v/v) CO2. 
2.2.4 Plasmid transfection of HeLa cells  
HeLa cells were seeded into 6-well plates and cultured until approximately 80 % confluent. 
On the day of transfection, culture media was replaced with 700 μL/well culture medium. 
Lipofectamine® 2000 was diluted 1:30 in 150 μL OptiMEM™, vortex-mixed, and 
incubated at room temperature for 5 min. Plasmid DNA (2.5 μg) was diluted in 150 μL 
OptiMEM™ and mixed by vigorous pipetting. The diluted Lipofectamine® 2000 and 
diluted DNA were combined, and further mixed by pipetting up and down. Complexes 
were allowed to form for 20 min at room temperature before 300 μL of complexes were 
added to each well of cells. Cells were cultured for 4 hours (37 °C, 5 % (v/v) CO2) before 
the complexes were removed and 2 mL of complete culture media was added. Cells were 
further cultured overnight before treatment and lysis as required. For control transfections, 
Lipofectamine® 2000 and/or DNA was replaced with an equal volume of OptiMEM™ 
media. 
2.2.5 Cell proliferation  
2.2.5.1  Real-time cell proliferation using the RTCA xCELLigence system 
Real time proliferation of HUVECs was measured using the RTCA xCELLigence system. 
This method utilises gold coated 96-well E-Plates into which cells are seeded. The 
instrument measures electrical impedance through this gold surface; changes in which are 
proportional to the area of the well occupied by cells.    
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In an E-Plate (96-well plate format), 100 μL of MV2 was dispensed into each well and the 
plate inserted into the RTCA xCELLigence instrument. At 1 min intervals 3 ‘sweeps’ were 
measured to obtain a background value. HUVEC were seeded, 2,000 cells/well in 50 μL 
MV2 and allowed to rest in the cell culture hood for 30 min. The plate was returned to the 
xCELLigence instrument and 30 measurements (sweeps) were recorded, performed at 5 
min intervals. The plate was removed and 30 pfu/cell of recombinant adenoviral vector 
was added in 25 μL MV2. The plate was returned to the xCELLigence and sweeps were 
performed at 15 min intervals for the remaining duration of the experiment. 6 hours after 
the addition of virus, the sweeping protocol was paused, and treatments were added to the 
wells, in a volume of 25 μL to achieve a final VEGF concentration of 10 ng/mL. The E-
Plate was returned to the xCELLigence, the sweeping protocol was resumed, and 
measurements recorded for a further 48 hours. 
2.2.5.2  MTS assay  
HUVEC proliferation was also determined using the CellTitre 96® Aqueous One Solution. 
This colourimetric assay relies on the reduction of a tetrazolium compound (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium 
inner salt; MTS) by living cells to a coloured formazan product which is soluble in cell 
culture medium. The quantity of formazan compound produced is measured by the 
absorbance at 490 nm, and is reported to be directly proportional to the number of living 
cells. 
Briefly, cells were treated in parallel to the xCELLigence method (2.2.5.1) in Falcon 96-
well cell culture plates, except for the absence of the addition of the initial 100 μL cell 
culture media. Two hours prior to completion of the xCELLigence protocol, 20 μL of 
CellTitre 96® Aqueous One Solution was added to each well and the cells were incubated 
under normal cell culture conditions (37 °C in 5 % (v/v) CO2). Upon completion of the 
xCELLigence protocol, the absorbance at 490 nm was measured using a FLUORstar 
OPTIMA Microplate Reader. Wells into which no cells had been seeded were taken as 
background. 
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2.2.6 Measurement of mitochondrial function using the Seahorse 
Bioscience XF24 Analyzer 
HUVEC mitochondrial function was assessed using the XF Cell Mito Stress Test Kit. The 
oxygen consumption rate (OCR) of cells is measured directly by the Seahorse XF24 
Extracellular Flux Analyzer, and serial injections of oligomycin, carbonyl cyanide-4 
(trifluoromethoxy) phenylhydrazone (FCCP) and a combination of rotenone and antimycin 
A allows for the measurement of cellular ATP production, maximal respiration and non-
mitochondrial respiration respectively. From these parameters proton leak and spare 
respiratory capacity can be determined. A schematic of an OCR profile is presented 
(Figure 2-2). 
Figure 2-2: A schematic of a Seahorse XF Cell Mito Stress Test profile, showing the key parameters of 
cellular respiration 
The sequential addition of oligomycin, FCCP and Rotenone/antimycin A allows cellular basal respiration, 
ATP production, proton leak, maximal respiration and spare capacity to be calculated, Redrawn from 
Seahorse XF Cell Mito Stress Test Kit User Guide (Seahorse Bioscience). 
HUVEC (at passage 3) were plated into an XF24 Cell Culture Microplate at a density of 
65,000 cells per well using a two-step seeding method to achieve an even monolayer of 
cells. Briefly, HUVEC were cultured, trypsinised and counted as described in 2.2. Cell 
density was adjusted to 6.5x10
5
 cells per mL in complete endothelial cell culture media 
(MV2) and 100 μL added to each well. Cell culture media with no cells was added to the 
control wells A1, B4, C3 and D6. Cells were allowed to adhere for 1 hour at 37 °C, 5 % 
(v/v) CO2 before a further 400 µL un-supplemented MV2 was added to each well, with or 
without the addition of 30 pfu/cell virus (Ad.GFP or Ad.AMPK.DN). After a further three 
hours of incubation (37 °C, 5 % (v/v) CO2), VEGF was added in an additional 100 μL of 1 
% (v/v) supplemented MV2 to achieve a final in well concentration of 10 ng/mL and MV2 
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supplement concentration of 1 % (v/v). The next day, culture media was replaced with 500 
µL of 1 % (v/v) supplemented MV2 with the addition of 10 ng/mL VEGF in the 
appropriate wells. On the evening prior to the assay, an XF24 Flux Pak was hydrated in the 
Utility Plate provided, by the addition of 1 mL/well XF Calibrant Solution. This was 
incubated overnight at 37 °C in the absence of supplemental CO2. The XF24 Analyzer was 
turned on and XF24 Software loaded, to ensure the XF24 Analyzer was running at a 
temperature of 37 °C on the day of the assay. 
 XF Assay Media was prepared on the day of the assay by the addition of 5.5 mM glucose, 
1 mM sodium pyruvate and 2 mM glutamine, to basal XF Assay Medium. The pH was 
adjusted with dilute NaOH to 7.4, at 37 °C. The XF Assay Media was then filter sterilised 
and kept at 37 °C until required. HUVEC cell morphology was observed to ensure cell 
health and that a confluent monolayer had been achieved, before the cells were washed 
with XF Assay Medium. Cells were washed by removing all but 50 µL of the cell culture 
medium, taking care not to disturb the cell monolayer, and adding 1 mL/well of XF Assay 
Media. This was performed a further two times with a final addition of 500 µL XF Assay 
Media. The cells were incubated at 37 °C without supplemental CO2 for 1 hour to allow 
equilibration. The XF24 Flux Pak was loaded with compounds as per Table 2-8, with final 
in well concentrations ([in well]) having been determined previously using the protocol 
described by Seahorse Bioscience, available on their website at: 
 www.seahorsebio.com/resources/documentation/basicprocedures/XFe24.php?xfe24  
The OCR measurement protocol was designed and run as described in Table 2-9. Upon 
completion of the protocol, the XF Assay Media was removed and cells lysed by the direct 
addition of 15 µL/well complete sample buffer. Cells were scraped and pooled according 
to experimental conditions and used for further analysis as described in 2.2.9 and 2.2.10. 
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Table 2-8: XF Cell Mito Stress Test kit reagents and injection protocol 
Table 2-9: XF Cell Mito Stress Test Kit OCR measurement protocol 
Step Cycles  
1. 1 Calibrate probes and insert cell plate 
2. 1 Equilibrate cells 
3. x 3 mix - 3 min, wait - 2 min, measure - 3 min 
4. 1 Inject port A 
5. x 3 mix - 3 min, wait - 2 min, measure - 3 min 
6. 1 Inject port B 
7. x 3 mix - 3 min, wait - 2 min, measure - 3 min 
8. 1 Inject port C 
9. x 3 mix - 3 min, wait - 2 min, measure - 3 min 
End of protocol. 
Compound Target  Port [Port] (μM) Port volume (µL) [In-well] (μM) 
Oligomycin 
ATP synthase 
(complex V) 
A 5 56 0.5 
FCCP 
inner mitochondrial 
membrane 
B 1.25 62 0.125 
Rotenone & 
antimycin A 
complex I and III 
respectively 
C 5 69 0.5 
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2.2.7 Preparation of cell lysates 
2.2.7.1  Treatment of cells prior to lysis 
Cells, typically cultured in 6-well plates, were incubated in 1 mL/well Medium 199 or 
KRH after a brief wash with 1 mL/well Medium 199 or KRH (volumes were adjusted 
accordingly for other plastic ware). Test substances were added for various durations as 
described, and cells were maintained at 37 °C, 5 % (v/v) CO2 for the duration of the 
experiments. 
2.2.7.2  Preparation of lysates 
2.2.7.2.1  Preparation of lysates from cultured cells 
With the cells on ice, cold cell lysis buffer (50-500 µL depending on plasticware used) was 
added and cells vigorously scraped with a cell lifter. Lysates were transferred to a pre-
chilled 1.5 mL microcentrifuge tubes, vortex-mixed then incubated on ice for 30 min. 
Lysates were centrifuged (20,000 x g, 5 min, 4 °C) before supernatant was transferred to 
fresh microcentrifuge tubes and used for protein quantification. 
2.2.7.2.2  Preparation of lysates from murine tissue 
Female mice were housed under standard conditions, under the personal project license 
No. 60/4504, Mechanisms of Aging, following the “principles of laboratory animal care” 
(NIH Publication No. 86-23, revised 1985) and experiments were approved by the 
University of Glasgow ethical review board. Mice had free access to water and food 
(D12450B, Research Diets Inc., New Brunswick, NJ, USA; protein 20 kcal%, 
carbohydrate 70 kcal% and fat 10 kcal%), and were fasted overnight prior to culling via a 
Schedule 1 procedure between 16 and 20 weeks of age. Tissues were harvested and snap 
frozen in liquid N2. Tissue was homogenised by the addition of 4 volumes of lysis buffer 
and by 20 passes in a Dounce homogeniser at 4 °C. Cell debris was pelleted by 
centrifugation (20,000 x g, 10 min, 4 °C), the supernatant was removed and subjected to a 
further centrifugation (20,000 x g, 10 min, 4 °C). Cleared lysate was used for the 
determination of protein concentration. 
2.2.7.2.3  Preparation of lysates from human muscle biopsies 
Particulate membrane fractions from human muscle (vastus lateralis) biopsy lysates were 
prepared in a previous study (Hall et al. 2010) from volunteers of European descent in 
which the insulin sensitivity index (ISI) derived by Matsuda and DeFonzo (Matsuda and 
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ISI = 10,000/√([fasting glucose][fasting insulin]) × ([x glucose][x insulin] during OGTT) 
 
DeFronzo 1999) was also calculated from data obtained during oral glucose tolerance tests 
whereby: 
 
The study was approved by the North Glasgow NHS Trust Research Ethics Committee and 
was conducted according to the principles expressed in the Declaration of Helsinki. 
Additional analyses received ethical approval from the National Research Ethics Service 
(Proportionate Review Sub-committee of the NRES Committee West Midlands – Solihull, 
REC ref 15/WM/0186). 
All participants were recruited via a study website and local advertising, and resided in 
Glasgow at the time of the original study (Hall et al. 2010). All participants reported 
low/moderate activity levels (physically inactive job and <2 hours of planned exercise per 
week), were non-smokers aged 18-40 years old with blood pressure <160/90 mmHg, and 
reported no previous history of diabetes or cardiovascular disease. All participants gave 
written informed consent. Volunteers attended the laboratory after 12-hour overnight fast 
with at least a 60-hour abstention from planned exercise. Fasting metabolic parameters and 
blood samples were taken followed by a muscle biopsy from the vastus lateralis of the 
right leg, 20 cm above the patella, under local anaesthesia using a ‘semi-open’ technique. 
Visible fat and connective tissue was removed with sterile forceps and samples were snap-
frozen in liquid N2. Muscle biopsies were thawed, weighed and homogenised in 8 volumes 
of homogenisation buffer (50 mM Tris-HCl (pH 7.4 at 4 °C), 250 mM sucrose, 1 mM 
EDTA, 1 mM EGTA, 5 mM NaF, 5 mM Na4P2O7, 1 mM DTT, 1 mM Na3VO4, 0.1 mM 
benzamidine, 0.1 mM PMSF, 5 µg/mL SBTI) by 20 passes in a Dounce homogeniser at 4 
°C. Homogenates were centrifuged at 350,000 x g (30 min, 4°C) to obtain cytosolic 
supernatant fractions. Pellets were then re-suspended in 150 µl homogenisation buffer 
supplemented with 1% (v/v) NP-40 and incubated on ice for 30 min prior to centrifugation 
(100,000 x g, 30 min, 4 °C) to obtain microsomal supernatant fractions which were stored 
at -80 °C. These were re-suspended in 80 μL HES buffer (20 mM HEPES (pH 7.4 at 4 °C), 
250 mM sucrose, 1 mM EDTA) prior to determining the protein concentration, and 
combination with SDS-PAGE sample buffer as described in 2.2.7.3 and 2.2.9.  
2.2.7.3  Determination of protein concentration 
To determine cell lysate protein concentration, spectrophotometric analysis was performed 
according to the method of Bradford (Bradford 1976). 
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Using disposable plastic cuvettes and in duplicate, 2, 4 and 6 µg of bovine serum albumin 
was diluted in 100 µL dH2O, to be used as reference standards. Cell lysates, again in 
duplicate, were diluted 1:19 in dH2O to a final volume of 100 µL. To all standards and 
samples, 1 mL Bradford’s reagent was added, and spectrophotometric analysis performed 
using a WPA S2000 spectrophotometer. The mean absorbance (mean A595) of each 
duplicate sample was calculated and protein concentration determined by comparison to 
the reference standards prepared (mean A595/µg BSA derived from the linear portion of the 
BSA standards curve). 
2.2.8 In vitro phosphorylation of AMPK 
HEK-293 cells were infected with Ad.AMPK-DN prepared as described in 2.2.2 and cell 
lysates prepared (2.2.7.2 and 2.2.7.3). AMPK was immunoprecipitated from 500 µg total 
protein (modified from 2.2.11.1) and incubated with 0.1 U/µL CIAP (calf intestinal 
alkaline phosphatase) for 30 min at 30 °C. The immunoprecipitated AMPK-bead 
complexes were washed once with high salt IP buffer, and a further two times with IP 
buffer prior to incubation in the presence or absence of 0.02 U or 0.1 U of PKC (active rat 
brain) or Akt (recombinant human), 1.7 mM Ca
2+
, 0.6 mg/mL PtdSer (phosphotidyl 
serine), 0.2 mM ATP, and 6 mM MgCl2 for 30 min at 30 °C. AMPK-bead complexes were 
pelleted by centrifugation and washed with IP buffer and HEPES-DTT prior to the addition 
of complete 1 X sample buffer and heating to 95 °C, then SDS-PAGE and immunoblotting 
(2.2.9 and 2.2.10). 
2.2.9 SDS polyacrylamide gel electrophoresis 
Protein samples were resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). 
SDS-gels used were typically 6-15 % (v/v) acrylamide, 1.5 mm thick, and were prepared 
as described previously (Sambrook 1989) using Bio-Rad mini-Protean III gel units. Cell 
lysates were combined with 4 X complete sample buffer in a ratio of 3:1 and heated to 95 
°C for 5 min. Equal amounts of protein were loaded per well (typically 10-12 µg) with a 
broad range pre-stained molecular mass marker included in at least one well. Proteins were 
stacked by electrophoresis at 80 V then, when in the resolving gel, the voltage was 
increased to 120-150 V, until the dye front had migrated the length of the gel and good 
resolution of the molecular mass markers had been achieved. 
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2.2.10 Western blotting 
2.2.10.1  Electrophoretic transfer of protein 
Proteins were resolved by SDS-PAGE as described in 2.2.9, before being transferred onto 
nitrocellulose membrane (0.45 µm pore size). Gels were removed from their glass supports 
and placed on an equal sized sheet of nitrocellulose membrane pre-wetted with transfer 
buffer. These were placed between sheets of 3 mm filter paper and transfer sponges, all 
pre-wetted with transfer buffer. This was then placed in a Bio-Rad mini Protean transfer 
cassette and electrophoretic transfer performed in a Bio-Rad mini Protean III Transblot 
Cell filled with transfer buffer. Electrophoretic transfer was performed at 60 V for 135 
min. After transfer, membranes were briefly stained with Ponceau S to visualise protein 
and ensure even loading, before being washed three times with PBS. 
2.2.10.2  Blocking of membranes and primary antibody incubation 
Non-specific binding to the nitrocellulose membrane was blocked by incubating the 
membrane in 5 % (w/v) milk powder made up in PBS for 30 min at room temperature on a 
shaking platform. Unbound milk protein was then removed by washing the membrane 
three times in PBS-T (~5 min for each wash, with shaking). Primary antibody (Table 2-2) 
in 50 % (v/v) LI-COR Odyssey Blocking Buffer, 50 % (v/v) PBS-T was added and the 
membranes incubated overnight at 4 °C, with shaking. 
2.2.10.3  Secondary antibody and immunodetection of proteins using the LI-COR 
Odyssey® imaging system 
Following an overnight incubation in primary antibody, membranes were washed three 
times in PBS-T, before secondary antibody with the appropriate fluorescent conjugate was 
added (Table 2-3), and incubated at room temperature for 1 hour, in the dark. After a final 
three washes with PBS-T, membranes were washed once with PBS before image 
acquisition was performed using the LI-COR Odyssey® Sa infrared imaging system.  
2.2.10.4  Densitometric quantification of protein bands 
Images were exported from the LI-COR Odyssey® Sa imaging program as a grey scale .tif 
and edited (cropped/rotated) using photo editing software. Protein band intensity was 
measured using ImageJ and subtracted from a representative background value. 
Densitometic quantification of protein bands is typically expressed here as a ratio of 
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phospho-specific immunoreactivity:total immunoreactivity, or immunoreactivity compared 
to an independent loading control, as indicated.  
2.2.11 AMPK activity assay 
Total catalytic AMPK was immunoprecipitated from cell lysates and AMPK activity was 
assessed by measuring the incorporation of [γ-32P] ATP into SAMS peptide, a synthetic 
AMPK substrate. 
2.2.11.1  Immunoprecipitation of AMPK 
Protein-G Sepharose beads (10 µL of 50 % (v/v) slurry per immunoprecipitation) were 
washed by the addition of 1 mL immunoprecipitation (IP) buffer and centrifuged at 17,500 
x g at 4 °C for 1 min, three times. The bead density was adjusted with IP buffer to 25 % 
(v/v) beads, and 1 μg of (each) antibody per IP reaction was added to the beads. Antibody-
bead complexes were allowed to form by incubating for 1 hour at 4 °C on a rotating 
platform. Beads were collected by centrifugation and again washed three times with 1 mL 
IP buffer. Antibody-bead complexes were distributed to give a final volume of 5 µL 
packed beads per IP reaction. Cell lysate prepared as described in 2.2.7 (volume equal to 
100 μg protein) was added to the antibody-bead complexes and the volumes adjusted with 
IP buffer, so as to be equal across all the samples. Protein was allowed to bind to the 
antibody-bead complexes by incubation for 3 hours at 4 °C on a rotating platform. IP 
reactions were centrifuged and washed as follows: 2 x high salt IP buffer (IP buffer with a 
final concentration of 1 M NaCl), 2 x IP buffer and finally with HEPES-Brij-DTT (HBD) 
buffer (50 mM HEPES-NaOH pH 7.4 at 4 °C, 0.02 % (v/v) Brij-35, 1 mM DTT). The 
supernatant was completely aspirated and the pellets were stored at -20 °C. 
2.2.11.2  AMPK activity assay 
Immunoprecipitated AMPK-Sepharose bead pellets were re-suspended by the addition of 
20 µL HBD buffer. Kinase reactions were prepared in chilled microfuge tubes as follows: 
5  µL re-suspended immunoprecipitated AMPK-beads, 5 µL HBD, 5 µL 1 mM AMP and 5 
µL 1 mM SAMS peptide. Reactions were started by the addition of 5 µL of 0.2 μCi/µL [γ-
32
P]-ATP, diluted in HBD containing 1 mM ATP and 25 mM MgCl2. All samples were 
incubated at 30 °C on a vibrating platform. 15 µL was removed from each tube and spotted 
onto a square of P-81 Whatman phosphocellulose paper which was submerged in 500 mL 
of 0.1 % (v/v) H3PO4 10 min after the addition of the [γ-
32
P]-ATP to each reaction. The 
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paper squares were then washed as follows: two water rinses, a further 0.1 % (v/v) H3PO4 
wash for 5 min, finally two further water rinses. The paper squares were allowed to air dry 
before being added to 5 mL scintillation fluid. Counts were obtained for 1 min using a 
Beckman LS6500 scintillation counter. All samples were assayed in duplicate, with an 
additional reaction for each sample omitting the SAMS peptide (replaced by an equal 
volume of HBD). To measure total counts, 5 µL of the [γ-32P]-ATP preparation was 
spotted onto phosphocellulose paper and added immediately to scintillation fluid for 
counting.  
2.2.12 Immunofluorescence methods 
For all incubations and washes, a volume of liquid sufficient to immerse the coverslips 
were used. 
2.2.12.1  Preparing, and seeding cells onto, coverslips 
Glass coverslips were immersed in 100 % (v/v) ethanol, placed into cell culture plates and 
allowed to dry completely in a laminar flow hood. When the coverslips were dry, cell 
culture plates were exposed to UV light (~30 min) to ensure sterility. Cells were 
trypsinised, as described in 2.2, and seeded into the culture plates with coverslips. Cells 
were cultured under normal culture conditions (2.2) until cells had reached the required 
density. 
2.2.12.2  Treatment and fixation of cells 
Cells were washed with, and then quiesced in Medium 199 for 2-3 hours prior to 
stimulation with compounds as previously described in 2.2.7.1. Cells were washed twice 
with PBS before the addition of 3 % (w/v) paraformaldehyde in PBS for 20 min at room 
temperature. After fixing, cells were washed again, three times with PBS before the 
coverslips were transferred to fresh cell culture plates containing PBS. Coverslips were 
either stained immediately or sealed with paraffin film and stored at 4 °C overnight. 
2.2.12.3  Staining of cells and mounting coverslips 
Fixed cells on coverslips were allowed to warm to room temperature and unless otherwise 
indicated, all staining incubations and washes were performed at room temperature. Cells 
were permeabilised by the addition of 0.1 % (v/v) Triton X-100 in PBS for 10 min before 
coverslips were washed three times with immunofluorescence buffer (IFB; 0.1 % (v/v) 
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Triton X-100, 1 % (w/v) BSA, in PBS). Non-specific staining was reduced by ‘blocking’ 
the coverslips with 10 % (v/v) donkey serum in IFB for 20 min before a further three 
washes with IFB. Primary antibodies were diluted as indicated (Table 2-4) in IFB and 
applied to the coverslips for 2 hours, before a further three washes with IFB. Secondary 
antibody was diluted as indicated ( Table 2-5), and applied to coverslips for 1 hour; this 
step and all subsequent incubations/washes were performed in the dark. Coverslips were 
washed a further three times before the addition of RedDot™2, diluted 1:200 in IFB; cells 
were incubated for 10 min. Coverslips were washed three times with IFB before a final 
wash with PBS. Excess PBS was blotted from the coverslip before they were mounted onto 
glass slides using ImmunoMount™ mounting media and allowed to set at room 
temperature overnight. 
2.2.12.4  Visualisation and image acquisition 
Images of immunolabelled cells were acquired using a Zeiss LSM Exciter laser scanning 
microscope utilising LSM imaging software. Images were obtained with a Plan-
Apochromat 63X/1.4 NA oil DIC objective lens and relevant filters. Images were exported 
from the LSM software in .tif format. 
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2.3  Molecular biology protocols 
2.3.1 Transformation of competent E.coli  
Chemically competent E.coli were thawed on ice and combined with 1 µL plasmid DNA 
(Table 2-6). Cells and DNA were incubated on ice for 30 min before being subjected to 
heatshock at 42 °C for 45 seconds. Cells were rested on ice for 2 min before the addition of 
300 µL SOC media. Cells were allowed to recover for 1 hour at 37 °C, with shaking. 75-
100 µL of transformed E.coli was spread onto pre-warmed 2YT-agar plates with the 
appropriate antibiotic (50 μg/mL kanamycin). Plates were allowed to dry briefly before 
being inverted and incubated at 37 °C overnight. Small-scale cultures were prepared by 
inoculating 5-10 mL 2YT (with appropriate antibiotic) with a single colony picked from a 
plate and incubating overnight with vigorous shaking. The next day, amplified plasmid 
DNA was prepared. 
2.3.2 Preparation of plasmid DNA  
Small scale plasmid DNA preparations were made from E.coli using Promega’s Wizard® 
Plus SV Miniprep DNA Purification System. 
Briefly, overnight cultures (2.3.1) were pelleted by centrifugation 1500 x g for 5 min. The 
cell pellet was re-suspended with Cell Re-suspension Solution and mixed thoroughly. Cells 
were lysed by the addition of Cell Lysis Solution and Alkaline Protease Solution was 
added. After 5 min of incubation, Neutralization Solution was added and cell debris 
pelleted by centrifugation using a bench-top centrifuge at 20,000 x g. The cleared cell 
lysate containing the plasmid DNA was passed through the Spin Columns provided by 
centrifugation 1500 x g for 1 min. Columns were washed twice with Wash Solution before 
a further 2 min centrifugation to remove residual Wash Solution. Columns were transferred 
to sterile 1.5 mL microfuge tubes and nuclease free water applied directly to the 
membrane. DNA was eluted from the column by centrifuging the columns for 1 min 1500 
x g. DNA concentration was determined at A260 using a Nanodrop spectrophotometer and 
stored at -20 °C. 
2.3.3 DNA sequencing 
All DNA sequencing was performed by DNA Sequencing & Services (MRCPPU, College 
of Life Sciences, University of Dundee, Scotland, www.dnaseq.co.uk) using Applied 
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Biosystems Big-Dye Ver 3.1 chemistry on an Applied Biosystems model 3730 automated 
capillary DNA sequencer. For each sequence, 600 ng of plasmid DNA was provided in a 
volume of 30 µL. Standard primers were provided by DNA Sequencing & Services. 
Custom sequencing primers were designed with the aid of primer-BLAST software, 
available at http://www.ncbi.nlm.nih.gov/tools/primer-blast/. Sequencing data was 
analysed using Chromas Lite version 2.2.1 and Serial Cloner version 1.3r11. 
2.3.4 RNA extraction 
Cells were cultured to near 100 % confluence in 10 cm diameter culture dishes before total 
cellular RNA was isolated using a Qiagen RNeasy Mini Kit according to the 
manufacturer’s instructions. All buffers were supplied by the manufacturer. 
Briefly, cells were directly lysed by the addition of 350 µL lysis buffer (‘RLT’) and 
collected with a cell scraper. Cell lysates were homogenised by passage through a 
sterile/RNase-free 21-gauge needle and syringe several times. An equal volume of 70 % 
(v/v) ethanol was added to the lysate, mixed by pipetting up and down, and then applied to 
an RNeasy Mini column in 700 µL aliquots which were then centrifuged at full speed in a 
benchtop centrifuge for 1 min, until the whole volume had passed through the column. 
Columns were washed with 700 µL of wash buffer (‘RW1’). The columns were washed 
twice with 500 µL of buffer ‘RPE’, with the second centrifugation performed for 2 min. 
The RNeasy columns were transferred to fresh collection tubes and centrifuged for a 
further min. The columns were transferred to fresh 1.5 mL collection tube and 30 µL of 
RNase-free water applied directly to the membrane and columns were centrifuged for 1 
min. Elute was reapplied to the membrane and centrifuged for a further min. Eluted RNA 
was quantified using a Nanodrop spectrophotometer before storage at -80 °C. 
2.3.5 First cDNA strand synthesis 
To synthesise cDNA, total RNA extracted (as described in 2.3.4) was reverse transcribed 
using M-MLV Reverse Transcriptase. 2 µg of RNA was combined with 1 μg of Oligo(dT) 
and made up to a final volume ≤ 14 µL in sterile water. Secondary mRNA structures were 
melted by heating the tubes to 70 °C for 5 min before tubes were chilled on ice and briefly 
centrifuged to collect all the solution. The following was added to each reaction: 5 µL M-
MLV 5X Reaction Buffer, 1.25 µL of each dNTP (10 mM stock of dATP, dCTP, dGTP 
and dTTP), 200 units of M-MLV Reverse Transcriptase. Each reaction was made up to a 
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final volume of 25 µL with nuclease free water and reactions were heated to 42 °C for 60 
min, before storage at -20 °C. 
2.3.6 Reverse transcriptase PCR 
PCR reactions were assembled on ice, in thin-walled PCR tubes as follows: 1 X Taq DNA 
polymerase buffer (20 mM Tris HCl pH 8.0, 50 mM KCl), 1.5 mM MgCl2, 0.2 mM 
dNTPs, 0.5 μM forward primer, 0.5 μM reverse primer (Table 2-7), 1 μg of template 
cDNA, 2.5 units of Taq DNA polymerase and sterile/RNase free dH2O to a final volume of 
50 µL. Reactions were subjected to thermocycling in a Progene FPR0G050 thermocycler 
as follows: 94 °C for 2 min, followed by 25-50 cycles of 94 °C for 2 min, 58 °C for 1 min 
and 72 °C for 50 seconds. A final extension step was performed at 72 °C for 5 min before 
reactions were chilled to 4 °C for overnight storage. 
2.3.7 Agarose gel electrophoretic resolution, visualisation and imaging of 
PCR products 
PCR products were separated on agarose gels (typically 1 % (w/v)) with 0.2 µg/mL 
ethidium bromide using a Mini-Sub Cell GT gel system (Bio-Rad). PCR products were 
combined 5:1 with 6 X DNA loading buffer and equal volumes of PCR products loaded 
per well. An appropriate DNA ladder was included in at least one well. PCR products were 
resolved for 20-40 min at 100 V. 
DNA was visualised on a UV trans-illuminator, before being photographed using a Gel 
Doc imaging system (BioRad). 
2.3.8 Quantitative (TaqMan®) Real time-PCR 
RNA was extracted and cDNA synthesised as described previously (2.3.4 and 2.3.5). 
Quantitative RT-PCR was performed in a 384-well plate using ABI-PRISM 7900HT 
Sequence Detection System. For each reaction, 1.5 µL cDNA, 0.5 µL FAM-labelled 
TaqMan® probe, 5 µL TaqMan® Universal Mastermix II (no UNG) and 3 µL 
RNase/DNase free H2O was combined and subjected to thermal cycling as follows: 2 min 
50 °C, 10 min 95 °C, then 40 cycles of 15 seconds 95 °C and 1 min 60 °C. All RNA 
isolates/synthesized cDNA were assessed for GAPDH expression levels and all PCR 
reactions were carried out in duplicate. 
H. R. Heathcote (2016)  Chapter 2 – Materials and Methods 69 
2.4 Statistical analysis 
Unless stated otherwise, results are expressed
 
as the mean ± SEM. Graphs were generated 
and statistically significant differences were determined using a two-tailed Student’s t-test 
using GraphPad Prism® software, with p<0.05 deemed to be statistically significant. 
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3.1 Introduction 
Previous work in our laboratory reported that AMPK is activated by VEGF in vascular 
endothelial cells in a CaMKK-dependent manner, and that AMPK is required for 
endothelial cell proliferation (Reihill et al. 2011); this is in contrast to the anti-proliferative 
actions of AMPK activation in other cell types. AMPK activation is reported to inhibit 
VSMC proliferation (Stone et al. 2013), suggesting that targeting VEGF-stimulated AMPK 
signalling in endothelial cells may be an attractive therapeutic strategy for promoting the 
re-endothelialisation of damaged vessels, thereby preventing the maladaptive remodelling 
that often follows vascular injury. This, in addition to the beneficial metabolic and anti-
inflammatory effects of AMPK activation in the vasculature, makes AMPK an attractive 
therapeutic target for a number of vascular pathologies. The current study therefore aimed 
to characterise the specific effect(s) of VEGF on AMPK to clarify the mechanism by 
which VEGF-stimulated AMPK activity is required for the proliferation of endothelial 
cells. 
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3.2 Results 
VEGF activates AMPK when measured by immunoblotting for activating AMPK Thr172 
phosphorylation, phosphorylation of the AMPK substrate ACC, and assessment of kinase 
activity (Figure 3-1). VEGF treatment (10 ng/mL, 5 min) stimulated a significant increase 
in both AMPK Thr172 phosphorylation and phosphorylation ACC at Ser79 (Figure 3-1A). 
When measured by kinase assay (Figure 3-1B), VEGF significantly stimulated AMPK 
activity >2-fold, a level which is comparable to AMPK activation stimulated by AICAR. 
To assess the relative contributions of the AMPK α1 and α2 catalytic subunits in both basal 
and VEGF/AICAR-stimulated AMPK activity, AMPK α1 and α2 containing complexes 
were separated by immunoprecipitation prior to the measurement of AMPK kinase activity 
(Figure 3-2). AMPK α1 activity accounts for the vast majority of both basal and VEGF-
stimulated AMPK activity, with comparable levels of activity measured when AMPK was 
immunoprecipitated with antibodies against either AMPK α1 or a combination of 
antibodies recognising AMPK α1 and AMPK α2. AMPK α2 activity (both basal and 
VEGF-stimulated) was negligible in HAEC (Figure 3-2Ai). A similar pattern (AMPK α1 
accounting for the majority of total AMPK activity) was measured for AMPK 
immunoprecipitated from HAEC treated with AICAR (Figure 3-2Aii). Successful 
separation of α subunit containing complexes was determined by subsequent 
immunoblotting (Figure 3-2B), and the successful measurement of AMPK α2 activity was 
confirmed using AMPK immunoprecipitated from rat liver (Figure 3-2C) which gave a 
ratio of α1:α2-mediated AMPK activity of 60:40. 
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Figure 3-1 
Figure 3-1: VEGF stimulates AMPK activity 
HAEC were stimulated with 10 ng/mL VEGF (5 min) or 2 mM AICAR (45 min) prior to cell lysis and the 
preparation of cell lysates. A. Proteins were resolved by SDS-PAGE/gel electrophoresis and subjected to 
immunoblotting using the antibodies indicated. i. a representative immunoblot is shown with the migration of 
molecular mass markers indicated on the right and ii. quantification of immunoblots from three independent 
experiments ± SEM. B. AMPK activity was also measured in HAEC lysate. Data in B. represents mean fold 
increase ± SEM of AMPK activity for five independent experiments. **p<0.01 and ***p<0.001 versus Veh. 
*** 
*** 
Ai. ii. 
B. 
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Figure 3-2 
Figure 3-2: α1 containing complexes account for the vast majority of basal and VEGF- or AICAR- 
simulated AMPK activity in HAEC 
HAEC were treated with A. VEGF (10 ng/mL, 5 min) or Aii. AICAR (2 mM, 45 min) prior to cell lysis and 
the preparation of cell lysates. AMPK α1, α2 or both α1 and α2 were immuoprecipitated as described in 
2.2.11, and AMPK activity measured. Data in A. represents AMPK activity from six independent 
experiments ± SEM. The remaining AMPK was eluted from the Sepharose beads used in the 
immunoprecipitations and assessed by SDS-PAGE and immunoblotting with the antibodies indicated in B. 
The migration of molecular mass markers is indicated on the right. C. AMPK activity was also assessed in 
rat liver after separation of AMPK α1 and α2 containing complexes, n=1. ns=not significant. #p<0.05 versus 
absence of VEGF/AICAR and ***p<0.001 versus untreated total AMPK (α1+α2). 
Ai. 
ii. 
B. C. 
H. R. Heathcote (2016)  Chapter 3 – Results 75 
AMPK subcellular distribution was also determined in HAEC using indirect 
immunofluorescence and imaging by confocal microscopy. AMPK α1 was observed to be 
localised to the cytoplasm of HAEC and highly concentrated in the perinuclear region 
(Figure 3-3A and C). Contrary to previous reports (Salt et al. 1998), AMPK α1 staining 
was observed in the nucleus of these cells but was not present in the nucleolus. AMPK α2 
was found to have a fibrous staining pattern (Figure 3-3B and D). Furthermore AMPK α2 
was present in the nucleus but absent from the nucleolus. These findings were confirmed 
using antibodies recognising different epitopes of the AMPK α1 and α2 subunits 
respectively. 
In order to characterise cell components with which AMPK might be interacting or 
localised to, HAEC were stained for the structural components actin and tubulin, and the 
endoplasmic reticulum resident proteins protein disulphide isomerase (PDI) or heat-shock 
protein 47 (Hsp47). Well defined actin fibres can be observed extending throughout the 
cells with distinct areas of actin deposition at the plasma membrane (Figure 3-4). Tubulin 
on the other hand, forms a fibrous network of filaments, concentrated around (but not 
inside) the nucleus and extending outwards towards the cell periphery (Figure 3-4B). 
Staining for both PDI and Hsp47 was concentrated in the perinuclear region and absent in 
the nucleus as might be expected for ER resident proteins (Figure 3-4C and D). 
Co-staining patterns for AMPK α1 and either PDI or Hsp47 showed a high level of overlap 
indicating that AMPK α1, may be concentrated in the ER of HAEC (Figure 3-5). AMPK 
α2 and tubulin showed a similar pattern of immunostaining, however this was by no means 
a perfect match when overlaid (Figure 3-6). Areas where fibrous AMPK α2 and tubulin 
staining ran in parallel were noted. 
To assess whether VEGF altered the subcellular distribution of AMPK α1 and α2 
containing complexes, HAEC were stimulated with VEGF (10 ng/mL) for 5-360 min (α1) 
or up to 24 hours (α2) prior to fixation and staining for AMPK α1 and PDI (Figure 3-7), or 
AMPK α2 and tubulin (Figure 3-8). No obvious redistribution of either AMPK α1 or α2 
was observed within the cell population over the duration of these experiments. 
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Figure 3-3 
Figure 3-3: AMPK α isoform specific subcellular distribution in HAEC 
Unstimulated HAEC were fixed and incubated with antibodies against A. AMPK α1 (amino acids 344-358), 
B. AMPK α2, C. AMPK α1 (amino acids 357-524) and D. AMPK α2 (amino acids 352-366), (all in green). 
Cells were further stained with the far-red nuclear stain RedDot™2 (blue) and localisation of antibodies 
assessed by immunofluorescence microscopy. Scale bar represents 20 μm. Images shown are representative 
of six to ten fields of view from four independent experiments.  
A. AMPK α1                                              B. AMPK α2 
C. AMPK α1 D. AMPK α2 
H. R. Heathcote (2016)  Chapter 3 – Results 77 
Figure 3-4 
Figure 3-4: Characterisation of structural and subcellular organelles in HAEC 
Unstimulated HAEC were fixed and incubated with antibodies against A. actin, B. tubulin, C. protein 
disulphide isomerase (PDI) or D. heat-shock protein 47 (Hsp47) (green). Cells were further stained with the 
far-red nuclear stain RedDot™2 (blue) and the localisation of antibodies was assessed by confocal 
microscopy. Scale bar represents 20 μm. Images shown are representative of five fields of view in a single 
experiment. 
A. actin B. tubulin C. PDI D. Hsp47 
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Figure 3-5 
Figure 3-5: AMPK α1 co-localises with both PDI and Hsp47 
Unstimulated HAEC were fixed and incubated with antibodies against A. AMPK α1 (red) and protein 
disulphide isomerase (PDI) (green) and B. AMPK α1 (red) and heat-shock protein 47 (Hsp47 - green). Cells 
were further stained with the far-red nuclear stain RedDot™2 (blue in overlay) and the localisation of 
antibodies assessed by immunofluorescence microscopy. Scale bar represents 20 μm. Images shown are 
representative of 5 fields of view from two independent experiments. 
 
 
 
 
 
 
AMPK α1 PDI Overlay 
AMPK α1 Hsp47 Overlay 
A. 
B. 
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Figure 3-6 
Figure 3-6: AMPK α2 in HAEC 
Unstimulated HAEC were fixed and incubated with antibodies against AMPK α2 (red) and tubulin (green). 
Cells were further stained with the far-red nuclear stain RedDot™2 (blue in overlay) and the localisation of 
antibodies assessed by immunofluorescence microscopy. Scale bar represents 20 μm. Images shown are 
representative of six to nine fields of view from two independent experiments. 
 
AMPK α2 tubulin Overlay 
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Figure 3-7: AMPK α1 subcellular distribution in VEGF treated HAEC 
Figure on facing page. Quiesced HAEC were stimulated with VEGF (10 ng/mL) for the times indicated prior 
to being fixed and incubated with antibodies against AMPK α1 (red) and PDI (green). Cells were further 
stained with the far-red nuclear stain RedDot™2 (blue in overlay) and the localisation of antibodies assessed 
by immunofluorescence microscopy. Scale bar represents 20 μm. Images shown are representative of six to 
nine fields of view from two independent experiments. 
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Figure 3-7 
Figure 3-7: AMPK α1 subcellular distribution in VEGF treated HAEC 
Legend on facing page 
AMPK α1 PDI Overlay 
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Figure 3-8 
Figure 3-8: AMPK α2 subcellular distribution in VEGF treated HAEC 
Quiesced HAEC were stimulated with VEGF (10 ng/mL) for the times indicated prior to being fixed and 
incubated with antibodies against AMPK α2 (red) and tubulin (green). Cells were further stained with the far-
red nuclear stain RedDot™2 (blue in overlay) and the localisation of antibodies assessed by 
immunofluorescence microscopy. Scale bar represents 20 μm. Images shown are representative of six to nine 
fields of view from two independent experiments. 
AMPK α2 tubulin Overlay 
0 min 
6 hrs 
24 hrs 
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The assessment of AMPK sub-cellular localisation reported here were performed in sub-
confluent HAEC. Given the confluent nature of the vascular endothelium, we assessed the 
subcellular distribution of AMPK α1 containing complexes in confluent HAEC. 
Intriguingly, when cells were cultured to near 100 % confluence, AMPK α1 staining was 
characterised by a punctate distribution, with a single distinct area of AMPK α1 staining 
adjacent to the nucleus: diffuse staining was also observed throughout the cell. Further co-
staining experiments identified the region in which AMPK α1 concentrates in confluent 
HAEC as being the Golgi body, assessed by co-staining with the Golgi matrix protein 130  
(GM130) (Figure 3-9). Therefore to assess whether confluency determines the sub-cellular 
distribution of AMPK α1 containing complexes, a confluent monolayer of HAEC was 
wounded by scratching with a pipette tip, and allowed to recover overnight. AMPK α1 in 
cells remote to the wounded area was found to be concentrated in the Golgi body whereas 
cells which had migrated into the wounded area displayed a diffuse perinuclear staining 
pattern for AMPK α1, similar to that observed in previous experiments. Furthermore this 
was found to correlate with PDI staining. Cells at the wound periphery displayed a 
combination of AMPK α1 concentrated in either the Golgi body or ER (Figure 3-10). 
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Figure 3-9 
Figure 3-9: AMPK α1 is concentrated in the Golgi of confluent HAEC 
HAEC were cultured to confluence prior to fixing and incubating with antibodies against A. AMPK α1 (red) 
and PDI (green) or B. AMPK α1 and Golgi marker 130 (GM130; green). Cells were further stained with the 
far-red nuclear stain RedDot™2 (blue in overlay). The localisation of antibodies was assessed by 
immunofluorescence microscopy. Scale bar represents 20 μm. Images shown are representative of six to nine 
fields of view from two independent experiments. 
AMPK α1 PDI Overlay 
AMPK α1 GM130 Overlay 
A. 
B. 
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Figure 3-10 
Figure 3-10: AMPK α1 subcellular localisation is dependent on confluency 
HAEC were cultured to confluence before being ‘wounded’ by scratching with a pipette tip and then cultured 
overnight. Cells were fixed and incubated with antibodies against AMPK α1 (red) and PDI (green). Cells 
were further stained with the far-red nuclear stain RedDot™2 (blue in overlay). The localisation of antibodies 
was assessed by immunofluorescence microscopy. Scale bar represents 20 μm. Images shown are 
representative of six to nine fields of view from two independent experiments. The upper panel shows an 
area of confluent cells not affected by wounding, and lower panel showing the periphery of the wound on the 
same coverslip (edge of wound indicated with white line). 
AMPKα1 Overlay PDI 
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We next re-examined the AMPK-dependence of VEGF-stimulated proliferation by 
infecting cells with a recombinant adenoviral vector expressing a dominant negative 
mutant AMPK (Ad.AMPK-DN). The resulting preparation of Ad.GFP and Ad.AMPK-DN 
was assessed for infection efficiency and the degree to which it inhibited AMPK activity 
(Figure 3-11). Treatment of HAEC with either 30 or 60 pfu/cell Ad.GFP resulted in >80 % 
GFP positive cells, whereas in cells transduced with Ad.AMPK-DN, 60 % of cells stained 
positive for Myc overexpression (Figure 3-11A and B). Increasing the amount of 
Ad.AMPK-DN virus to 60 pfu/cell caused a 10 % increase in the number of Myc-positive 
cells however at this titre, cells with atypical morphologies were observed (not shown). 
Subsequent experiments therefore used a titre of 30 pfu/cell Ad.GFP and Ad.AMPK-DN. 
HAEC were transduced with 30 pfu/cell Ad.GFP or Ad.AMPK-DN prior to stimulation 
with the direct AMPK activator A769662. Substantial levels of GFP protein was measured 
in cell lysates prepared from cells transduced with Ad.GFP which was absent in cells not 
treated with virus, or Ad.AMPK-DN transduced cells. Conversely, high levels of Myc and 
AMPK α1 were measured in cells transduced with Ad.AMPK-DN compared to 
untransduced or GFP-transduced HAEC (Figure 3-11C). In the presence of A769662, ACC 
Ser79 phosphorylation is robustly stimulated in cells transduced with Ad.GFP whereas 
HAECs transduced with Ad.AMPK-DN, exhibited substantially reduced basal and 
A769662-stimulated ACC Ser79 phosphorylation compared to Ad.GFP-transduced cells 
(Figure 3-11Cii). Despite there being detectable levels of AMPK Thr172 phosphorylation 
after Ad.AMPK-DN infection, the ratio of Thr172 phosphorylated to total AMPK α1 
indicates that although a proportion of AMPK is still phosphorylated after Ad.AMPK-DN 
treatment (Figure 3-11Ciii), by far the vast majority of AMPK present is exogenous 
adenoviral derived kinase-dead AMPK. 
Previous studies in our laboratory reported that AMPK was required for VEGF-stimulated 
endothelial cell proliferation as assessed by MTS assay, as over expression of dominant-
negative AMPK prevented VEGF-stimulated cell proliferation (Reihill et al. 2011). This 
assay determines the number of viable cells present using the reduction of a tetrazolium 
compound into a coloured formazan product which is soluble in tissue culture media. This 
reaction is presumed to be catalysed by NADPH or NADH, and produced by 
dehydrogenase enzymes in metabolically active cells (Berridge and Tan 1993). To confirm 
this previous report, cell proliferation was measured using the MTS assay as described 
previously (Reihill et al. 2011), in parallel with proliferation measured using the RTCA 
xCELLigence system. The xCELLigence system measures impedance of an electrical 
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current caused by cells actively growing on a gold substrate. Cell indices are generated, 
defined by: (Rn – Rb)/15, with Rn defined as the cell-electrode impedance and Rb the 
impedance of the well with cell culture media alone. As such, the xCELLigence system 
can be thought of as measuring the area of a well occupied by cells, in real time. 
In agreement with previous studies (Reihill et al. 2011), infection of HUVEC with 
Ad.AMPK-DN prevents VEGF-stimulated cell proliferation when assessed using the MTS 
assay (Figure 3-12). Furthermore, AICAR inhibited HUVEC proliferation by 
approximately half in both un-transduced cells and cells transduced with either Ad.GFP or 
Ad.AMPK-DN. In contrast to this however, infection of HUVEC with Ad.AMPK-DN had 
no effect on VEGF-stimulated cell proliferation when measured using the RTCA 
xCELLigence system (Figure 3-13). 
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Figure 3-11 
Figure 3-11: Assessment of virus transduction efficiency 
HAEC were transduced with the indicated pfu/cell A. Ad.GFP or B. Ad.AMPK-DN. Ad.AMPK-DN-
transduced cells were stained with anti-Myc (green) prior to imaging by confocal microscopy. Scale bar 
represents 20 μm. Cells were further stained with the far-red nuclear stain RedDot™2 (blue) as shown in Aii. 
and Bii. Positive (green) cells were counted and expressed as a percentage of total cells, determined by the 
number of nuclei (blue) present. Representative fields of view are shown for HAEC transduced with 30 
pfu/cell Ad.GFP and Ad.AMPK-DN in Aii. and Bii. respectively. C. HAEC were also transduced with 30 
pfu/cell Ad.GFP or Ad.AMPK-DN prior to treatment with A769662 (100 μM, 60 min) and the preparation of 
cell lysates. Proteins were resolved by SDS-PAGE/gel electrophoresis and immunoblotted with the 
antibodies indicated in C. Pixel densitometry analysis of immunoblots from C are shown in ii. and iii. Virus 
infection efficiency was assessed in a single experiment (data presented here, n=1), and confirmed during 
subsequent experiments. 
Ai. ii. 
Bi. ii. 
Ci. 
ii. 
iii. 
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Figure 3-12 
Figure 3-12: Infection with Ad.AMPK-DN prevents VEGF-stimulated HUVEC proliferation as 
measured by MTS assay 
HUVEC were seeded, into 96-well plate (2000 cells/well) and once adhered transduced with 30 pfu/cell 
Ad.GFP or Ad.AMPK-DN for 6 hours. VEGF (10 ng/mL) was then added to the cells, which were cultured 
for a further 48 hours. Two hours prior to the end of the experiment, 25 µL/well MTS reagent was added. 
Proliferation of cells was determined by measuring the absorbance at 490 nm. Background values (wells into 
which no cells had been seeded) were subtracted and results were normalised to vehicle (Veh)-treated cells. 
Data represents the mean of triplicate measurements, for two independent experiments. 
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Figure 3-13 
Figure 3-13: Infection with Ad.AMPK-DN has no effect on VEGF-stimulated HUVEC proliferation as 
measured using the xCELLigence system 
HUVEC were seeded, into 96-well E-plate (2000 cells/well) and once adhered transduced with 30 pfu/cell 
Ad.GFP or Ad.AMPK-DN for 6 hours. VEGF (10 ng/mL) was then added to the cells, which were cultured 
for a further four days in the xCELLigence instrument. A. Data represents the mean cell index of triplicate 
measurements for two independent experiments, normalised to vehicle (Veh)-treated cells. B. An example 
trace of the raw data from a single experiment is shown, lines represents the mean normalised cell index for 
triplicate measurements for vehicle (dashed line) and VEGF-stimulated cells (solid line) normalised to cell 
index measured at the addition of treatment, indicated by the vertical line and arrow (grey). For comparison 
with the end-point MTS assay Figure 3-12, the normalised cell index measured 48 hours after the addition of 
vehicle/VEGF was used (black arrow on x axis). 
A. 
B. 
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Given the discrepancy between the results in Figure 3-12 and Figure 3-13, we hypothesised 
that AMPK might be required for a VEGF-stimulated parameter of mitochondrial function, 
given that the MTS is not necessarily a direct measure of cell proliferation. 
We therefore assessed whether VEGF alters mitochondrial morphology or complex 
composition. HUVEC were stained with MitoTracker Red and imaged by confocal 
microscopy (Figure 3-14). At the resolution we are currently able to achieve, it has not 
been possible to quantify mitochondrial mass, however mitochondria in HUVEC do appear 
to be concentrated within the perinuclear region. 
To assess whether Ad.AMPK-DN or chronic VEGF treatment affected mitochondrial 
complex expression, mitochondrial complex protein levels were assessed by 
immunoblotting using an OXPHOS antibody cocktail (Figure 3-15). Robust complex I, IV 
and V expression was detected (Figure 3-15B, E and F respectively), with lesser amounts 
of complex II and III detected (Figure 3-15C and D). Neither Ad.AMPK-DN nor VEGF 
affected the expression of any of the complexes detected. 
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Figure 3-14 
Figure 3-14: Assessment of mitochondria morphology in HUVEC 
HUVEC were cultured in either reduced serum MV2 (0.5 % (v/v)) or ‘complete’ MV2 (5 % (v/v)), in the 
presence or absence of VEGF (10 ng/mL, 48 hours) prior to the addition of MitoTracker (red) to the cell 
culture medium for 30 min. After a brief washout period, cells were fixed and stained with anti-tubulin 
antibody (green) and the far-red nuclear stain RedDot™2 (blue) prior to imaging by confocal microscopy. 
Scale bar represents 20 μm. Representative images are shown from two independent experiments. 
Mitotracker Overlay Tubulin 
Reduced serum MV2 
Reduced serum MV2 + 10 
ng/ml VEGF 
MV2 
MV2 + 10 ng/ml VEGF 
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Figure 3-15 
Figure 3-15: Complex I-V expression in HUVEC 
Cells used for OCR measurements (Figure 3-17) were lysed by the direct addition of sample buffer and 
subjected to vigorous scraping and pooled according to virus and VEGF treatment regime. Equal volumes of 
protein were subjected to SDS-PAGE/gel electrophoresis and immunoblotted using an OXPHOS antibody 
cocktail (Table 2-2) A. A representative blot is shown with the complex identities indicated on the left and 
the migration of molecular mass standards on the right. B-F. Mean pixel density (au) of immunoblots for 
individual mitochondrial complexes are shown for two independent experiments. 
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Given that VEGF did not obviously alter mitochondrial morphology or complex 
composition, we characterised parameters of mitochondrial activity in HUVEC using the 
Seahorse Mito Stress Test kit. In the first instance 65,000 HUVEC/well were found to 
produce an oxygen consumption rate (OCR) of approximately 100 pmol/min, within the 
suggested optimal range (personal communication – Dr Amy Sinclair, University of 
Glasgow – not shown). Increasing concentrations of oligomycin or FCCP (final 
concentration of ≤2 μM) were injected and three OCR values were recorded (Figure 3-16). 
Oligomycin at all concentrations tested (0.5, 1 and 2 μM) significantly reduced the OCR of 
HUVEC by approximately half (Figure 3-16A). FCCP at the lowest concentration tested 
(0.125 μM) significantly increased the OCR to the greatest extent (~50% increase). At 
lower concentrations, FCCP (0.5 μM) stimulated a lesser but still significant increase in 
OCR, but at a concentration of 2 μM OCR was not significantly increased above untreated 
HUVEC (Figure 3-16B). 
OCRs were subsequently measured for cells transduced with either Ad.GFP or Ad.AMPK-
DN (Figure 3-17B), in the presence and absence of VEGF (Figure 3-17C and D). For cells 
transduced with both Ad.GFP and Ad.AMPK-DN, VEGF caused a small vertical shift in 
the OCR profile, but this increase did not reach statistical significance. This increase 
however was found to be greater in cells transduced with Ad.GFP, when compared to cell 
transduced with Ad.AMPK-DN (Table 3-1). 
Infection of HUVEC with Ad.AMPK-DN consistently decreased OCR in both the presence 
and absence of VEGF (Table 3-2), and this was more apparent in VEGF-stimulated cells, 
indicating that AMPK inhibition tends to attenuate the VEGF-induced increase in OCR. 
Average OCRs was calculated for the three OCR measurements prior to the addition of 
compounds, and after the sequential addition of oligomycin, FCCP and a combination of 
rotenone and antimycin A. From these values, basal respiration (Figure 3-18A), ATP 
production (Figure 3-18B), proton leak (Figure 3-18C), maximal respiration (Figure 
3-18D) and spare capacity (Figure 3-18E) were calculated for each treatment group. 
Neither VEGF nor infection of HUVEC with Ad.AMPK-DN significantly affected any 
parameters of metabolic activity calculated, although maximal respiration and spare 
capacity tended to be reduced by infection of HUVEC with Ad.AMPK-DN in both the 
presence and absence of VEGF (Figure 3-18D and E). 
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Figure 3-16 
Figure 3-16: Optimisation of oligomycin and FCCP concentrations for oxygen consumption rate 
(OCR) experiments 
HUVEC (65,000 cells/well) were seeded (as described in 2.2.6). Three OCR measurements were obtained 
prior to the addition of A. oligomycin (final concentration of 0 - 2 μM) and B. FCCP (final concentration of 0 
– 2 μM) in a single reagent injection (arrow). A further three OCR measurements were then obtained. Values 
in Ai. and Bi. represent mean OCR (pmol/mL) for triplicate wells in a single experiment. Aii. and Bii. Mean 
OCR was determined for each well prior to and after the addition of oligomycin and FCCP. Bars represent 
the mean OCR ± SEM for three wells before and after reagent addition, for a single experiment. *p<0.05 
**p<0.01 and ***p<0.001 compared to OCR before compound injection. 
μM 
Ai. 
Bi. 
ii. 
ii. 
μM 
μM 
 Figure 3-17 Oxygen consumption rate profiles for HUVEC 
Figure on facing page. HUVEC were seeded using the two-step method described in 2.2.6 and were transduced with C. Ad.GFP or D. Ad.AMPK-DN. Three hours after the addition of 
virus to the plate, cells were stimulated with VEGF (10 ng/mL) for a further 48 hours. OCR values were measured prior to reagent addition, and after the sequential addition of 
oligomycin (0.5 μM), FCCP (0.125 μM) and rotenone/antimycin A (0.5 μM of both). A. An example OCR profile is shown and B. HUVEC used in C. and D. were lysed by the direct 
addition of SDS-PAGE sample buffer, vigorously scraped, and pooled according to the virus treatments received. Equal volumes of protein were resolved by SDS-PAGE/gel 
electrophoresis and immunoblotted using the antibodies indicated. The migration of molecular mass markers is indicated on the right. Data in C. and D. represents the mean OCR of 
triplicate measurements ± SEM, for three independent experiments. 
 Figure 3-17 
Figure 3-17: Oxygen consumption rate profiles for HUVEC 
Legend on facing page 
A. 
B. 
C. 
D. 
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Table 3-1: Numerical summary of data presented in Figure 3-17 – Effect of VEGF 
Numerical values demonstrating the effect of VEGF treatment (Δmean) on OCR (pmol/min) in GFP and 
AMPK-DN transduced HUVEC. Δ(Δmean) indicates the difference in effect of VEGF for GFP vs AMPK-
DN transduced HUVEC. 
Table 3-2: Numerical summary of data presented in Figure 3-17 – Effect of recombinant adenoviral 
transduction 
Effect (Δmean) of AMPK-DN vs GFP on OCR (pmol/min) in HUVEC, in the presence and absence of 
VEGF. 
 
Time 
(min) 
Mean OCR (pmol/min) ± SEM for 3 independent experiments 
GFP 
GFP  
+VEGF 
Δmean AMPK-DN 
AMPK-DN 
+VEGF 
Δmean Δ (Δmean) 
0 94.8 ± 1.6 118.4 ±6.9 +23.6 79.1 ± 0.6 99.2 ± 3.0 +20.1 -3.5 
9 94.3 ± 5.8 129.4 ± 6.5 +35.1 77.4 ± 1.6 95.9 ± 2.9 +18.5 -16.6 
18 97.2 ± 4.9 133.0 ± 5.7 +35.8 74.4 ± 1.6 103.4 ± 1.8 +29.0 -6.8 
27 49.6 ± 4.2 68.4 ± 4.3 +18.8 31.8 ± 0.5 44.4 ± 1.1 +12.6 -6.2 
36 52.4 ± 3.0 73.0 ± 6.6 +20.6 34.0 ± 0.9 48.5 ± 1.8 +14.5 -6.1 
45 49.5 ± 3.4 73.2 ± 5.3 +23.8 33.8 ± 1.1 48.4 ± 1.5 +14.6 -9.2 
54 161.0 ± 2.0 193.2 ± 12.8 +32.2 125.0 ± 1.4 153.0 ± 7.2 +28.0 -4.1 
63 171.2 ± 1.4 212.3 ± 10.4 +41.1 139.9 ± 0.9 162.0 ± 5.0 +22.2 -18.9 
72 184.0 ± 0.7 227.2 ± 11.9 +43.3 151.0 ± 1.3 176.4 ± 5.0 +25.4 -17.8 
81 34.2 ± 3.6 50.8 ± 4.7 +16.5 15.1 ± 2.7 30.8 ± 2.9 +15.7 -0.9 
90 33.7 ± 3.4 49.7 ± 5.5 +16.0 15.7 ± 2.1 30.4 ± 3.9 +14.7 -1.3 
99 34.6 ± 2.8 49.8 ± 4.9 +15.2 21.1 ± 1.8 31.2 ± 4.0 +10.0 -5.2 
Time 
(min) 
Mean OCR (pmol/min) ± SEM for 3 independent experiments 
GFP AMPK-DN Δmean 
GFP 
+VEGF 
AMPK-DN 
+VEGF 
Δmean 
0 94.8 ± 1.6 79.1 ± 0.6 -15.8 118.4 ±6.9 99.2 ± 3.0 -19.3 
9 94.3 ± 5.8 77.4 ± 1.6 -16.9 129.4 ± 6.5 95.9 ± 2.9 -33.6 
18 97.2 ± 4.9 74.4 ± 1.6 -22.8 133.0 ± 5.7 103.4 ± 1.8 -29.6 
27 49.6 ± 4.2 31.8 ± 0.5 -17.8 68.4 ± 4.3 44.4 ± 1.1 -24.0 
36 52.4 ± 3.0 34.0 ± 0.9 -18.3 73.0 ± 6.6 48.5 ± 1.8 -24.5 
45 49.5 ± 3.4 33.8 ± 1.1 -15.7 73.2 ± 5.3 48.4 ± 1.5 -24.8 
54 161.0 ± 2.0 125.0 ± 1.4 -36.1 193.2 ± 12.8 153.0 ± 7.2 -40.2 
63 171.2 ± 1.4 139.9 ± 0.9 -31.4 212.3 ± 10.4 162.0 ± 5.0 -50.3 
72 184.0 ± 0.7 151.0 ± 1.3 -33.0 227.2 ± 11.9 176.4 ± 5.0 -50.8 
81 34.2 ± 3.6 15.1 ± 2.7 -19.1 50.8 ± 4.7 30.8 ± 2.9 -20.0 
90 33.7 ± 3.4 15.7 ± 2.1 -18.0 49.7 ± 5.5 30.4 ± 3.9 -19.2 
99 34.6 ± 2.8 21.1 ± 1.8 -13.5 49.8 ± 4.9 31.2 ± 4.0 -18.6 
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Figure 3-18 
Figure 3-18: Key parameters of metabolism in HUVEC 
Analysis of the data in Figure 3-17. C and D. calculating key parameters of mitochondrial metabolism. For 
each well, the mean OCR was calculated for each of the three measurements before any additions were made, 
and then after the sequential addition of oligomycin, FCCP, and a combination of rotenone and antimycin A. 
The mean of three wells were then used to calculate the key parameters of mitochondrial metabolism (as 
summarised in Figure 3-17A). A. basal respiration, B. ATP production, C. proton leak, D. maximal 
respiration and E. spare capacity for each of three independent experiments. Data represents the mean OCR 
for three independent experiments ± SEM. 
A. B. 
C. 
D. E. 
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3.3 Discussion 
Numerous reports suggest that AMPK is a viable therapeutic target for the treatment of 
cardiovascular disease however the activation of AMPK by VEGF, an essential growth 
factor is somewhat of a paradox. Previous studies report that AMPK activity is required for 
VEGF-stimulated endothelial cell proliferation, as measured by MTS assay, and migration 
(Reihill et al. 2011), effects in contrast to the anti-proliferative effects of AMPK activation 
by other agents e.g. AICAR, in the absence of growth factor stimulation (Igata et al. 2005). 
VEGF is also reported to promote local inflammation in VSMC (Koga et al. 2009), 
whereas AMPK activation by agents other than VEGF is reported to suppress 
inflammation and proliferation in VSMC (Ferri 2012). The specific activation of AMPK 
by VEGF may therefore facilitate, or permit endothelial cell proliferation and migration, 
while suppressing inflammation and proliferation in VSMC. This would be especially 
desirable in treating vascular pathologies such as restenosis, where the promotion of 
endothelial cell, but not VSMC proliferation is desired. We therefore sought to characterise 
the differential effects of AMPK activation by VEGF and AICAR, in order to determine 
the specific mechanisms by which AMPK is mediating VEGF-stimulated EC proliferation. 
Two possible mechanisms explaining the opposing effects of VEGF and other AMPK 
activators such as AICAR, on cell proliferation are: 1. VEGF activates a different AMPK 
α/β/γ isoform complex compared to other AMPK activators, or that 2. VEGF activates a 
discreet subcellular pool of AMPK and/or alters AMPK subcellular distribution to 
facilitate interaction with VEGF-specific signalling mediators. Targeting specific isoform 
containing complexes with pharmaceutical compounds is possible, as demonstrated by 
reports that A769662 activates only AMPK complexes containing the β1 subunit isoform 
(Scott et al. 2008). It is possible that VEGF specifically targets a specific isoform of the α-
catalytic subunit. AMPK α1-containing complexes contribute the vast majority of both 
basal and VEGF-stimulated AMPK activity in human vascular endothelial cells. This is 
consistent with previous reports that AMPK α1 is the predominant isoform that is 
expressed and active in vascular cells (Schulz et al. 2005, Goirand et al. 2007, Zou et al. 
2004). AICAR-stimulated AMPK activity is also mediated via α1 containing complexes, 
making it unlikely that VEGF preferentially activates a particular α isoform, different to 
that activated by other AMPK activators/mechanisms of activation. 
Basal AMPK α1 activity is reported to be a protective, redox-regulating element of 
vascular homeostasis. AICAR-induced activation of AMPK α1, but not α2, in VSMC 
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induces dose-dependent vasorelaxation in endothelium denuded aortic ring segments 
(Goirand et al. 2007). Furthermore in WT mice challenged with Ang II, AMPK activation 
protected the vasculature in vivo against superoxide production, inflammation and 
impaired endothelial function, a protective effect that was absent in PRKAA1
-/-
 mice 
(Schuhmacher et al. 2011). A role for AMPK α2 in endothelial homeostasis cannot be 
excluded however. PRKAA2
-/-
 mice are reported to demonstrate elevated expression of the 
subunits of NADPH-oxidase (p47
phox
, p67
phox
, gp91
phox
 and Nox1 and -4), with an 
associated elevation in ROS levels (p22
phox 
and p40
phox
 levels were however not reported in 
this study) (Wang et al. 2010). AMPK α2 may therefore have a homeostatic role in 
suppressing vascular endothelial NADPH-oxidase expression and ROS generation. 
Having determined that VEGF does not activate a different α isoform-containing complex 
to that activated by AICAR, we assessed whether VEGF activated a specific subcellular 
pool of AMPK α1, and/or stimulated a change in the subcellular distribution of AMPK. 
Previous studies report that α2 containing complexes exhibit preferential nuclear 
localisation compared to α1 containing complexes, which are mostly cytosolic (Salt et al. 
1998). The subcellular localisation of AMPK is reported to be sensitive to various stresses 
including heat shock, nutrient restriction and oxidants (Kodiha et al. 2007), and the cell 
cycle. It has been reported that AMPK complexes recruited to the cytokinetic apparatus of 
proliferating HUVEC exhibit distinct subunit isoform composition (Pinter et al. 2012). 
Furthermore, cellular fractionation identified enriched AMPK α1 in the cytoskeletal 
fraction whereas α2 was enriched in the cytosolic, cytoskeletal and membrane/particulate 
fractions, with lesser amounts found in the nucleus (Pinter et al. 2012). A number of 
reports now suggest that AMPK activation and function depend upon its subcellular 
localisation; studies in Schizosaccharomyces pombe report that the AMPK α subunit 
homolog Ssp2 is phosphorylated at Thr189 (orthologous to Thr172) by the CaMKK 
homolog Ssp1, stimulating nuclear translocation and accumulation which is required for 
adaptation to nutritional stress (Valbuena and Moreno 2012). Aberrant AMPK α1 
activation was also observed in the nuclei of striatal neurons of both mouse models and 
human patients with Huntington’s disease, which was closely associated with mHtt-
induced cell death (Ju et al. 2011). The authors of this study report that the activation and 
nuclear translocation of AMPK α1 suppresses Bcl2 expression promoting cell death, which 
was not observed in healthy control subjects (Ju et al. 2011). 
Few reports agree on the subcellular distribution of AMPK in endothelial cells, we 
therefore assessed the basal and VEGF-stimulated subcellular distribution of AMPK α1 
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and α2 containing complexes in human endothelial cells. Specific immunostaining and 
confocal imaging of α1 and α2 subunits suggests that α1 containing complexes are 
localised to the perinuclear region of HAEC with lesser amounts diffusely distributed 
throughout the cytoplasm. Contrary to previous reports, AMPK α1 was observed in the 
nucleus of HAEC, but exclusively absent in the nucleolus: this distribution pattern was 
confirmed using an independently sourced antibody recognising a different epitope of the 
α1 subunit. Also in contrast to previous reports, substantial α2 immunostaining was 
observed in the cytoplasm of HAEC, and appeared fibrous in nature: this was also 
confirmed using multiple anti-AMPK α2 antibodies. Staining of actin with phalloidin 
revealed the characteristic filamentous staining pattern of actin fibres whereas tubulin 
exhibits a more delicate fibrous distribution, which is absent in the nucleus. The 
endoplasmic reticulum resident proteins protein disulphide isomerase (PDI) and heat shock 
protein 47 (Hsp47) were found to be concentrated in the perinuclear region and defined the 
subcellular extent of the ER; both PDI and Hsp47 were excluded from the nucleus as 
would be expected for ER resident proteins. 
Co-staining of HAEC for α1 and either PDI or Hsp47 indicates that AMPK α1 is resident 
in the ER of sub confluent HAEC. Furthermore, acute and chronic VEGF treatment 
appears to have no obvious effect on AMPK distribution, with substantial amounts found 
in both the ER and nucleus (but not the nucleoli) in both the presence and absence of 
VEGF, however given the rapid nature of AMPK activation by VEGF we might have 
missed potential rapid, reversible changes in distribution of AMPK using this method.  
By its very nature, the vascular endothelium is required to be a confluent monolayer of 
endothelial cells. Basal AMPK activity is reported to increase in keratinocytes as they 
approach confluence suggesting that AMPK is an endogenous inhibitor of proliferation 
(Saha et al. 2006). We have not assessed AMPK activity in cells at different densities 
during the current study, all experiments were performed when cells were >95 % 
confluent, however we did assess the distribution of AMPK α1 in HAEC which had been 
cultured to confluence. Intriguingly, AMPK α1 was found to be concentrated in the Golgi 
apparatus of confluent cells, as indicated by co-staining with the Golgi resident protein 
GM130. Furthermore, when confluent HAEC are subjected to ‘wounding’, two distinct 
populations with differential α1 distributions were observed; ER resident α1 in cells which 
had migrated into, or were adjacent to the wound, and Golgi resident AMPK α1 in 
confluent cells remote from the wounded area.  
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The reversible redistribution of protein from the cytosol to Golgi apparatus has been 
reported previously. Herbert and colleagues reported that cytosolic phospholipase A2-α 
(cPLA2α) is redistributed in HUVEC when cells are cultured to confluence and mature 
cell-cell contacts are established (Herbert et al. 2005). Furthermore, the activity of cPLA2α 
is reported to be inhibited by 87 % when associated with the Golgi apparatus, and this is a 
characteristic of contact-inhibition in endothelial cells, given that cPLA2α relocation and 
activation is required for the induction of Ki67 expression and entry into the cell cycle 
(Herbert et al. 2005). The reversible redistribution of cPLA2α has also been reported to be 
dependent upon the formation of VE-cadherin/α-catenin/PAR3complexes, facilitating the 
attachment of filamentous actin and subsequent direction to the Golgi apparatus (Odell et 
al. 2011). Additionally, a distinction was made between VEGF-A-stimulated signalling 
and cPLA2α localisation. VEGF-R2 activation and downstream signalling did not 
contribute to the relocalisation of cPLA2α to the Golgi, nor did depletion of cPLA2α affect 
short term VEGF-R2 signalling (>60 min) (Odell et al. 2011). At this time we can only 
speculate as to why AMPK α1 is localised in the ER when sub-confluent, and transported 
to the Golgi body upon reaching confluence but further studies into the significance of this 
are certainly warranted. There is evidence that AMPK is involved in regulating the cell 
cycle and sensing cell density, it therefore remains feasible that AMPK acts as a sensor to 
diminish cell proliferation when cells near confluence as has been previously suggested 
(Saha et al. 2006), and that this redistribution represents a mechanism for regulating 
AMPK activity/interactions when switching to this quiescence phenotype as has previously 
been reported for cPLA2α (Herbert et al. 2005, Odell et al. 2011). 
So far we have shown that AMPK α1 accounts for the vast majority of VEGF-stimulated 
AMPK activity in vascular endothelial cells, and that this is also the case under basal and 
AICAR-stimulated conditions. Furthermore, we report that AMPK α1 appears to reside 
within the ER and nucleus whereas AMPK α2 appears to be associated with a structural 
cellular component. VEGF treatment doesn’t stimulate a substantial redistribution of 
AMPK, however confluency does. Given these findings, we reassessed the previous 
reports that AMPK is required for VEGF-stimulated endothelial cell proliferation (Reihill 
et al. 2011). Consistent with this previous report, infection of HUVEC with Ad.AMPK-DN 
prevents VEGF-stimulated HUVEC proliferation when assessed by MTS assay. However, 
when assessed using the real-time RTCA xCELLigence system, expression of dominant 
negative AMPK had no effect on VEGF-stimulated HUVEC proliferation. Furthermore, 
assessment of the raw data generated during the xCELLigence experiments actually 
indicates that rather than stimulating cell proliferation by significantly increasing the cell 
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index, VEGF prevents cell death under nutrient deprived conditions, without significantly 
increasing the cell index. 
This finding demonstrates that expressing end point assay data relative to the absence of 
VEGF does indeed suggest that VEGF stimulates cell proliferation despite there being no 
absolute increase in cell number. Unfortunately, due to factors beyond our control, data 
from a third replicate was not available for inclusion in the present analysis, and is 
something that is worth repeating and including at a later date. The current data however, 
suggests that the effect of Ad.AMPK-DN on cell proliferation depends on the technique 
used to measure proliferation and how data is interpreted. The MTS based assay relies on 
the conversion of a tetrazolium compound to form a coloured formazoan compound that is 
soluble in tissue culture media, presumed to be accomplished by NADPH or NADH 
produced by dehydrogenase enzymes in metabolically active cells (Berridge and Tan 
1993). The change in absorbance at 490 nm is reported to be directly proportional to the 
number of cells present, however this assay technically measures the metabolic capacity of 
the cells present in a well and as such would not necessarily distinguish between an 
increase in the metabolic capacity of a given number of cells, and an increase in the 
number of cells present but with no change in their metabolic activity. The RTCA 
xCELLigence system however measures the area of a well occupied by cells, although is 
again limited by a lack of distinction between cell proliferation and cell spreading. 
Together however, these data suggest that VEGF has an AMPK-dependent effect on 
HUVEC metabolism, without affecting the area occupied by cells (either changes in cell 
number or cell spreading). Endothelial cells from VEGF
lox/lox 
mice that were isolated and 
treated with Ad.Cre in vitro, demonstrated reduced basal glucose consumption, lactate 
production and triglyceride synthesis, in addition to reduced basal OCR and mitochondrial 
respiratory capacity in both the presence and absence of serum. Furthermore HUVEC 
subjected to siRNA-mediated VEGF knockdown exhibited fragmented mitochondria 
(indicated by Hsp60 staining) (Domigan et al. 2015), indicating that depletion of VEGF 
has detrimental effects on metabolism in the vasculature. Although anaerobic glycolysis 
appears sufficient to support the low metabolic demands of quiescent non-proliferating 
cells under aerobic conditions and where nutrients are in excess (Davidson and Duchen 
2007), there are reports that anaerobic glycolysis can be supported or indeed replaced to 
some extent by the utilisation of fatty acids and glutamine as energy sources 
(Unterluggauer et al. 2008, Dagher et al. 2001), such that aberrant mitochondrial activity 
has the capacity to significantly affect HUVEC cell energetics. 
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We therefore hypothesised that AMPK is required for an element(s) of VEGF-stimulated 
mitochondrial function, which at this time is poorly characterised in human vascular 
endothelial cells. We went on to assess the AMPK dependence of a number of 
mitochondrial metabolic parameters using the XF Seahorse platform and Mito Stress Test 
kit. Optimisation experiments indicated that 65,000 cells per well are required to achieve 
oxygen consumption rates (OCR) within the range required to perform the XF Cell Mito 
Stress Test consistent with previous reports (Domigan et al. 2015), however it must be 
noted that this is a much higher cell density than that used in the previous proliferation 
experiments. It was also determined that 0.5 μM of oligomycin and 0.125 μM FCCP were 
the optimal concentrations for inhibiting complex V and uncoupling oxygen consumption 
from ATP production respectively, the lowest concentrations tested. Given that the 
experimental OCR values continued to rise after the addition of FCCP however suggests a 
delay for the full effect of FCCP to be achieved, which was not evident during the initial 
optimisation experiments, but could represent a window of recovery from the effects of the 
oligomycin. In two of the three Mito Stress Test experimental replicates, chronic VEGF 
treatment increased OCR at all the time points assessed in cells transduced with Ad.GFP. 
At the same time VEGF no longer increased OCR in cells transduced with Ad.AMPK-DN. 
When put together these data suggest that VEGF tends to increase HUVEC OCR, and that 
this effect is suppressed by prior infection with Ad.AMPK-DN. However, neither the 
VEGF-stimulated increase in OCR, nor its suppression by infection with Ad.AMPK-DN 
reached statistical significance. Increasing the number of experimental replicates may 
clarify whether this is in fact the case or not. Furthermore, VEGF did not significantly alter 
any of the metabolic parameters calculated (basal respiration, ATP production, proton leak, 
maximal respiration or spare capacity) but this is not unexpected given the vertical shift in 
all points of the OCR profile in response to VEGF. This suggests that VEGF increases 
overall mitochondrial activity, rather than a specific mitochondrial complex. To assess the 
relative expression of the mitochondrial complexes between treatments, lysates prepared 
from cells used in the Mito Stress Test were lysed and assessed by immunoblotting. We 
readily detected complex I, VI and V, however observed far lower immunoreactivity for 
complexes II and III. Together these data suggest that inhibiting AMPK activation by 
VEGF, using Ad.AMPK-DN, does not affect the expression of a single mitochondrial 
complex, but may still affect overall mitochondrial activity, potentially by influencing 
mitochondrial mass. We therefore also assessed whether mitochondrial mass and/or 
morphology might be altered in response to VEGF by fluorescence imaging. Using this 
method however it was not apparent whether VEGF treatment, or the presence or absence 
of serum in the culture media affected mitochondrial mass. The major limitation of using 
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this method is that assessing fluorescence and the fraction of the cell occupied by 
fluorescence is subjective. Furthermore, dyes previously used in the assessment of 
mitochondrial mass and thought to be membrane potential independent may in fact depend 
upon mitochondrial membrane potential (Gohil et al. 2005). Obtaining Z-stacks and 
assembling high resolution 3D models of mitochondria within individual cells or using 
transmission electron microscopy may provide more accurate ways of assessing 
mitochondrial volume (Medeiros 2008), and is something that should be considered 
optimising in the future. 
Long term (6 hr) VEGF exposure caused the induction of several nuclear encoded 
mitochondrial genes in HUVEC, including COX8, TIM23 and TOM70 (Wright et al. 
2008). Furthermore, VEGF has been linked to PGC-1α activity via Akt3-dependent nuclear 
trafficking. Interestingly, VEGF is however reported to have no effect on PGC-1α 
expression, and furthermore Wright and co-workers were not able to detect a direct 
interaction between Akt3 and PGC-1α (Wright et al. 2008). AMPK activation is also 
reported to promote mitochondrial biogenesis and respiration in muscle, via PGC-1α 
induced gene transcription (Jäger et al. 2007). The AMPK activators metformin and 
AICAR are reported to significantly inhibit mtROS production by stimulating increased 
MnSOD expression. Furthermore, metformin and AICAR induced the expression of NRF-
1 and mtTFA mRNA, increased mitochondrial DNA content, and the absolute 
mitochondrial number; all these effects are reported to be inhibited by overexpression of 
dominant-negative AMPK (Kukidome et al. 2006), such that it would be interesting to 
assess whether VEGF has similar effects. Given the link between AMPK and 
mitochondrial biogenesis, it seems reasonable to speculate that as VEGF stimulates cell 
proliferation, the metabolic demands of endothelial cells increases, which can be 
compensated for to some degree by AMPK-regulated mitochondrial biogenesis. In the 
absence of functional AMPK, cells may no longer be able to compensate for the increased 
metabolic demand in response to VEGF. The methods we have employed here are not able 
to resolve mitochondrial morphology sufficiently to assess mitochondrial mass, but this 
might be assessed in the future using transmission electron microscopy. Furthermore, 
assessing the expression of genes such as PGC-1α, NRF-1 and mtTFA in addition to 
mtDNA content should also be considered. 
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3.4 Conclusion 
These data indicate that AMPK α1 accounts for the vast majority of both basal and 
VEGF/AICAR-stimulated AMPK activity in human vascular endothelial cells. 
Furthermore, VEGF does not appear to alter the subcellular localisation of AMPK, 
suggesting that VEGF does not redistribute AMPK in order to facilitate binding with 
unique substrates. Data presented here also suggests that AMPK α1 is concentrated in the 
Golgi apparatus of cells when they are cultured to near 100 % confluence, which may 
represent a mechanism of regulating AMPK activity. 
Previous studies using the MTS assay may have generated misleading results, as the assay 
is essentially a measure of the cells metabolic activity, not absolute cell number. 
Conflicting data obtained using the RTCA xCELLigence system suggests that a direct 
measure of cell proliferation such as [
3
H]-thymidine or BrdU incorporation should be 
performed. At this time, the available data suggests that VEGF is actually promoting cell 
survival rather than proliferation in serum deprived endothelial cells. 
We also assessed cellular oxygen consumption using the Seahorse Mito Stress Test. Initial 
experiments suggest that VEGF increases all aspects of mitochondrial activity, as seen by a 
vertical shift in the OCR profile. There is a suggestion that whatever this effect of VEGF 
on OCR is, it may be dependent on AMPK, although further experiments are required to 
elucidate this. 
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Chapter 4 - Investigating the mechanism by which 
VEGF stimulates increased [Ca
2+
]i and AMPK activation 
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4.1 Introduction 
Increasing the concentration of intracellular calcium ([Ca
2+
]i) represents a fundamental 
mechanism by which VEGF stimulates endothelial cell proliferation and vascular 
permeability (Bates et al. 2001, Becker et al. 2001, Cullen et al. 2000). Binding of VEGF 
to its receptor stimulates PLCγ-induced PIP2 hydrolysis resulting in the generation of IP3 
and diacylglycerol (DAG). IP3 stimulates Ca
2+
 release via the IP3 receptor (IP3R) on the 
endoplasmic reticulum, whereas DAG resulting from PIP2 hydrolysis remains associated 
with the plasma membrane, signalling via downstream signalling cascades such as PKC, 
and stimulating the influx of extracellular Ca
2+
 via DAG-sensitive Ca
2+
 channels (Bates 
and Harper 2002). Increases in VEGF-stimulated endothelial permeability have previously 
been shown to be inhibited by prior treatment with anti-VEGF-R2 antibodies, the PLC 
inhibitor U-73122 (Wu et al. 1999), and calcium chelation by BAPTA-AM (Jho et al. 
2005), indicating that endothelial cell permeability is regulated via a VEGF-R2, PLCγ and 
Ca
2+
-dependent mechanism. 
VEGF has previously been shown to activate AMPK in human vascular endothelial cells 
(Reihill et al. 2007). VEGF-stimulated AMPK activation was later shown to be dependent 
on CaMKK activation (Reihill et al. 2007), the influx of extracellular Ca
2+
, and not 
affected by LKB1 or IP3R antagonism (Reihill 2009). In addition to this, the phospholipase 
C inhibitor U-73122 inhibited VEGF-stimulated AMPK activation (Reihill et al. 2007), as 
did hyperpolarisation of the cells by replacing 60 mM of extracellular Na
+ 
with K
+
 (Reihill 
2009). The DAG mimetic OAG was also shown to activate AMPK in a manner that is 
similarly sensitive to CaMKK inhibition and cell hyperpolarisation (Reihill 2009). 
Together these findings suggest that VEGF, via PLCγ, stimulates the production of DAG 
which then causes the influx of extracellular Ca
2+ 
via DAG-regulated cation channels 
(which can be inhibited by cell hyperpolarisation), subsequently activating CaMKK and 
AMPK (Figure 4-1). 
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Figure 4-1 
Figure 4-1: Proposed mechanism of AMPK activation by VEGF 
VEGF has previously been shown to activate AMPK in a PLCγ, extracellular Ca2+ and CaMKK-dependent 
manner which is independent of both IP3-stimulated Ca
2+
 release and LKB1 activation. 
The identity of the calcium channel mediating VEGF-stimulated Ca
2+
 influx and activation 
of AMPK however remains unclear. In non-excitable cells such as endothelial cells, Ca
2+
 
influx typically occurs via voltage-independent calcium channels; endothelial cells express 
several different types of voltage-independent non-selective cation channels including 
members of the cyclic gated nucleotide-gated channels, P2X purinoceptor subfamilies and 
transient receptor potential (TRP) cation channels, a subset of which (TRPCs 3,6 and 7) are 
directly regulated by DAG (Hofmann et al. 1999). 
There is an ever-expanding body of evidence proposing a role for TRPCs in mediating 
VEGF/VEGF-R2-mediated Ca
2+
 influx. Overexpression of TRPC6 was sufficient to 
enhance HUVEC proliferation in the absence of VEGF, whereas TRPC6 inhibition with 
SKF96365 prevented VEGF-stimulated HUVEC proliferation and caused cell cycle arrest 
at G2/M (Ge et al. 2009). Furthermore, SKF96365 caused inhibition of VEGF-induced 
angiogenesis in vitro (assessed by tube length and number of branch points) (Ge et al. 
2009). This is in agreement with a previous report that expression of dominant negative 
TRPC6 in human microvascular endothelial cells (HMVEC) inhibits VEGF-stimulated 
HMVEC migration, sprout formation and reduces the percentage of cells in S-phase when 
treated with VEGF (Hamdollah Zadeh et al. 2008). Expression of dominant-negative 
TRPC6 also inhibited OAG-stimulated Ca
2+
 entry (Hamdollah Zadeh et al. 2008). Frog 
mesenteric vessels which demonstrated increased permeability in response to VEGF 
treatment responded in a similar manner when stimulated with OAG, and this was not 
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dependent on PKC (Pocock et al. 2004) suggesting that VEGF and OAG might share a 
common mechanism to stimulate Ca
2+
 influx. 
In HEK-293 cells co-transfected with VEGF-R2 and TRPC6, VEGF stimulation resulted in 
a robust Ca
2+
 transient similar to that measured in vivo, which was not present in cells 
transfected with either VEGF-R2 or TRPC6 alone suggesting a link between VEGF-R2 
and TRPC-mediated Ca
2+
 influx (Pocock et al. 2004). This is in agreement with other 
studies reporting that co-transfection of CHO cells with VEGF-R2 and either TRPC6 or 
TRPC3 made these cells sensitive to VEGF stimulation (Cheng et al. 2006). In co-
transfected cells VEGF-induced Ca
2+
 influx which was not observed when VEGF-R2 or 
the TRPC channels were expressed alone (Cheng et al. 2006). 
Evidence suggesting a mechanism linking VEGF-R2 activation and TRPC Ca
2+
 influx is 
however not limited to TRPC6 and 3. TRPC4 expression was demonstrated to be elevated 
during hypoxia in human retinal microvascular endothelial cells (HRMEC), and siRNA-
mediated suppression of TRPC4 expression prevented VEGF-induced retinal 
neovascularisation in a mouse model of oxygen-induced retinopathy and VEGF-stimulated 
angiogenesis in HRMEC in vitro (Song et al. 2015). It has also been suggested that TRPC-
mediated VEGF-induced Ca
2+
 influx is not limited to mature vascular endothelial cells. A 
population of CD133
+
 adipose-resident immature endothelial progenitor stem cells were 
shown to express both VEGF-R2 and TRPC3. VEGF-stimulated Ca
2+
 transients in these 
cells were shown to be inhibited by Gd
3+
 or expression of a dominant negative TRPC3 
fragment (Poteser et al. 2008). 
In addition to the evidence supporting a role for TRPCs in VEGF-induced Ca
2+
 influx, 
TRPCs have also been shown to regulate AMPK activity. TRPC channels have been 
proposed to be a necessary component of thrombin-stimulated AMPK activation via 
CaMKKβ activation (Bair et al. 2009) and more recently, in the presence of serum, trans-
3,4',5-trimethoxy-stilbene, a methylated derivative of resveratrol, has been shown to 
induce autophagy via TRPC4-mediated Ca
2+
 influx in vascular endothelial cells. This Ca
2+
 
influx was shown to stimulate the activation of CaMKK and AMPK, subsequently 
suppressing mTOR resulting in autophagy initiation (Zhang et al. 2015). 
Other Ca
2+
 channels have been implicated in VEGF-stimulated endothelial cell Ca
2+ 
influx. 
VEGF-R2 activation has been proposed to stimulate the synthesis of the incompletely 
characterised second messenger NAADP, which stimulates two-pore channel (TPC)-
H. R. Heathcote (2016)  Chapter 4 – Results 112 
dependent Ca
2+
 release from acidic intracellular Ca
2+
 stores (Favia et al. 2014). The authors 
further suggest that NAADP-dependent increases in [Ca
2+
]i and resulting downstream 
signalling contribute towards the angiogenic effects of VEGF. 
Given the dependence of VEGF-stimulated AMPK activation on extracellular Ca
2+
 influx, 
and that OAG mimics the effects of VEGF stimulation on AMPK, we sought to determine 
whether the DAG-sensitive TRPC channels (TRPCs 3, 6 and 7) mediate AMPK activation 
by VEGF. Data presented in this chapter therefore aims to clarify the isoform-specific 
expression of TRPC channels in cultured human vascular endothelial cells and to 
determine the specificity of pharmacological agents reported to be selective modulators of 
TRPC channel activity, with the aim of measuring the effect of inhibiting the activity of 
these channels on VEGF-stimulated AMPK activation. We also sought to determine the 
role of NAADP dependent Ca
2+ 
release from acidic intracellular stores in the mechanism of 
AMPK activation by VEGF. 
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4.2 Results 
To assess the expression of TRPC channels in human vascular endothelial cells, 
immunoblot analysis was performed using commercially available antibodies recognising 
specific TRPC channel isoforms. Immunoblot analysis of HAEC lysates identified bands 
of the predicted molecular mass for the TRPC channels 3, 6 and 7 indicated by arrow 
heads in Figure 4-2 (97, 110 and 100 kDa respectively). However, antibodies 
commercially available at the time of this study also showed unacceptably high levels of 
non-specific immunoreactivity when used for immunoblotting (Figure 4-2). 
To assess the expression of TRPC channels at the level of mRNA, RNA was also isolated 
from early passage HAECs and reverse transcription performed to synthesise cDNA. 
Reverse transcriptase PCR (RT-PCR) and quantitative real-time PCR (qRT-PCR) was then 
performed using the HAEC cDNA as the template. RT-PCR generated PCR products of 
the predicted size when primers designed to detect TRPCs 1, 5 and 7 were used (505, 325 
and 187 base pairs respectively) (Figure 4-3). No PCR products were amplified when 
primers designed to detect TRPCs 3, 4 or 6 were used, despite a PCR product for the 18S 
ribosomal subunit being amplified from the same cDNA templates. 
qRT-PCR also failed to detect expression of the DAG-sensitive TRPC channels 3, 6 and 7 
however GAPDH expression was detected in all reactions, with Ct values of between 15 
and 20 cycles. Additionally TRPC channel 3, -6 and -7 mRNA was detected, with the same 
TaqMan® probes, when using template cDNA synthesised from RNA isolated from 
human testes, with Ct values of between 37 and 38 (data not shown). 
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Figure 4-2  
Figure 4-2: Immunoblotting assessment of TRPC expression in HAEC 
HAEC were cultured and when confluent, the cells were washed briefly and lysates prepared. 10 or 20 µg of 
total cellular protein was subjected to SDS-PAGE and immunoblotting with the antibodies indicated. The 
predicted molecular mass of TRPCs 3, 6 and 7 are 97, 110 and 99 kDa respectively; arrowheads indicate 
corresponding bands. The migration of molecular mass markers is indicated on the left. Image shown is 
representative of immunoblots from three HAEC donors. 
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Figure 4-3 
Figure 4-3: Reverse transcriptase PCR assessment of TRPC expression in HAEC 
RNA was isolated from HAEC and used as a template to synthesise cDNA. RT-PCR was performed using 
the resultant cDNA as the template. A. Primers designed to amplify TRPCs 1 to 7 (with the exception of 
TRPC2) were tested. B. All experiments included positive control (detection of 18S RNA), and negative 
controls (no cDNA added to PCR reaction) and a genomic DNA control (no reverse transcriptase added to 
reverse transcription reaction) for all targets assessed (e.g. lower panel). Image shown is representative of 
TRPC1, 5 and 7 expression measured in four, three and a single experiment respectively. The migration of 
molecular mass markers is indicated on the left of each image. 
A. 
B. 
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Having experienced difficulties in measuring TRPC protein and mRNA expression, 
pharmacological agents reported to selectively modulate the activity of TRPC channels 
were therefore investigated. Hyperforin, a bicyclic polyprenylated acylphloroglucinol 
derivative, is reported to selectively activate TRPC6 (Leuner et al. 2007). Hyperforin (1 
µM, 5 min) stimulated a 2.3-fold increase in AMPK Thr172 phosphorylation, with 
comparable potency at 2.5 µM (5 min) and 5 µM when added for 5, 10 or 15 min (Figure 
4-4). All subsequent experiments therefore used hyperforin at a concentration of 1 µM for 
5 min. 
The sensitivity of hyperforin-stimulated AMPK phosphorylation to the CaMKK inhibitor 
STO-609 and to the removal of extracellular calcium was subsequently assessed. 
Hyperforin-stimulated AMPK Thr172 phosphorylation was not affected by either prior 
treatment with STO-609 (Figure 4-5) or the removal of extracellular Ca
2+
 (Figure 4-6). 
VEGF-stimulated AMPK Thr172 phosphorylation was inhibited by STO-609 treatment at 
a concentration that had no effect on AICAR-stimulated AMPK Thr172 phosphorylation 
(Figure 4-5). VEGF-stimulated AMPK Thr172 phosphorylation was inhibited, whereas 
AICAR-stimulated AMPK Thr172 phosphorylation was not affected, by the removal of 
extracellular Ca
2+ 
(Figure 4-6). 
Pyr3 and ML-9, the reported inhibitors of TRPC channels 3 and 6 respectively (Shi et al. 
2007, Kiyonaka et al. 2009) had no effect on VEGF- or AICAR-stimulated AMPK Thr172 
phosphorylation (Figure 4-7), however due to the calcium and CaMKK independent effects 
of hyperforin, a specific positive control for these inhibitors has been difficult to identify. 
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Figure 4-4 
Figure 4-4: Hyperforin stimulates AMPK Thr172 phosphorylation 
HAEC were stimulated with increasing concentrations of hyperforin (1, 2.5 or 5 µM) for the durations 
indicated before cell lysates were prepared. Cell lysates were then subjected to SDS-PAGE and 
immunoblotting using the primary antibodies as indicated in A. The migration of molecular mass standards 
are indicated on the right. A. the immunoblot and B. quantification of pixel density is shown for a single 
experiment. 
A. 
B. 
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Figure 4-5 
Figure 4-5: Hyperforin-stimulated AMPK Thr172 phosphorylation is not sensitive to STO-609 
HAEC were pre-treated with STO-609 (1 µM) for 60 min. Cells were then stimulated with VEGF (10 ng/mL, 
5 min), hyperforin (1 μM, 5 min) or AICAR (2 mM, 45 min) and cell lysates prepared. Lysates were 
subjected to SDS-PAGE and immunoblotting using the primary antibodies as indicated. A. Image shown is 
representative of three independent experiments. The migration of molecular mass standards are indicated on 
the right. B. and C. Data are presented as mean pixel density ± SEM, for three independent experiments in 
each case. **p<0.01 and *p<0.05 vs absence of hyperforin or VEGF, $$p<0.01 vs absence of STO-609. 
A. 
B. 
C. 
H. R. Heathcote (2016)  Chapter 4 – Results 119 
Figure 4-6 
Figure 4-6: Hyperforin-stimulated AMPK Thr172 phosphorylation is not sensitive to the removal of 
extracellular calcium 
HAEC were quiesced in KRH with the addition of 2.5 mM CaCl2 or KRH with no Ca
2+
 with the addition of 1 
mM EGTA prior to stimulation with VEGF (10 ng/mL, 5 min), hyperforin (1 µM, 5 min) or AICAR (2 mM, 
45 min). Cell lysates were prepared and subjected to SDS-PAGE and immunoblotting with the antibodies 
indicated. A. Blot shown is representative of three independent experiments and the migration of molecular 
mass standards are indicated on the right. B. and C. Data are presented as mean pixel density ± SEM, for 
three independent experiments in each case. ***p<0.001, **p<0.01 and *p<0.05 vs absence of hyperforin, 
VEGF or AICAR. ††p<0.01 vs presence of Ca2+. 
A. 
B. 
C. 
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Figure 4-7 
Figure 4-7: The TRPC inhibitor Pry3 stimulates AMPK Thr172 phosphorylation 
HAEC were pre-treated with 20 µM Pyr3, ML-9 or an equal volume of DMSO. Cells were stimulated with 
VEGF (10 ng/mL, 5 min) or AICAR (2 mM, 45 min) or an equal volume of vehicle before cell lysates were 
prepared. Cell lysates were subjected to SDS-PAGE and immunoblotting using antibodies as indicated. A. A 
representative immunoblot is shown with the migration of molecular mass standards indicated on the right 
and B. quantification of immunoblots from three independent experiments. **p<0.01 and *p<0.05 vs absence 
of VEGF, and #p<0.05 and †p<0.05 for Veh and VEGF-stimulation respectively vs the absence of inhibitor. 
A. 
B. 
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It has previously been reported that VEGF induced neoangiogenesis is mediated by the 
second messenger NAADP, and two-pore channel-2 (TPC-2)-dependent Ca
2+
 mobilisation 
from acidic intracellular stores (Favia et al. 2014). In agreement with this, the NAADP 
antagonist Ned 19 inhibited VEGF-stimulated phosphorylation of Akt and Erk1/2 (Figure 
4-8A) whereas VEGF-stimulated p38 MAPK phosphorylation was not significantly 
altered. In contrast, VEGF-induced JNK phosphorylation was not observed (Figure 
4-8Aii). In addition to the previous report of Ned 19 action in endothelial cells, neither 
VEGF-stimulated phosphorylation of the PKC substrate MARCKS (Ser152/156) nor 
AMPK Thr172 phosphorylation was inhibited by pre-treatment with Ned 19 (Figure 
4-8Biv and v). 
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Figure 4-8 
 
Continued on facing page
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ii. 
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Figure 4-8: The NAADP antagonist Ned 19 has no effect on VEGF-stimulated MARCKS or AMPK 
Thr172 phosphorylation 
HUVEC were pre-treated for 30 min in the presence or absence of 100 µM Ned 19 prior to stimulation with 
10 ng/mL VEGF for a further 15 min as previously described (Favia et al. 2014), or 5 min as indicated by * 
in Aiii. Cell lysates were prepared and subjected to SDS-PAGE and immunoblotting with the antibodies 
indicated. A. Representative immunoblots are shown. ii. Cell lysate (40 µg protein) from IL-1β-stimulated 
MEFs (10 ng/mL, 15 min – kind gift from Dr. Sarah Mancini) was included as a positive control for JNK 
phosphorylation, and the migration of molecular mass standards are indicated on the right. B. Data shown 
represent mean band intensity ± SEM, relative to VEGF-stimulation in the absence of Ned 19, for three 
independent experiments in each case. #p<0.05, and ##p<0.01vs absence of Ned 19, and *p<0.05, **p<0.01, 
***p<0.05 vs absence of VEGF. 
Bi. 
iii. 
iv. v. 
ii. 
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4.3 Discussion 
4.3.1 TRPC channels 
VEGF signals via its cognate receptor, VEGF-R2, stimulating PLCγ-mediated PIP2 
hydrolysis resulting in IP3 and DAG synthesis. IP3 diffuses freely into the cytoplasm where 
it activates IP3 receptors (IP3R) on the membrane of the smooth endoplasmic reticulum 
stimulating calcium mobilization from intracellular stores. This initial rapid Ca
2+ 
release 
can induce further Ca
2+
 influx via store-operated calcium (SOC) channels in the plasma 
membrane, resulting in sustained Ca
2+ 
influx. When it was initially characterised, VEGF 
was thought to increase vascular permeability via IP3 induced Ca
2+
 release from 
intracellular stores. It was however later shown by Pocock and colleagues that VEGF 
increases vascular permeability independently of thapsigargin-induced Ca
2+ 
store 
depletion, providing evidence that VEGF is acting via Ca
2+
 store/IP3  independent 
mechanism(s) to increase [Ca
2+
]i (Pocock et al., 2000). DAG resulting from PIP2 
hydrolysis remains associated with the plasma membrane stimulating signalling cascades 
such as PKC and ERK1/2. DAG has also been shown to directly stimulate extracellular 
Ca
2+
 influx via a number of the family of non-selective cation channels called transient 
receptor potential (TRP) channels (Hofmann et al. 1999). 
Seven mammalian TRPC channel isoforms have been identified (TRPCs 1-7) which can be 
further sub-categorised into four groups based on their sequence homology and functional 
similarities; TRPCs 2, 1, 4/5, and 3/6/7. TRPC2 is a pseudogene in humans, old world 
monkeys and apes, but forms functional cation channels in other mammalian species, 
including rodents (Vannier et al. 1999). Consequently, most studies utilising human 
derived cell lines, including the present one, do not investigate the role of TRPC2. 
Figure 4-9: Phylogenetic relationship of the TRPC protein family 
Evolutionary distance is shown by the total branch lengths in point accepted mutations (PAM) units, which is 
the mean number of substitutions per 100 residues, (Clapham et al. 2001). 
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Functional TRPC channels are tetrameric complexes with assembly typically occurring 
between the phylogenetically related TRPCs 1/4/5 and 3/6/7, although complexes 
containing other combinations have been reported (Zagranichnaya et al. 2005, Poteser et 
al. 2006, Antoniotti et al. 2006). Generally TRPCs 1, 4 and 5 are reported to form Ca
2+ 
store-regulated channels while TRPCs 3, 6 and 7 are thought to be Ca
2+
 store independent, 
receptor (including DAG) activated calcium channels. 
Many studies investigating the role of TRPC channels initially investigate the expression 
pattern of the different TRPC channel isoforms in the model system under investigation, an 
approach we have utilised here at both the level of protein and mRNA. Commercially 
available antibodies and qRT-PCR have recently become available for detecting TRPC 
channel expression. Immunoblot analysis of HAEC cell lysates generated immune-reactive 
bands corresponding to the predicted molecular mass of TRPC 3, 6 and 7 (97, 110 and 99 
kDa respectively). The antibodies however show unacceptably high levels of non-specific 
immunoreactivity. Membrane containing fractions were isolated from HAEC and high 
ionic strength washes were used during the immunoblotting process in an attempt to reduce 
non-specific immunoreactivity, however unacceptably high levels of immunoreactivity 
were again observed (data not shown) consistent with previous reports crititransing the 
specificity of commercial antibodies for TRPCs (Flockerzi et al. 2005, Ong et al. 2002). 
Ong and co-workers successfully employed a combined immunoprecipitation and 
immunoblotting protocol using two antibodies recognising different epitopes of 
endogenous TRPC1 (a polyclonal antibody recognising the C-terminal 18 amino acids of 
human TRPC1 for immunoprecipitation and then immunoblotting with a mouse 
monoclonal antibody representing the N-terminus of human TRPC1 - immunogen 
sequence not specified). Either antibody alone was not sufficient to detect endogenous 
levels of TRPC1 (Ong et al. 2002). Using this approach, proteins with a low copy number 
may be concentrated sufficiently by immunoprecipitation to detect by immunoblotting. In 
addition, partial purification by immunoprecipitation or isolation of membranes may 
remove proteins that would otherwise cross react with the antibody resulting in TRPC 
detection that is more specific. The failure of either antibody alone to detect endogenous 
TRPC expression might represent a low specificity or affinity of the antibody for the 
denatured protein. Given the degree of homology between TRPCs 3, 6 and 7 
improvements to the specificity of TRPC antibodies is limited, we therefore also assessed 
TRPC mRNA levels in HAEC. 
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To measure TRPC expression at the level of mRNA, the methods employed by Yip and co-
workers were utilised (Yip et al. 2004). In their study, the authors demonstrate the 
expression of TRPCs 1, 3, 4, 5, 6, and 7 in in human coronary artery endothelial cells by 
RT-PCR (TRPC2 is a pseudogene in humans and was therefore not included in this study 
as mentioned previously). Using the methods described by the authors of this particular 
study, we detected PCR products of the predicted size for TRPCs 1, 5, and 7, but failed to 
detect TRPCs 3, 4 or 6. TRPC6 expression has previously been demonstrated in HAECs by 
our lab (Reihill 2009), however it was not detected during this present study. HAECs are 
derived from individual donors; HAEC cells from six individual donors, and over 
sequential passages, were therefore included in this study with inconsistent results. cDNA 
synthesised from RNA isolated from HUVEC (pooled from 6 individual isolations), HEK-
293, HeLa cells and human brain was also assessed for TRPC mRNA expression, again 
with varying and inconsistent results (data not shown). On a technical note, it must be 
made apparent that 50 cycles of PCR were required to amplify the PCR products shown in 
Figure 4-3. Although consistent with the methods employed by Yip and co-workers, 
requiring this number of cycles to detect mRNA expression by RT-PCR suggests that the 
mRNA for these channels is present in negligible amounts, is highly susceptible to 
degradation or generates very stable protein, and is therefore expressed only under certain 
conditions yet to be determined. In addition to reverse transcriptase PCR, we have also 
used the more sensitive and quantitative approach of real-time PCR on HAEC derived 
cDNA using commercially available TaqMan® RT-PCR probes. Using this approach we 
again failed to detect the expression of TRPCs 3, 6 or 7 (data not shown) in any of the 
individual HAEC lines used. Expression of these TRPC channels was measured in cDNA 
derived from human testicular RNA using this method indicating that the probes are able to 
amplify the PCR product, and GAPDH expression levels measured in tandem indicated 
that good quality RNA isolation and efficient cDNA synthesis had been performed. 
What is clear from the literature is that no consensus has been reached regarding the 
expression of TRPCs in commonly used vascular endothelial cells, and studies report 
different TRPC expression in cells isolated from different vascular beds of the same 
organism. In fact different expression patterns have even been reported in the same 
vascular endothelial cell type. The expression of TRPC channels 1, -3, -4, -6 and -7 have 
previously been reported in HUVEC (Paria et al. 2003) whereas other studies failed to 
detect TRPC4 or -6 in HUVEC (Kohler et al. 2001). We have presently used the same 
experimental conditions reported in detail by Yip and colleagues yet this failed to show the 
expression of TRPCs 3, 4 and 6 despite our lab having reported TRPC6 expression in 
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HAEC previously (Reihill 2009). Methods have been developed to allow the assessment of 
mRNA expression in single cells (Jones 2011, Kohler et al. 2001), however this is 
probably not representative of the organismal cell population as a whole and so is probably 
of little use. Although we demonstrate TRPC1, 5 and 7 expression at the level of mRNA, 
mRNA levels do not always reflect relative protein abundance therefore the significance of 
studies analysing mRNA levels is difficult to assess without also assessing protein levels, 
ideally by immunoblot or immunofluorescence. 
TRPCs are not essential for the development of a mature vasculature, as mice deficient in 
each of the mammalian TRPCs have been generated (Freichel et al. 2005). The use of 
knockout models however might not be the solution to our technical issues, as TRPC3 
expression has been shown to be elevated in ~2-3 fold in vascular smooth muscle of 
TRPC6
-/-
 mice, and demonstrated enhanced responsiveness to agonists, suggesting that 
functional redundancy or compensatory mechanisms exists between the TRPC isoforms 
(Dietrich et al. 2005). Furthermore, deletion of either TRPC3 or TRPC6 is not protective 
against pressure overload induced cardiac hypertrophy in vivo whereas combined TRPC3 
and -6 deletion is (Seo et al. 2014) suggesting TRPC isoforms may act in concert. 
Much of the data describing the activities of TRPC channels has been obtained in 
experiments using heterologously expressed TRPC proteins in cell lines optimised for the 
expression of the protein being investigated, no cells with a truly TRPC null background 
have been described to our knowledge. Ectopic expression may result in TRPC channels 
being localised to intracellular compartments or form complexes with other TRP isoforms, 
not necessarily occurring in vivo. Ectopic TRPC expression may also result in the 
expression of TRPC channels at levels far greater than those observed in vivo. Although 
helpful, this may not be a useful strategy when extrapolating findings to native 
tissues/systems. 
TRPC expression within a cell population may also be temporally and spatially regulated. 
TRPC4 has been shown to be absent in the plasma membrane of sub-confluent human 
microvascular endothelial cells (Graziani et al. 2010). Epidermal growth factor initiated the 
recruitment of TRPC4 to the plasma membrane which was retained there until the cells had 
formed mature cell-cell contacts. Upon growth factor stimulation of quiescent, barrier 
forming cells, TRPC4 was internalised, suggesting the subcellular distribution of TRPCs is 
cell cycle dependent (Koenig et al. 2013). The fate of the internalised TRPC4 was not 
reported in this study (e.g. whether it was retained in storage vesicles or degraded) but it is 
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interesting to speculate as to whether the same is true for other TRPC isoforms, adding 
further complication when attempting to determine their expression pattern. 
It has previously been proposed that caution is required when interpreting data regarding 
the expression of TRP channels in cultured cells (Yao and Garland 2005). Culture under 
different conditions and the serial passaging of cells is believed to alter TRP channel 
expression. Therefore data obtained from cultured cell lines may not accurately represent 
native tissue expression (Yao and Garland 2005). Studies have measured TRPC expression 
in intact vessels (Yip et al. 2004), however studies using in situ hybridisation or 
immunohistochemistry are made technically difficult due to low specificity and cross 
reactivity of commercially available detection reagents, as is apparent in Figure 4-2. 
A large number of the studies investigating the role of TRPCs use heterologous expression 
system culture models however given the variation in expression; it is not difficult to 
foresee how introducing heterologous TRPC proteins might further complicate the 
interpretation of TRPC channel activity. No consensus regarding the expression of TRPCs 
within a given cell model can be agreed upon. In fact, it has been suggested the TRP-
channel expression is highly sensitive and dependent upon how tissue has been isolated, 
cultured and the method used to assess expression (Yao and Garland 2005). The cells we 
have used here therefore either express TRPC mRNA at a level too low to detect or the 
TRPC mRNA is rapidly turned over and the window of protein expression was missed, or 
the culture methodology was not conducive to TRPC expression. If this is the case and 
they are present either in low numbers or not at all, their functional relevance in VEGF 
signalling must be questioned, given the consistent response of vascular endothelial cells to 
VEGF. Numerous studies have demonstrated TRPC channel expression in vascular 
endothelial cells (Yip et al. 2004, Antoniotti et al. 2006, Pocock et al. 2004, Tiruppathi et 
al. 2002, Riccio et al. 2002, Antoniotti et al. 2002, Hamdollah Zadeh et al. 2008, Ge et al. 
2009, Graziani et al. 2010, Song et al. 2015), yet this study was unable to confirm their 
expression. 
To add further complexity, TRPC channels exist as multimeric complexes in the plasma 
membrane. TRPCs form homo- or heteromeric complexes, typically within their related 
families e.g. TRPC1 will form complexes with TRPC4 or TRPC5 and complexes will form 
within the TRPC 3/6/7 family, although other complex combinations have been reported 
(J. Chen et al. 2009). The composition of native TRPC heteromeric complexes in vivo is 
however poorly understood. While TRPC1 is regarded to be a SOC channel, TRPCs 3 and 
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6 are regarded to be independent of calcium stores. If TRPC1 does complex with TRPCs 3 
or 6 as suggested by Chen and co-workers, TRPC1 may confer SOC sensitivity to 
otherwise SOC insensitive complexes (J. Chen et al. 2009). TRPC1 also forms complexes 
with the other TRP superfamily members TRPP2 and TRPV6 (Kobori et al. 2009, Schindl 
et al. 2012).  TRPC1 activity is also interesting given that it is not currently known whether 
TRPC1 forms homomeric channels, or acts to regulate the activity of the other TRP 
channels. With such diverse combinations of TRPC complexes possible, it is therefore not 
surprising that TRPC channels with a variety of biophysical and biological properties exist, 
which are entirely dependent upon the homo/heterogeneity of the complex (Kiselyov et al. 
2005). 
Given the difficulties in measuring the expression of TRPCs in vascular endothelial cells, 
the feasibly of pharmacologically modulating the activity of TRPCs was assessed. A 
number of compounds have been reported to selectively modulate the activity of TRPC 
channels, which we have utilised to assess the effect of VEGF-stimulation on AMPK 
Thr172 phosphorylation. 
Hyperforin, the main anti-anxiolytic and anti-depressive compound found in St. John’s 
wort has been proposed to specifically activate TRPC6 channels (Harteneck and Gollasch 
2011). HAEC were therefore stimulated with hyperforin which, rapidly stimulates the 
phosphorylation of AMPK Thr172 in a concentration dependent manner up to 5 µM. 
Activation of AMPK by hyperforin supports our hypothesis that TRPC-mediated Ca
2+
 
influx is able to stimulate AMPK activation via CaMKK. Unfortunately, hyperforin-
stimulated AMPK Thr172 phosphorylation was not affected by either the inhibition of 
CaMKK using STO-609 nor the removal of extracellular calcium. This data indicates that 
hyperforin is activating AMPK in a Ca
2+ 
and CaMKK independent manner and not via 
TRPC6 induced Ca
2+
 influx. A mechanism describing hyperforin-stimulated AMPK 
activation has been described recently in HL-60 cells (a human promyelocytic leukemia 
cell line) (Wiechmann et al. 2015). Hyperforin stimulation of HL-60 cells reduced cell 
viability by approximately 90% at concentrations above 5 µM, and caused a significant 
decrease in MTT reduction capacity by isolated mitochondria at concentrations as low as 
0.01 µM. This was demonstrated to be associated with disruption of ΔΨm and suppression 
of ATP synthesis, thought to be the stimulus for AMPK activation, but whether AMPK 
activation contributes to, or facilitates hyperforin-stimulated apoptosis in this system 
remains to be determined (Wiechmann et al. 2015). Wiechmann and colleagues 
demonstrate a 6.5-fold increase in AMPK Thr172 phosphorylation, exclusively at a 
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hyperforin concentration of 3 µM (10 min). In the present study, we demonstrate a lower, 
2.3-fold increase, which may represent a difference in hyperforin sensitivity due to the cell 
lines used (e.g. immortalised vs primary, suspension vs adherent).  
Hyperforin is therefore a poor tool for helping us determine whether VEGF-stimulated 
AMPK activation is via TRPC6-mediated Ca
2+
 influx. There are however an increasing 
number of studies utilising the compounds Pyr3 and ML-9, reported to be selective 
inhibitors of the TRPCs 3 and 6 respectively. Pyr3 is based on the structure of BTP2, an 
inhibitor of store operated calcium induced calcium release and has been reported to 
directly interact with and inhibit TRPC3 (Kiyonaka et al. 2009). Pyr3 is reported to 
significantly reduce carbamylcholine-induced Δ[Ca2+ ]i in endothelial cells derived from 
WT and TRPC1
-/-
 but not TRPC3
-/-
 mice (Kochukov et al. 2012). Despite being reported to 
be a selective inhibitor of TRPC3, it was later shown that Pyr3 also inhibits store operated 
calcium entry in Jurkat cells with a similar potency to TRPC3 (Seo et al. 2014). 
ML-9 inhibits both OAG and carbachol induced TRPC6-mediated Ca
2+
 influx with similar 
efficacy in HEK-293 cells heterologously expressing TRPC6 (Shi et al. 2007). Treatment 
of cells with 100 μM ML-9 inhibits TRPC6-mediated relative current by ~90%, however at 
100 μM, the concentration required to achieve almost complete inhibition of TRPC6 
channel conductance, ML-9 potentiates basal TRPC7 channel activity 2-3 fold (Shi et al. 
2007). In addition to this, ML-9 may have other non-specific effects as it has also been 
reported to inhibit calmodulin activity in cell free assays (Harteneck and Gollasch 2011).  
In intact cells however, due to its structure, ML-9 is unlikely to cross the plasma 
membrane and so would likely act only via effectors present on the extracellular surface of 
the plasma membrane. 
Despite the limitations of using these compounds, modulation of TRPC activity using Pyr3 
is reported to have direct effects on vascular function, cell proliferation resulting in vessel 
remodelling, and cardiac hypertrophy. Pyr3 inhibited bradykinin-stimulated nitric oxide 
production and vasodilation in primary porcine coronary arteries. In addition, exposure of 
porcine coronary artery endothelial cells to hypoxia/re-oxygenation inhibited TRPC 
translocation to the plasma membrane and Ca
2+
 influx, proposed to underlie impaired NO 
production and vasodilation after ischemia-reperfusion (Yang et al. 2011). Pyr3 also 
demonstrated a concentration-dependent anti-proliferative effect on human coronary 
arterial smooth muscle (HCASM) cells (0.1-10 μM), an effect that was not observed in 
HMVEC across the same concentration range (Koenig et al. 2013). Significantly higher 
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TRPC3 expression was detected in human coronary artery smooth muscle cells compared 
to MVEC such that it has been suggested that TRPC3 may be a therapeutic target for 
preventing the development of neointimal hyperplasia after percutaneous coronary 
intervention (Koenig et al. 2013). Furthermore, Pyr3 suppressed pathological cardiac 
hypertrophy in response to pressure-overload in vivo (Seo et al. 2014). The use of ML-9 as 
a therapeutic agent is not possible due to systemic complications and non-specific effects 
on other kinases in whole organisms (Shen et al. 2010), however TRPC6 selective 
modulators are being developed that would allow greater insight into the function of 
TRPC6 channel activity (Urban et al. 2012). 
Using a similar approach to Harteneck and colleagues, we had intended to use hyperforin 
as a positive control for measuring the degree of ML-9-mediated TRPC6 inhibition, 
however due to the non-TRPC6 effects of hyperforin that we and others have reported, this 
was not possible. Endothelial cells treated with Pyr3 and ML-9 at concentrations 
previously reported to inhibit TRPC3 and 6, had no inhibitory effect on VEGF- or AICAR-
stimulated AMPK Thr172 phosphorylation. Pyr3 may in fact potentiate basal and VEGF-
stimulated AMPK activation. At this time given the tools available, we are not able to 
conclude definitively whether TRPCs 3 and 6 are required, but neither can we rule out a 
role for them in the mechanism of VEGF-stimulated AMPK activation. 
4.3.2  NAADP -mediated Ca2+ mobilisation from acidic organelles 
Extracellular stimuli stimulate the synthesis of the well characterised Ca
2+ 
mobilising 
second messengers IP3 and cyclic ADP-ribose (cADPR) in addition to the less well 
characterised nicotinic acid adenine dinucleotide (NAADP) (Galione et al. 2010). NAADP 
differs from the co-factor NADP only by the substitution of the nicotinamide group for 
nicotinic acid, this substitution however confers potent Ca
2+
 mobilising qualities not 
possessed by NADP. The mechanism and regulation of NAADP synthesis in vitro has not 
been determined empirically, but the best hypothesis suggests an ADP-ribosyl cyclase 
(specifically CD38)-mediated ‘base-exchange’ mechanism (Aarhus et al. 1995), whereby: 
 
CD38 has been reported to catalyse the synthesis of NAADP in vitro via the base-exchange 
mechanism, but whether CD38 and base-exchange contribute to the in vivo synthesis of 
NAADP however is still to be determined. In vivo, the de-amination of NADP
+ 
or 
NADP + nicotinic acid 
ADP-ribosyl cyclases?
  NAADP + nicotinamide 
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phosphorylation of NAAD
+
 represent mechanisms of NAADP synthesis that have not yet 
been excluded (Soares et al. 2007). 
NAADP, much like IP3 and cADPR, triggers Ca
2+ 
release by binding to and opening Ca
2+
 
channels on intracellular organelles. Unlike IP3 and cADPR, which stimulate Ca
2+
 release 
from the endoplasmic reticulum (via IP3R and the ryanodine receptor (RyR) respectively), 
NAADP specifically mobilises Ca
2+ 
from acidic stores such as endosomes and lysosomes, 
via two-pore channel (TPC) activation (Pitt et al. 2010). Three isoforms of TPCs exist 
(TPCs 1-3) however these isoforms exhibit differential organelle distribution; TPC1 is 
widely distributed throughout the endo-lysosomal system whereas while TPC2 expression 
is restricted to the late endo/lysosome (Calcraft et al. 2009). Ca
2+ 
uptake into acidic 
organelles is best characterised in yeast and plants and occurs via a thapsigargin insensitive 
high affinity Ca
2+
-ATPase, and a low affinity Ca
2+
/H
+
 antiporter. In higher organisms 
however the mechanism is less clear but is usually thapsigargin independent, and 
dependent on H
+
 gradient. 
NAADP/TPC-mediated Ca
2+ 
release may further contribute to global Ca
2+ 
signalling via 
localised cross-talk with other Ca
2+
 mobilisation mechanisms when in close proximity. 
Ca
2+
 release from acidic organelles can act as a trigger for calcium induced calcium release 
from the sarco/endoplasmic reticulum, potentially dependent on IP3/cADPR. Additionally 
the release of Ca
2+
 from acidic organelles in close proximity to the plasma membrane 
could stimulate extracellular Ca
2+
 influx via Ca
2+
-activated plasma membrane channels. 
Recent published data demonstrates that the cell-permeant, selective NAADP antagonist 
Ned 19 inhibits VEGF-induced neoangiogenic processes in HUVEC (Favia et al. 2014). 
The authors reported that VEGF-R activation leads to NAADP synthesis, and two pore 
channel (TPC)-mediated (specifically TPC2) Ca
2+
 release from acidic Ca
2+
 stores. 
Furthermore, VEGF-stimulated phosphorylation of ERK1/2, JNK, Akt and eNOS in 
HUVEC was prevented by prior-treatment with 100 µM Ned 19 (Favia et al. 2014). The 
authors proposed that NAADP-dependent Ca
2+
 mobilisation is mediating the angiogenic 
effects of VEGF in HUVEC via these signalling mediators. 
Given the dependence of Ca
2+
 in AMPK activation by VEGF (Reihill 2009), we assessed 
the effect of NAADP antagonism with Ned 19 on VEGF-stimulated AMPK Thr172 
phosphorylation in HUVEC. Using the reported concentration and duration of Ned 19 pre-
treatment (100 µM, 30 min) and duration of VEGF treatment (15 min), Ned 19 pre-
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treatment caused a significant decrease in VEGF-stimulated Akt (Ser473) and ERK1/2 
(Thr183/Tyr185) phosphorylation, whereas pre-treatment of HUVEC with Ned 19 had no 
effect on VEGF-stimulated phopsho-p38 MAPK; these results are in agreement with 
previous reports (Favia et al. 2014). In contrast to previous findings however, VEGF did 
not stimulate the phosphorylation of JNK (Thr183/Tyr185. The role of JNK in regulating 
the effects of VEGF is debated. It has been suggested that growth factor stimulated 
angiogenesis requires ERK1/2 activation and subsequent ERK1/2-stimulated JNK 
activation, and that JNK acts as the final effector of VEGF-stimulated angiogenesis 
(Pedram et al. 1998). On the other hand studies have also demonstrated the inhibition of 
stress (serum withdrawal or ceramide) induced JNK phosphorylation by VEGF (Gupta et 
al. 1999). 
Ned 19 pre-treatment had no effect on VEGF-stimulated phosphorylation of the PKC 
substrate MARCKS (Ser152/156), nor AMPK Thr172 phosphorylation. This data showing 
that phosphorylation of the PKC substrate MARCKS is not affected by NAADP 
antagonism is interesting given that classical PKC isoforms are stimulated by VEGF and 
are Ca
2+
 regulated. It must be noted however that MARCKS is also a substrate for Ca
2+
-
independent PKC isoforms, therefore identifying unique substrates of the Ca
2+
-dependent 
PKCs may be of benefit in elucidating any VEGF/NAADP/Ca
2+
/classical PKC signalling 
axis. As reported previously (Reihill 2009) and replicated later (Figure 5-1), VEGF-
stimulated AMPK Thr172 phosphorylation is rapid and transient, with phospho-Thr172 
levels returning to basal levels 10-15 min after the addition of VEGF. It is therefore not 
surprising that VEGF-stimulated AMPK Thr172 phosphorylation was increased, but not 
significantly so above basal levels after 15 min of VEGF treatment. To address this, cells 
were pre-treated with Ned 19 as before, however VEGF was added for only 5 min prior to 
the preparation of cell lysates. VEGF retains the ability to stimulate the phosphorylation of 
AMPK Thr172 in the presence of Ned 19 after a relevant duration of VEGF treatment. 
This suggests that VEGF-stimulated AMPK activation is not dependent on Ca
2+
 
mobilisation from acidic organelles stimulated by NAADP. 
A major limitation of NAADP biology is that the mechanism coupling cell-surface 
receptor activation and stimulation of NAADP synthesis has not yet been determined. To 
our knowledge, no mechanistic link between VEGF-R2 activation and NAADP synthesis 
has been described. To determine the role of acidic Ca
2+
 mobilisation in VEGF-stimulated 
AMPK activation, the lysolytic agent GPN (glycyl-l-phenylalanine-β-naphthylamide) 
could be utilised to assess VEGF-stimulated AMPK activation under conditions where the 
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endo/lysosomal acidic stores have been disrupted. It may also be prudent to test the effect 
of Ned 19 at lower concentrations although low nanomolar concentrations of Ned 19 (1-
100 nM) have been shown to activate TPCs in cardiomyocytes in a dose dependent manner 
(Pitt et al. 2010). Treatment of cardiomyoctes with 1 µM Ned 19 completely shuts TPCs, a 
concentration one hundred times lower than that used presently. At a concentration of 100 
µM, Ned 19 has been shown to significantly reduce the Ca
2+
 content of the sarcoplasmic 
reticulum of cardiomyocytes to a similar extent as treatment with 10 µM ryanodine, or pre-
emptying the SR of Ca
2+ 
with both caffeine and thapsigargin (10 mM and 100 nM 
respectively) (Pitt et al. 2010, Davidson et al. 2015). Ned 19 at higher concentrations may 
therefore have off-target effects on Ca
2+ 
handling, which may explain some of the findings 
by (Favia et al. 2014) given than EKR1/2, Akt, eNOS and JNK can be regulated via Ca
2+
 
dependent mechanisms. 
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4.4 Conclusion 
TRPC channels represent a large family of proteins which exhibit differential expression 
among a variety of different cell types, even within a single cell type when cultured under 
different conditions. TRPCs are not essential for the development of a mature functional 
vasculature given the development of viable KO mouse strains, but may be involved in 
responding to chemical or physical insult such as growth factor stimulation. However, 
attributing an effect to a specific TRPC isoform is made problematic by the difficulties in 
assessing both native and homologous TRPC expression, and the degree to which TRPC 
channels form hetero/homomeric complexes: TRPC channels forming heteromeric 
complexes have been shown to differ in their electrophysical properties based upon the 
subunit composition of the complex. TRPC channels are regulated via multiple, complex 
and overlapping mechanisms: Gα/q, PIP2, IP3, DAG, IP3Rs, fatty acids and their metabolites 
and intracellular Ca
2+
-store depletion. Due to the interwoven nature of these signalling 
mechanisms, it may not be possible to resolve them sufficiently to characterise the 
mechanism resulting in AMPK activation by VEGF. 
VEGF-stimulated AMPK activation has previously been shown to be dependent on Ca
2+ 
influx, and independent of IP3R antagonism and thapsigargin-mediated depletion of Ca
2+
 
stores (Reihill et al. 2011), however NAADP-mediated Ca
2+
 release was not considered in 
these previous experiments. The present study has assessed the effect of NAADP 
antagonism on VEGF-stimulated AMPK activation and concludes that NAADP-mediated 
Ca
2+
 mobilisation is not mediating VEGF-stimulated AMPK activation. 
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Chapter 5 - Regulation of AMPK activity by PKC 
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5.1 Introduction 
VEGF has previously been demonstrated to activate AMPK in a CaMKK-dependent 
manner (Reihill et al. 2007). In addition to phosphorylation at the activating Thr172, recent 
studies have shown that AMPK can also be phosphorylated at α1 Ser485/α2 Ser491 
(Woods et al. 2003b). Phosphorylation of AMPK α at Ser485/491 is reported to be 
associated with reduced Thr172 phosphorylation and AMPK activity, so can be thought of 
as an inhibitory regulation mechanism (Horman et al. 2006, Hawley et al. 2014). Several 
studies have reported that Akt activation by insulin or IGF-1 stimulates AMPK Ser485 
phosphorylation, and Akt has since been validated as a bona fide AMPK α1 Ser485 kinase 
(Horman et al. 2006, Soltys et al. 2006, Berggreen et al. 2009, Ning et al. 2011). AMPK α2 
Ser491 has more recently been shown to be a poor Akt substrate in vitro and 
phosphorylation of this residue is therefore more likely to result from AMPK auto-
phosphorylation (Hawley et al. 2014). 
Further studies have also reported that inhibition of PKA, IKK and MEK-ERK1/2 
attenuate AMPK Ser485 phosphorylation (Hurley et al. 2006, Park et al. 2014, Lopez-
Cotarelo et al. 2015). The angiogenic effects of VEGF are effected via multiple signalling 
cascades including Akt and ERK1/2. Together these findings suggest that VEGF may be 
an endogenous AMPK activator which stimulates both activating Thr172 and inhibitory 
Ser485 phosphorylation, via CaMKK and Akt or ERK1/2 respectively. The current study 
therefore aimed to characterise the effect of VEGF on AMPK regulation by 
phosphorylation at both the activating Thr172 and inhibitory Ser485/491 residues. 
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5.2 Results 
The effect of VEGF on the phosphorylation of AMPK α Thr172 and Ser485/491 over 30 
min was assessed in the human vascular endothelial cells HAEC and HUVEC. In HAEC, 
VEGF stimulation caused a rapid but transient increase in both Thr172 and Ser485/491 
phosphorylation over the 30 min duration of the experiment (Figure 5-1A). AMPK α 
Thr172 phosphorylation was significantly increased 2, 5 and 10 min after the addition of 
VEGF, with maximal (5-fold) increase in Thr172 phosphorylation measured after 5 min of 
VEGF treatment. By 15 min, Thr172 phosphorylation was no longer significantly elevated 
and at 20 min had returned to basal levels (Figure 5-1Aii). AMPK α1/2 Ser485/491 
phosphorylation in response to VEGF-treatment mimicked the time course of Thr172 
phosphorylation and maximal α Ser485/491 phosphorylation was observed between 5 and 
10 min of VEGF treatment (4-fold increase). Elevated AMPK α Ser485/491 
phosphorylation was maintained for 20 min, before returning to basal levels 30 min after 
the addition of VEGF. AMPK α1 specific Ser485 phosphorylation was found to have 
similar kinetics to that of AMPK α1/2 Ser485/491 in response to VEGF (Figure 5-1Ai). 
The effect of VEGF treatment over time on AMPK phosphorylation in HUVEC was also 
assessed (Figure 5-1B). A rapid and transient increase in AMPK α phosphorylation was 
observed for both Thr172 and Ser485 in HUVEC which mimicked that observed in HAEC 
(Figure 5-1A). 
VEGF mediates some of its angiogenic effects via ERK1/2 and Akt. Therefore the effect of 
VEGF on ERK1/2 Tyr204/Thr202 and Akt Ser473 phosphorylation over time in HAEC 
was assessed. ERK1/2 phosphorylation was increased 3-fold (p<0.05) after 5 min of VEGF 
treatment with maximal phosphorylation observed between 5 and 10 min (Figure 5-2ii). 
ERK1/2 phosphorylation was submaximal 15 min after the addition of VEGF, but did not 
return to basal levels within the time course of this experiment. Akt phosphorylation was 
significantly increased after 10 min of VEGF treatment, and increased further 15 min after 
the addition of VEGF (Figure 5-2iii). The time taken to reach maximal Akt 
phosphorylation and return to basal levels was not determined over the course of this 
particular experiment. 
Data presented in Chapter 4 of this study and elsewhere (Reihill et al. 2007, Reihill 2009), 
describes evidence for a PLCγ, extracellular Ca2+ and CaMKK-mediated mechanism of 
AMPK activation by VEGF, yet the mechanism of VEGF-stimulated AMPK 
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phosphorylation at Ser485/491 remains uncharacterised. Akt and ERK1/2 have previously 
been identified as AMPK Ser485 kinases (Hawley et al. 2014, Lopez-Cotarelo et al. 2015). 
VEGF stimulates both ERK1/2 and Akt (Figure 5-2), therefore the effect of Akt and 
ERK1/2 inhibition on AMPK α Ser485/491 phosphorylation in HAEC was assessed. 
Inhibition of Akt and ERK1/2, as indicated by the complete ablation of Akt Ser473 and 
ERK1/2 Thr202/Tyr204 phosphorylation with Akti-1/2 and PD184352 respectively had no 
effect on the phosphorylation of AMPK α1/2 at Ser485/491 or Thr172 in response to 
VEGF (Figure 5-3). To assess further the effect of Akt inhibition on VEGF-stimulated 
AMPK Ser485 phosphorylation, the PI3K inhibitor wortmannin was utilised. Pre-treatment 
of HUVEC with wortmannin significantly reduced Akt Ser473 phosphorylation in both the 
presence and absence of VEGF (Figure 5-4i) however inhibition of PI3K activity had no 
effect on basal or VEGF-stimulated AMPK α1 Ser485 phosphorylation (Figure 5-4ii) 
indicating that Akt is not necessary for AMPK α1 Ser485 phosphorylation. VEGF 
treatment (10 ng/mL, 5 min) however robustly stimulated AMPK α1 Ser485 
phosphorylation in these cells. To determine whether activation of Akt is sufficient to 
stimulate the phosphorylation of AMPK α1 Ser485 in EC, HAEC were treated with 
insulin, a known activator of Akt which has previously been reported to stimulate AMPK 
Ser485 phosphorylation in other tissues (Horman et al. 2006, Berggreen et al. 2009). 
Insulin (1 µM) robustly stimulated the phosphorylation of Akt Ser473 at all the time points 
assessed (5-30 min) (Figure 5-5), without also stimulating AMPK α1 Ser485 
phosphorylation. 
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Figure 5-1 
Figure 5-1: VEGF stimulates both AMPK α Thr172 and Ser485/491 phosphorylation in HAECs and 
HUVECs 
A. HAEC were stimulated with 10 ng/mL VEGF for the times indicated before cell lysates were prepared. 
Proteins were resolved by SDS-PAGE and immunoblotting using the antibodies indicated.                                 
Ai. A representative blot is shown and ii. densitometric quantification of immunoblots from three 
independent experiments. B. HUVECs were stimulated with 10 ng/mL VEGF for the times indicated before 
cell lysates were prepared. Proteins were resolved by SDS-PAGE and immunoblotting using the antibodies 
indicated. A representative immunoblot is shown with similar results observed on two further occasions. The 
migration of molecular mass markers is indicated on the right. *p<0.05, **p<0.01 and ***p<0.001 relative to 
time 0. 
Ai. 
ii. 
B. 
ii. 
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Figure 5-2 
Figure 5-2: VEGF stimulates both ERK1/2 Thr202/Tyr204 and Akt Ser473 phosphorylation in HAECs 
HAEC were stimulated with 10 ng/mL VEGF for the times indicated prior to the preparation of cell lysates. 
Proteins were resolved by SDS-PAGE and immunoblotted with the antibodies indicated. i. A representative 
blot is shown with the migration of molecular mass markers indicated on the right.. ii. and iii. Densitometric 
quantification of immunoblots from three independent experiments *p<0.05 and **p<0.01 relative to time 0. 
i. ii. iii. 
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Figure 5-3 
Figure 5-3: VEGF-stimulated AMPK α Thr172 and Ser485/491 phosphorylation is independent of Akt 
and ERK1/2 
HAECs were pre-incubated in the presence or absence of 1 µM Akti-1/2 (Akt inhibitor) or PD184352 (MEK 
inhibitor) for 60 min prior to VEGF stimulation (10 ng/mL, for the times indicated). Cell lysates were 
prepared, proteins resolved by SDS-PAGE and immunoblotted with the antibodies indicated. A 
representative immunoblot is shown with the migration of molecular mass markers indicated on the right. 
Immunoblot shown is representative of three independent experiments, with similar results. 
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Figure 5-4 
Figure 5-4: Wortmannin has no effect on VEGF-stimulated AMPK α1 Ser485 phosphorylation 
HUVEC were pre-incubated with 100 nM wortmannin for 45 min prior to stimulation with 10 ng/mL VEGF 
(5 min). Cell lysates were prepared and subjected to SDS-PAGE/immunoblotting with the antibodies 
indicated. i. A representative blot is shown with the migration of molecular mass markers indicated on the 
right, and ii-iii. Densitometric analysis of immunoblots from three independent experiments. Data represents 
mean band intensity relative to VEGF-stimulated in the absence of inhibitor. ***p<0.001 relative to absence 
of VEGF, $$$p<0.001 relative to absence of wortmannin. 
i. 
ii. iii. 
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Figure 5-5 
Figure 5-5: Insulin-mediated Akt activation has no effect on AMPK α1 Ser485 phosphorylation 
HAECs were stimulated with 1 μM insulin for the times indicated, or 10 ng/mL VEGF for 5 min. Cell lysates 
were prepared and proteins resolved by SDS-PAGE/immunoblotting with the antibodies indicated. 
Representative immunoblots are shown, repeated on two further occasions with similar results. 
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As VEGF has previously been demonstrated to activate AMPK in a CaMKK-dependent 
manner (Reihill et al. 2007) and AMPK α2 has previously been reported to auto-
phosphorylate at Ser491 (Hawley et al. 2014), HUVEC were pre-treated with the CaMKK 
inhibitor STO-609 prior to stimulation with VEGF or AICAR. As has been shown 
previously (Reihill et al. 2007), STO-609 pre-treatment inhibited VEGF-stimulated AMPK 
Thr172 phosphorylation, and furthermore had no effect on AICAR-stimulated Thr172 
phosphorylation (Figure 5-6ii). AICAR tended to increase Ser485 phosphorylation in both 
the presence and absence of STO-609, however this did not reach statistical significance. 
As previous studies indicated that removal of extracellular Ca
2+
 ablated VEGF-stimulated 
AMPK activation (Figure 4-6), the dependence of VEGF-stimulated Ser485 
phosphorylation on Ca
2+
 influx was determined. HAEC were depleted of extracellular Ca
2+
 
by incubation in KRH, or KRH without Ca
2+ 
and the addition of 1 mM EGTA, prior to 
VEGF or AICAR stimulation. VEGF- but not AICAR-stimulated AMPK Thr172 
phosphorylation was prevented by the depletion of extracellular Ca
2+
 (Figure 5-7ii) in 
agreement with previous reports (Reihill 2009) and Figure 4-6. VEGF-stimulated Ser485 
phosphorylation was similarly prevented by prior depletion of extracellular calcium 
whereas AICAR-stimulated Ser485 phosphorylation was not affected by the removal of 
extracellular calcium (Figure 5-7iii). 
In order to characterise the role of intracellular calcium in AMPK Ser485 phosphorylation, 
HUVEC were pre-treated with the membrane permeant Ca
2+ 
chelator BAPTA-AM, prior to 
stimulation with VEGF. In the presence of BAPTA-AM, basal AMPK Thr172 
phosphorylation was significantly increased; this was not further enhanced by VEGF 
treatment (Figure 5-8ii). The addition of BAPTA-AM tended to increase VEGF-stimulated 
AMPK Ser485 phosphorylation but this did not reach statistical significance (Figure 
5-8iii). 
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Figure 5-6 
Figure 5-6: VEGF-stimulated AMPK α1 Ser485 phosphorylation is insensitive to STO-609 
HAEC were incubated in the presence or absence of 10 µM STO-609 for 60 min prior to stimulation with 
VEGF (10 ng/mL, 5 min) or AICAR (2 mM, 45 min). HAEC lysates were prepared, proteins resolved by 
SDS-PAGE and immunoblotted with the antibodies indicated. i. A representative immunoblot is shown. The 
migration of molecular mass markers is indicated on the right, and this was repeated with similar results on 
two further occasions. ii and iii. Densitometric quantification of immunoblots from three independent 
experiments displaying mean ± SEM. * p<0.05 and *** p<0.001 compared to absence of VEGF, $$ p<0.01 
compared to absence of STO-609. 
Vehicle 
STO-609 
Vehicle 
STO-609 
i. 
ii. 
iii. 
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Figure 5-7 
Figure 5-7: VEGF-stimulated AMPK α1 Ser485 phosphorylation is sensitive to Ca2+ removal 
HAEC were incubated in the presence or absence of extracellular Ca
2+
 for 60 min, prior to stimulation with 
VEGF (10 ng/mL, 5 min) or AICAR (2 mM, 45 min). HAEC lysates were prepared, proteins resolved by 
SDS-PAGE and immunoblotted with the antibodies indicated. i. A representative immunoblot is shown. The 
migration of molecular mass markers is indicated on the right, and this was repeated with similar results on 
two further occasions. ii and iii. Densitometric quantification of immunoblots from three independent 
experiments displaying mean ± SEM. *p<0.05, **p<0.01 and ***p<0.001 compared to absence of 
VEGF/AICAR, ††p<0.01 compared to KRH. 
i. 
ii. 
iii. 
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Figure 5-8 
Figure 5-8: Effect of Ca
2+
 chelation on VEGF-stimulated AMPK phosphorylation 
HUVEC were incubated in the presence or absence of 25 μM BAPTA-AM for 25 min, prior to stimulation 
with VEGF (10 ng/mL, 5 min). Cell lysates were prepared, proteins resolved by SDS-PAGE and 
immunoblotted with the antibodies indicated. i. A representative immunoblot is shown. The migration of 
molecular mass markers is indicated on the right, and this was repeated with similar results on two further 
occasions. ii. and iii. Densitometric quantification of immunoblots from three independent experiments 
displaying mean ± SEM. *p<0.05, **p<0.01 compared to absence of BAPTA-AM, ††p<0.01 compared to 
absence of VEGF. 
i. 
ii. 
iii. 
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Previous data (Chapter 4) suggested a role for DAG-stimulated Ca
2+
 influx in AMPK 
activation induced by VEGF. VEGF stimulates members of the PKC family of protein 
kinases, and the conventional PKCs (α, β1/2 and γ) are regulated by DAG and Ca2+. To 
assess the effect of PKC inhibition on VEGF-stimulated AMPK α Thr172 and Ser485 
phosphorylation, selective PKC inhibitors were utilised. Prior incubation of HUVEC with 
the classical PKC inhibitor GF109203X, or the PKCβ selective inhibitor LY33531 had no 
effect on Thr172 phosphorylation stimulated by VEGF (Figure 5-9Aii) however both 
GF109203X and LY333531 significantly inhibited VEGF-stimulated Ser485 
phosphorylation (Figure 5-9Aiii). GF109203X treatment of HAEC resulted in a 40% 
increase in basal AMPK activity (p<0.05), and tended to increase AMPK activity after 
VEGF-stimulation (44% increase in mean activity) although this was not quite significant 
(§p=0.06; Figure 5-9B). To determine whether the PKC inhibitor LY333531 directly 
influences AMPK activity, immuoprecipitated AMPK was incubated in the presence or 
absence of 0.2 mmol/L AMP, and LY333531 (0.1 or 1 μM). In the presence of AMP, 
purified AMPK activity was increased approximately 2-fold (Figure 5-9C) and this was not 
further increased by the inclusion of either 0.1 or 1 µM LY333531. 
Due to the inhibitory effect of GF109203X and LY333531 on VEGF-stimulated AMPK 
Ser485 phosphorylation, the effect of PKC activation on AMPK Ser485 phosphorylation 
was subsequently assessed, using the synthetic PKC activator phorbol 12-myristate 13-
acetate (PMA) and the DAG mimetic OAG. AMPK α1 or α2 was immunoprecipitated 
from HUVEC previously stimulated with PMA or the DAG mimetic OAG, and 
phosphorylation of AMPK α1 Ser485 or α1/2 Ser485/491 was assessed (Figure 5-10). Both 
PMA and OAG stimulate α1 Ser485 phosphorylation and no immune reactive bands were 
observed in AMPK α1 immuno-depleted lysates when an antibody recognising both 
AMPK α1/2 Ser485/491 phosphorylation was used. Further to this, no α1/2 Ser485/491 
immune reactive bands were observed in AMPK α2 immuno-precipitates but were present 
in AMPK α2 immuno-depleted cell lysates. This data indicates that PKC activation 
preferentially stimulates the Ser485 phosphorylation in AMPK α1 containing complexes. 
The phosphorylation of AMPK α1 Ser485 and the PKC substrate MARCKS (Ser152/156) 
was assessed after PMA treatment for various durations. In response to 1 µM PMA, 
phosphorylation of the PKC substrate MARCKS at Ser152/156 was stimulated 8.8-fold 
(p<0.001) reaching maximal phosphorylation within 2 min (Figure 5-11). This maximal 
level of phosphorylation was maintained for the 20 min duration of this experiment (Figure 
5-11). PMA-stimulated AMPK α1 Ser485 phosphorylation was also rapidly stimulated but 
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reached maximal phosphorylation only after 10 min of PMA treatment. The time taken to 
reach 50% max PMA-stimulated phosphorylation for MARCKS and AMPK α1 Ser485 
were 1.0 and 2.6 min respectively. 
To assess the sensitivity of both VEGF- and PMA-stimulated AMPK Ser485 
phosphorylation to PKC inhibition, HUVEC were pre-treated with increasing 
concentrations of LY333531 for 60 min prior to stimulation with VEGF or PMA. 
Phosphorylation of AMPK α1 Ser485 and MARCKS Ser152/156 was then assessed. PMA 
(1 µM) stimulated the phosphorylation of both AMPK α1 Ser485 and MARCKS 
Ser152/156 to a greater extent than 10 ng/mL VEGF (Figure 5-12i). LY333531 
concentration-dependent inhibition of VEGF-stimulated AMPK α1 Ser485 and MARCKS 
was remarkably similar with an IC50 value of ~0.1-0.15 µM (Figure 5-12ii). Significant 
inhibition of VEGF-stimulated AMPK Ser485 and MARCKS Ser152/156 phosphorylation 
was measured at all concentrations of LY333531 tested (0.1-1 µM; Figure 5-12ii). In 
contrast, PMA-stimulated AMPK α1 Ser485 and MARCKS phosphorylation had IC50 
values of ~0.1 and ~0.4 µM respectively (Figure 5-12iii). Inhibition of PMA-stimulated 
AMPK α1 Ser485 phosphorylation was inhibited by all concentrations tested (p<0.001) 
whereas significant inhibition of PMA-stimulated MARCKS was only measured at 
LY333531 concentrations ≥0.5 µM (Figure 5-12iii). 
Previous reports have suggested that, in certain cell lines (typically immune cells), PMA 
indirectly stimulates Akt activation (usually as assessed by increased Akt Ser473 or 
Thr308 phosphorylation) (Kawakami et al. 2004, Barragan et al. 2006, Douda et al. 2014). 
To assess whether PMA effects Akt phosphorylation, HUVEC were pre-treated with Akti 
or wortmannin, prior to stimulation with PMA or insulin. Insulin stimulated a robust 
increase in both Akt Thr308 and Ser473 phosphorylation (Figure 5-13A) which was 
ablated by prior treatment with either Akti or wortmannin. Similarly to VEGF (Figure 5-3 
and Figure 5-4), PMA stimulation robustly increased AMPK Ser485 phosphorylation and 
this was not affected by either Akti or wortmannin treatment. PMA treatment in the 
absence of Akti or wortmannin actually reduced the intensity of phospho-Akt Thr308 and 
Ser473 immuno-reactive bands (Figure 5-13A). Furthermore, increasing the duration 
(Figure 5-13B) or concentration (Figure 5-13C) of PMA treatment results in the concurrent 
increase in AMPK Ser485 and reduced Akt Ser473 phosphorylation. 
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Figure 5-9 
Continued on facing page… 
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Figure 5-9: PKC inhibitors ablate VEGF-stimulated AMPK α1 Ser485 phosphorylation and stimulate 
AMPK activity 
A. HUVEC or B. HAEC were pre-incubated in the presence or absence of either 1 μM GF109203X (GFX) or 
LY333531 (LY3) for 1 hr prior to stimulation with VEGF (10 ng/mL, A. 5 min or B. 10 min). Cell lysates 
were prepared and A. subjected to SDS-PAGE and immunoblotting with the antibodies indicated, or B. 
AMPK immunoprecipitated and assayed for AMPK activity. Ai. Representative immunoblots are shown with 
the migration of molecular mass markers indicated on the right. ii. and iii. Densitometric quantification of 
immunoblots from three independent experiments. Data are expressed relative to VEGF-treated HUVECs in 
the absence of inhibitor. ††p<0.01 phospho-Thr172 relative to absence of VEGF, #p<0.05 phospho-Ser485 
relative to absence of VEGF and ***p<0.001 relative to absence of PKC inhibitor. B. AMPK activity from 
five independent experiments. *p<0.05 relative to absence of PKC inhibitor, §p=0.06 relative to absence of 
VEGF. C. AMPK α1 was immunoprecipitated and activity was assayed in the presence or absence of AMP 
and LY333531 at the concentrations indicated. Data represents results from three independent experiments. 
C. 
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Figure 5-10 
Figure 5-10: PKC activators preferentially stimulate AMPK α1 Ser485 phosphorylation 
HUVEC were stimulated with 1 μM PMA or 100 μM OAG for 20 min prior to cell lysis. AMPK was 
immunoprecipitated (IP) using anti-AMPK α1 or anti-AMPK α2 antibodies. i. The AMPK immune-
precipitate (P) and immune-depleted lysate (D) samples were subjected to SDS-PAGE and immunoblotting 
with the antibodies indicated. ii. Densitometric quantification of immunoprecipitate (P) immunoblots from 
two independent experiments.   
i. 
ii. 
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Figure 5-11 
Figure 5-11: PKC activators stimulate AMPK α1 Ser485 phosphorylation 
HUVEC were stimulated with PMA (1 µM) for the indicated durations and lysates prepared. Proteins were 
resolved by SDS-PAGE and immunoblotted using the antibodies indicated. i. representative blots are shown 
with the migration of molecular mass markers indicated on the right, and ii. Densitometric quantification of 
immunoblots. Data represents mean ± SEM relative to 20 min of treatment, for three independent 
experiments in each case. ***p<0.001 for phospho-MARCKS and †††p<0.001 for phospho-Ser485 relative 
to absence of PMA stimulation. 
i. ii. 
H. R. Heathcote (2016)  Chapter 5 – Results 155 
Figure 5-12 
Figure 5-12: The sensitivity of VEGF- and PMA-stimulated AMPK α1 Ser485 and MARCKS 
phosphorylation to PKC inhibition by LY333531  
HUVEC were pre-treated with the indicated concentrations of LY333531 for 1 hour prior to stimulation with 
VEGF (10 ng/mL, 5 min) or PMA (1 µM, 20 min). Lysates were resolved by SDS-PAGE and immunoblotted 
using the antibodies indicated. i. representative blots are shown with the migration of molecular mass 
markers indicated on the right. ii-iv. Densitometric quantification of immunoblots. iv. Dashed line indicates 
the plasma concentrations achieved in previous studies and indicate AMPK α1 Ser485 phosphorylation at 
this level. Data represents mean ± SEM relative to % max phosphorylation for three independent 
experiments. **p<0.01 and ***p<0.001 for phospho-MARCKS, †††p<0.001 for phosphor-Ser485 relative to 
absence of LY333531. 
i. 
iv. 
ii. iii. 
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Figure 5-13 
Figure 5-13: PMA does not stimulate Akt phosphorylation at either Thr308 or Ser473 
A. HUVEC were pre-incubated with 1 µM Akti-1/2 (A) or 100 nM wortmannin (W) prior to stimulation with 
1 µM PMA, or 1 μM insulin for a further 15 min. B. HUVEC were stimulated with 1 µM PMA for the times 
indicated or C. with the indicated concentration of PMA for 20 min. Cell lysates were prepared and proteins 
resolved by SDS-PAGE/immunoblotting using the antibodies indicated. Immunoblots shown are 
representative of A. two, B and C. single experiments respectively The migration of molecular mass markers 
is indicated on the right. 
A.  
B. 
C. 
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Data to this point indicates that PKC activation stimulates AMPK α1 Ser485 
phosphorylation independently of Akt. To assess the ability of PKC to phosphorylate 
AMPK in vitro, commercially purified PKC (reported by the manufacturers to be primarily 
α, β and γ, with lesser amounts of δ and ζ) was incubated with immuoprecipitated kinase-
inactive AMPK α1 in the presence of phosphatidylserine (PtdSer) and Ca2+. PKC 
phosphorylates AMPK α1 Ser485 in vitro with similar efficiency to a comparable number 
of units of active recombinant human Akt (Figure 5-14). 
The PKC family of protein kinases in humans consists of at least 15 members. To identify 
the PKC isoform(s) involved in the regulation of AMPK activity, HAEC and HUVEC 
were cultured overnight in the presence of 200 nM PMA prior to the preparation of cell 
lysates and immunoblotting with PKC isoform specific antibodies. Chronic PMA treatment 
downregulated the expression of PKC α, β1, γ, η, θ and µ, whereas PKC δ expression was 
unaffected (Figure 5-15A and B). PKC β2, ε, ζ and λ were not detected in endothelial cell 
lysates (data not shown). Upon determining the PKC isoforms downregulated by chronic 
PMA, HUVEC were then exposed to chronic PMA overnight, prior to stimulation with 
VEGF, AICAR, A769662 or OAG (Figure 5-15B). After PMA treatment PKC β1 and pan 
immune-reactive bands were significantly reduced in endothelial cell lysates, to a level that 
was approximately 2 % of basal expression (p<0.001; Bii and iii). Down regulation of 
active PKC was indicated by significantly reduced VEGF-stimulated MARCKS 
phosphorylation after chronic PMA treatment (Figure 5-16Biv). Chronic PMA treatment 
also caused a significant reduction in both VEGF- and OAG-stimulated AMPK α1 Ser485 
phosphorylation (Figure 5-16Bv). AICAR treatment stimulated an increase in AMPK α1 
Ser485 phosphorylation which was not effected by PKC depletion, and AICAR did not 
affect phospho-MARCKS. A769662 did not alter the phosphorylation of AMPK at α1 
Ser485, nor MARCKS Ser152/156. 
siRNA-mediated downregulation of PKC α by 90 % was measured, (Figure 5-16i and ii), 
however significant knockdown of PKC α did not affect VEGF-stimulated AMPK α1 
Ser485 phosphorylation (Figure 5-16iv). Intriguingly, downregulation of PKC α also 
caused a significant reduction in PKC β1 expression (Figure 5-16iii). Conversely, 
overexpression of PKC α or β1 (2.6-fold and 3.9-fold respectively, p<0.001; Figure 5-17i 
and ii) in HeLa was sufficient to significantly increase basal AMPK α1 Ser485 
phosphorylation in the absence of a stimulus (Figure 5-17iii). Overexpression of PKC β2 
tended to increase AMPK Ser485 phosphorylation however increased PKC β2 protein 
levels were not observed. 
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Figure 5-14 
Figure 5-14: In vitro phosphorylation of AMPK by PKC and Akt 
Immunoprecipitated AMPK α1 (kinase-inactive) was incubated in the presence of calf intestine alkaline 
phosphatase (CIAP) for 30 min at 30 °C prior to extensive washing. Immunoprecipitated AMPK α1 was then 
incubated with purified rat brain PKC, or recombinant Akt1 (with the indicated units of activity) for 30 min 
at 30 °C in the presence of Ca
2+
 and phosphatidyl serine (PtdSer). i. Proteins were resolved by SDS-PAGE 
and analysed by immunoblotting with the antibodies indicated. Blot shown is representative of two 
independent experiments. The migration of molecular mass markers is indicated on the right and ii. 
densitometric quantification of immunoblots from i.  
This experiment was performed by Dr Ian Salt. 
ii. 
i. 
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Figure 5-15 
Figure continues on facing page… 
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Figure 5-15: Chronic down regulation of PKC prevents VEGF-stimulated α1 Ser485 phosphorylation 
A. HUVEC or HAEC, or B. HUVEC were cultured for 20 h in the presence of 200 nM PMA (cPMA) A. 
prior to lysis, or B. stimulation with VEGF (10 ng/mL, 5 min), AICAR (2 mM 45 min), A769662 (100 µM 
60 min) or OAG (100 µM, 20 min). Cell lysates were prepared and subjected to immunoblotting with the 
antibodies indicated. A. and Bi. Representative immunoblots are shown with the migration of molecular mass 
markers indicated on the right, and Bii-vi Densitometric quantification of immunoblots from three 
independent experiments (Veh = vehicle). *p<0.05, **p<0.01 and ***p<0.001 relative to absence of cPMA 
pre-treatment and † p<0.05, †† p<0.01 and †††p<0.001 relative to absence of VEGF or OAG as indicated. 
Bii. iii. 
iv. 
v. 
vi. 
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Figure 5-16 
Figure 5-16: siRNA-mediated downregulation of PKC α has no effect on VEGF-stimulated AMPK α1 
Ser485 phosphorylation 
HUVEC were treated with 200 nM siRNA targeting PKCα for 48 hours prior to stimulation with VEGF     
(10 ng/mL) for 5 min. Cell lysates were prepared and subjected to SDS-PAGE/immunoblotting with the 
antibodies indicated. i. Blots shown are representative of three independent experiments with the migration 
of molecular mass markers indicated on the right, and ii-iv. Densitometric quantification of i. *p<0.05, 
**p<0.01 and ***p<0.001 relative to scrambled siRNA treated cells in the presence of VEGF. (TR = 
transfection reagent with no siRNA). 
iv. 
iii. 
i. 
ii. 
* 
*** 
*** *** 
** ** 
** 
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Figure 5-17 
Figure 5-17: Overexpression of PKC is sufficient to increase basal AMPK α1 Ser485 phosphorylation 
HeLa were transfected with 2 µg plasmid DNA/well in a 6 well plate, 24 hours prior to cell lysis. Cell lysates 
were subjected to SDS-PAGE/immunoblotting with the antibodies indicated. i. a representative blot is shown 
with the migration of molecular mass markers indicated on the right. ii. and iii. Densitometric quantification 
of immunoblots in i. Data shown represents three independent experiments. *p<0.05 and ***p<0.001 relative 
to basal expression. 
i. ii. 
iii. 
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To determine whether PKC activation stimulates AMPK α1 Ser485 phosphorylation in 
other cell types, HeLa (LKB1-null) were treated with PMA in the presence or absence of 
STO-609. PKC-stimulated AMPK α1 Ser485 phosphorylation is not unique to human 
endothelial cells nor is it dependent on the characterised AMPK-kinases LKB1 and 
CaMKK. In HeLa, inhibition of CaMKK with STO-609 significantly reduced AMPK 
activity (assessed by ACC Ser79 phosphorylation) in both the presence and absence of 
PMA, and in the absence of STO-609 PMA did not alter ACC Ser79 phosphorylation 
(Figure 5-18ii). PMA stimulated a 7.9-fold increase in AMPK α1 Ser485 phosphorylation 
(Figure 5-18iii) and 2.1-fold increase in MARCKS Ser152/156 phosphorylation (Figure 
5-18iv), in both the absence and presence of STO-609 (p<0.001). 
As HeLa cells are LKB1 null, in order to assess the inhibitory effect of AMPK α1 Ser485 
phosphorylation on AICAR-stimulated AMPK activation HeLa expressing tetracyclin 
inducible LKB1 described previously (Boyle et al. 2008) were used. In HeLa cells 
expressing LKB1, stimulation with AICAR causes a 3-fold increase in ACC Ser79 
phosphorylation (Figure 5-19ii). Acute pre-treatment of HeLa with PMA significantly 
reduces AICAR-stimulated ACC Ser79 phosphorylation (Figure 5-19ii). In the presence of 
PMA, basal AMPK Thr172 phosphorylation is also reduced in these cells whereas AICAR 
stimulation has no effect on PMA-stimulated AMPK α1 Ser485 phosphorylation. 
Furthermore, PMA stimulates AMPK α1 Ser485 phosphorylation, and reduces AMPK 
Thr172 phosphorylation in cells from other species. Stimulation of mouse embryonic 
fibroblasts (MEFs) with 1 µM PMA resulted in a 4.1-fold increase in Ser485 
phosphorylation (p<0.05), and concurrently reduced basal Thr172 phosphorylation by 
approximately half (p<0.001) (Figure 5-20ii). ACC Ser79 phosphorylation was also 
markedly reduced (Figure 5-20i) in agreement with previous data (Figure 5-19ii). 
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Figure 5-18 
Figure 5-18: PMA stimulates AMPK α1 Ser485 phosphorylation in HeLa independently of CaMKK 
Cell lysates were prepared from HeLa cells incubated with 10 µM STO-609 for 1 hr prior to stimulation with 
1 µM PMA (20 min). Lysates were resolved by SDS-PAGE and immunoblotting with the antibodies 
indicated i. A representative immunoblot is shown, the migration of molecular mass markers is indicated on 
the right. This was repeated with similar results on four further occasions. ii-iv. Quantification of 
immunoblots in i. †††p<0.001 vs absence of STO-609. **p<0.01 and ***p<0.001 vs absence of PMA. 
This experiment was performed with the help of Kunzah Jamal 
i. 
iv. 
iii.  
ii. 
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Figure 5-19 
Figure 5-19: PMA stimulates AMPK α1 Ser485 phosphorylation and inhibits AICAR-stimulated ACC 
Ser79 phosphorylation in HeLa cells expressing LKB1 
Cell lysates were prepared from HeLa cells stably expressing LKB1 incubated in the presence or absence of 
AICAR (1 mM, 45 min) and/or PMA (1 µM) for 15 or 60 min as indicated. Lysates were resolved by SDS-
PAGE and immunoblotting with the antibodies indicated. i. A representative immunoblot is shown, repeated 
with similar results two further occasions. The migration of molecular mass markers is indicated on the right. 
ii. Densitometric quantification of ACC Ser79 phosphorylation in i. *p<0.05 relative to absence of PMA. 
This experiment was performed by Kunzah Jamal 
i. 
ii. 
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Figure 5-20 
Figure 5-20: PMA stimulates AMPK α1 Ser485 phosphorylation in MEFs 
Mouse embryonic fibroblasts were stimulated with 1 µM PMA for 20 min. Cell lysates were prepared and 
subjected to SDS-PAGE and immunoblotting with the antibodies indicated. i. representative blots are shown 
with the migration of molecular mass markers indicated on the right. ii. Densitometric quantification of 
immunoblots shown in i. Data represents three independent experiments. *p<0.05 and ***p<0.001 relative to 
absence of PMA. 
i. ii. 
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Given that AMPK α1 Ser485 phosphorylation in response to PKC activation is seen in 
both human and murine tissue, and that caloric excess is associated with elevated PKC 
activity, we assessed the AMPK Ser485/491 phosphorylation status of mice fed either a 
normal chow or high fat diet (HFD). In white adipose tissue, skeletal muscle and kidney, 
Akt Ser473 phosphorylation was significantly increased in mice fed a HFD compared to 
chow (p<0.05; Figure 5-21), however no difference in AMPK Ser485/491 phosphorylation 
was detected between the two groups, in either white adipose or skeletal muscle; 
Ser485/491 was not detected in kidney tissue lysate. Given the discrepancies between 
mouse and human models of diabetes, and that PKC activation is reported to mediate lipid-
induced insulin resistance in muscle, liver and vascular tissues, which has previously been 
reported to be associated with reduced AMPK activity in humans (Geraldes and King 
2010, Schmitz-Peiffer 2013), the AMPK α1 Ser485 phosphorylation status of muscle 
biopsy membrane fractions obtained from a previous study of European men in which 
insulin sensitivity index (ISI) had been also been calculated (Hall et al. 2010), was 
therefore assessed (Figure 5-22). A significant (p<0.05) increase in AMPK α1 Ser485 
phosphorylation was observed in individuals with an ISI score <7 (less insulin sensitive) 
compared to >7 (more insulin sensitive) (Figure 5-22ii). Furthermore, AMPK α1 Ser485 
phosphorylation showed a significant inverse relationship with ISI (p<0.05, r
2
=0.7337; 
Figure 5-22iii). MARCKS phosphorylation was not detected in any muscle biopsy sample 
tested (not shown). 
 
 Figure 5-21 
Figure 5-21: Assessment of Akt and AMPK Ser485/491 phosphorylation in murine tissue 
Tissue (A. white adipose, B. skeletal muscle and C. kidney) harvested from wild type mice fed either chow or high fat diet (a kind gift from Dr Colin Selman, University of Glasgow) 
was homogenized. Prepared lysates were subjected to SDS-PAGE/immunoblotting using the antibodies idicated. Lysate prepared from HAEC treated with either 1 μM insulin (INS) or 
PMA (1 μM, 20 min), or pooled INS and PMA lysates (kidney immunoblots) was used as a positive control in each case (lane 1 and 2 respectively, or lane 1 for kidney). Tissue from 
three animals in each sample group was assessed. The migration of molecular mass markers is indicated on the right. #p<0.05 vs chow diet. 
# 
# # 
Ai. 
ii. ii. ii. 
Bi. 
Ci
. 
iii. iii. 
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Figure 5-22 
Figure 5-22: AMPK α1 Ser485 phosphorylation is inversely related to insulin sensitivity in human 
muscle 
Human muscle biopsy membrane fractions were prepared in a previous study (Hall et al. 2010) and stored at 
-80
o
C. i. Membrane fraction proteins of individuals with the indicated insulin sensitivity index (ISI) were 
resolved by SDS-PAGE and immunoblotting using the antibodies shown. ii. and iii. Quantification of AMPK 
α1 Ser485 phosphorylation relative to total AMPK α. *p<0.05 comparing individuals with an ISI < 7 to those 
with an ISI > 7. 
* 
r2=0.7337 
i. 
ii. iii. 
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Figure 5-23 
Figure 5-23: The effect of CRT0066101 on VEGF-stimulated AMPK phosphorylation 
HAEC were incubated in the presence or absence of 10 µM CRT0066101 for 60 min prior to stimulation 
with VEGF (10 ng/mL, 5 min). HAEC lysates were prepared and proteins resolved by SDS-PAGE and 
immunoblotted with the antibodies indicated. i. a representative blot is shown with the migration of 
molecular mass markers indicated on the right. ii.–v. Densitometric quantification of immunoblots from four 
independent experiments showing mean ± SEM. *p<0.05, **p<0.01 and ***p<0.001 compared to absence of 
VEGF, ††p<0.01 and ††† p<0.001. 
This experiment was performed by Dr Sarah Mancini 
ii. 
iii. iv. 
v. 
i. 
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5.3 Discussion 
Data presented here demonstrates for the first time that in addition to activating AMPK, 
VEGF also stimulates the inhibitory phosphorylation of AMPK α1 Ser485 in human 
vascular endothelial cells. 
5.3.1 VEGF and AICAR stimulate both AMPK Thr172 and Ser485 
phosphorylation, but by different mechanisms 
Data presented here is in agreement with the previous findings of Reihill and co-workers, 
confirming that VEGF-stimulated AMPK α Thr172 phosphorylation is dependent on 
CaMKK activity (Reihill et al., 2007) and Ca
2+
 influx (Reihill, 2009), although the identity 
of the Ca
2+
 channel mediating VEGF-stimulated Ca
2+ 
influx has still to be determined 
(discussed in Chapter 4). AICAR-stimulated AMPK activation is neither CaMKK nor 
Ca
2+
-dependent. The present study further demonstrates that VEGF-stimulated AMPK 
Ser485 phosphorylation is Ca
2+
 dependent but independent of CaMKK. AMPK α2 Ser491 
is proposed to be a poor substrate for Akt in vivo (Hawley et al. 2014). Phosphorylation of 
this residue (α2 Ser491) is likely to result from auto-phosphorylation by active AMPK. 
Data demonstrating that inhibition of VEGF-stimulated AMPK activation (using STO-609) 
has no effect on AMPK α1 Ser485 phosphorylation argues against an AMPK auto-
phosphorylation event in response to AMPK activation. Furthermore, AMPK activation 
using the direct AMPK activator A769662 does not stimulate AMPK α1 Ser485 
phosphorylation. In agreement with previous reports (Javadov et al. 2009, Lu et al. 2010, 
Stone et al. 2012), AICAR was also demonstrated to stimulate AMPK α1 Ser485 
phosphorylation however the mechanism of AICAR-stimulated AMPK Ser485 
phosphorylation has not been described to date. However, AICAR-stimulated AMPK α1 
Ser485 phosphorylation is not sensitive to Ca
2+
 depletion indicating that VEGF and 
AICAR stimulate AMPK α1 Ser485 phosphorylation via different mechanisms. AICAR 
has previously been reported to activate Akt in HAEC (Morrow et al. 2003) such that it 
remains possible that AICAR-stimulated AMPK α1 Ser485 phosphorylation is mediated 
via Akt, and it would be interesting to assess this hypothesis in future studies. 
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5.3.2 Investigating the Akt and ERK1/2 dependence of AMPK α1 Ser485 
phosphorylation 
Previous reports have demonstrated that Akt and ERK1/2 (or an ERK1/2 regulated kinase) 
can act as AMPK Ser485 kinases (Horman et al. 2006, Lopez-Cotarelo et al. 2015). Insulin 
or IGF-1 (insulin-like growth factor) has been shown to stimulate Akt activity and 
concomitantly reduce AMPK Thr172 phosphorylation (or activity) in multiple model 
systems, including heart (Kovacic et al. 2003, Horman et al. 2006), adipocytes (Berggreen 
et al. 2009), tumour cells (Hawley et al. 2014), vascular smooth muscle (Ning et al. 2011) 
and hepatocytes and myotubes (Valentine et al. 2014). In all of these studies, with the 
exception of Kovacic and colleagues who were not able to define the mechanism 
explaining the observed insulin-stimulated reduction in AMPK activity, Akt-mediated 
inhibition of AMPK activity in response to insulin/IGF-1 was attributed to increased 
AMPK Ser485/491 phosphorylation.  
Further mechanisms describing the regulation of AMPK α1 Ser485 phosphorylation 
independent of Akt have also been described. Cyclic AMP-dependent protein kinase 
(PKA) is reported to phosphorylate AMPK α1 at Ser485 in addition to Ser173, Ser497, and 
AMPK β1-Ser24 (Djouder et al. 2010). More recently, IKK inhibition in neutrophils and 
macrophages was reported to effectively diminish LPS-induced AMPK α1 Ser485 
phosphorylation and Thr172 de-phosphorylation, whereas Akt inhibition had negligible 
effects on LPS-induced Thr172 de-phosphorylation and cytokine production (Park et al. 
2014). Furthermore, CCR7 is reported to promote the survival of mature dendritic cells via 
Gα/Gβ/γ-mediated activation of the MEK1/2-ERK1/2 cascade resulting in AMPK α1 
Ser485 phosphorylation (Lopez-Cotarelo et al. 2015). 
VEGF stimulates the phosphorylation of Akt and ERK1/2. Therefore, to assess the 
dependence of VEGF-stimulated AMPK Ser485 phosphorylation on Akt and ERK1/2, 
selective kinase inhibitors were used. Contrary to previously described mechanisms, the 
present study demonstrates that VEGF-stimulated AMPK α1 Ser485 phosphorylation is 
not dependent on ERK1/2 or Akt, as complete inhibition of VEGF-stimulated ERK1/2 
Thr202/Try204 and Akt Ser473 phosphorylation using the MEK inhibitor PD184352 or the 
Akt inhibitor Akti-1/2 respectively had no effect on either VEGF-stimulated Thr172 or α1 
Ser485 phosphorylation. At the inhibitor concentration used here (1 µM), VEGF-
stimulated ERK and Akt phosphorylation were not affected by Akt and ERK inhibition 
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respectively, suggesting specific inhibition by these compounds as reported previously 
(Logie et al. 2007, Allen et al. 2003).  
Furthermore, pre-treatment of endothelial cells with the PI3K inhibitor wortmannin, had no 
effect on VEGF-stimulated AMPK Thr172 or α1 Ser485 phosphorylation, while both basal 
and VEGF-stimulated Akt Ser473 phosphorylation were significantly reduced suggesting 
that AMPK phosphorylation at both Thr172 and α1 Ser485 is independent of PI3K 
activity. In the absence of wortmannin, VEGF stimulated only a modest increase in Akt 
Ser473 phosphorylation. This was not however unexpected, given the modest increase in 
Akt Ser473 phosphorylation observed after 5 min of VEGF treatment). 
Together this data strongly suggests that Akt activity is not necessary for VEGF-stimulated 
AMPK α1 Ser485 phosphorylation. To determine whether Akt activation is sufficient to 
induce AMPK α1 Ser485 phosphorylation, HAEC were stimulated with the Akt activator 
insulin, which has previously been reported to stimulate AMPK α1 Ser485 
phosphorylation in other cell types (Horman et al. 2006, Soltys et al. 2006, Berggreen et al. 
2009, Ning et al. 2011). Robust Akt activation was indicated by increased phosphorylation 
of Akt at Ser473, however no increase in AMPK α1 Ser485 phosphorylation was observed, 
whereas in these cells VEGF stimulated substantial AMPK α1 Ser485 phosphorylation. 
Akt activation by insulin is therefore not sufficient to stimulate AMPK α1 Ser485 
phosphorylation in human vascular endothelial cells. 
Previous studies in cultured immune cells (neutrophils and B cell chronic lymphocytic 
leukaemia cells) report that Akt is activated in response to PMA (Barragan et al. 2006, 
Douda et al. 2014). To assess the effect of PMA-stimulation on Akt phosphorylation in 
endothelial cells, HUVEC were pre-treated with Akti-1/2 or wortmannin prior to PMA or 
insulin stimulation. Both Akt Thr308 and Ser473 phosphorylation are robustly stimulated 
by insulin, an effect ablated by pre-treatment with wortmannin or Akti. As previously 
demonstrated, insulin-mediated Akt activation does not stimulate AMPK α1 Ser485 
phosphorylation. 
PMA treatment however causes robust stimulation of AMPK α1 Ser485 phosphorylation 
which is not affected by PI3K or Akt inhibition. PMA stimulation actually reduces Akt 
phosphorylation at both Thr308 and Ser473, and is ablated in the presence of wortmannin 
or Akt. This data strongly supports our previous findings in endothelial cells indicating that 
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VEGF-, and now PMA-stimulated AMPK α1 Ser485 phosphorylation is not mediated via a 
PI3K/Akt signalling axis. 
Together these data indicate that VEGF-stimulated AMPK α1 Ser485 phosphorylation is 
independent of PI3K/Akt and ERK1/2 signalling in vascular endothelial cells, contrary to 
findings in other model systems and to our expectations. We therefore conclude that Akt 
activation is neither necessary, nor sufficient for AMPK α1 Ser485 phosphorylation in 
primary human vascular endothelial cells. Activation of PKC using the synthetic phorbol 
ester PMA decreases Akt activity and as such is unlikely to stimulate AMPK α1 Ser485 
phosphorylation via increased Akt activity as suggested previously (Djouder et al. 2010). 
Previous reports suggesting that Akt is an AMPK α1 Ser485 kinase might be describing 
cell and/or stimuli specific effects/mechanisms.   
5.3.3 Investigating the mechanism of VEGF-stimulated AMPK α1 
Ser485 phosphorylation 
In light of these findings, we hypothesised that an alternative, novel and as yet 
uncharacterised, Ca
2+
-dependent mechanism mediates VEGF- and PMA-stimulated AMPK 
α1 Ser485 phosphorylation. Given the Ca2+ dependence of VEGF-stimulated AMPK α1 
Ser485 phosphorylation and previous suggestions that DAG-regulated Ca
2+
 channels may 
be mediating VEGF-stimulated Ca
2+
 influx in endothelial cells (Chapter 4), we asked 
whether the PKC family of protein kinases were involved in regulating AMPK activity.  
The protein kinase C (PKC) family contains of a number of structurally and functionally 
related serine-threonine kinases, derived from multiple genes and alternative mRNA 
splicing. At least 15 isoforms have been identified in humans and these can be further 
subcategorised according to their primary domain structures and second messenger 
requirements, summarised in Table 5.1. Conventional or classical PKCs (α, βI, βII, γ) 
require calcium and diacylglycerol for activation, whereas the novel PKCs (δ, ε, η, θ) 
require DAG but not calcium. Because they both require DAG for activation, both the 
conventional and novel PKCs can be activated via phospholipase C-mediated signalling 
cascades, including those downstream of VEGF-receptor activation. The final PKC 
subfamily, the atypical PKCs (ζ, ι/λ) require neither DAG nor calcium for activation. 
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Table 5-1: Protein kinase C subfamily categorisation and co-factor requirements 
subcategory isoforms 
Co-factor requirements 
Ca2+ DAG Phospholipid 
conventional α, βI, βII, γ 
   
novel δ, ε, η, θ, µ - 
  
atypical ζ, ι/λ - - 
 
 
Inhibition of the classical PKCs or PKC β using GF109203X or LY333531 respectively 
abolished VEGF-stimulated AMPK α1 Ser485 phosphorylation without significantly 
altering VEGF-stimulated AMPK Thr172 phosphorylation. The mechanism by which 
VEGF stimulates AMPK activity (Thr172) was investigated and discussed in Chapter 4, 
however, since only AMPK α1 Ser485 phosphorylation is ablated by PKC inhibition we 
hypothesised that these phosphorylation events are regulated via different mechanisms: 
Thr172 independently of  PKC, and α1 Ser485 in a PKC dependent manner. 
Although not significant (p>0.05) treatment of HUVEC with LY333531 caused a modest 
increase in VEGF-stimulated Thr172 phosphorylation (23 % increase in mean 
phosphorylation) suggesting that inhibition of PKC may increase AMPK activity. Basal 
AMPK activity was later shown to be significantly increased by the PKC inhibitor 
GF109203X, which also tended to increase VEGF-stimulated AMPK activity indicating 
that PKC negatively regulates AMPK activity. There are contradictory reports in the 
literature as to whether PKC positively or negatively regulates AMPK activity. Saberi and 
colleagues report that H2O2 induced necrosis in primary hepatocytes is associated with 
increased PKC activation and reduced AMPK activity, and inhibition of PKC using 
multiple different PKC inhibitors (Ro-31-8425 and Gö6850) increased AMPK activity and 
protected against H2O2 induced necrosis (Saberi et al. 2008). Furthermore, in rat cardiac 
myocytes PMA treatment reduced AMPK activity in a GF109203X sensitive manner 
(Tsuchiya et al. 2012) such that PKC-mediated AMPK inhibition may underlie these 
previous reports. Contrary to this, Nishino and colleagues report that AMPK activation and 
GLUT4 upregulation stimulated by ischemic preconditioning was abrogated by prior 
infusion with GF109203X (Nishino et al. 2004), whereas Chang and co-workers report that 
AMPK activation is required for PMA-stimulated monocyte adhesion, suggesting that 
PKC is upstream of LKB1 and AMPK activation (Chang et al. 2012). LY333531 (10 µM) 
has previously been reported to inhibit AMPK activity in a cell free assay of activity 
(Komander et al. 2004). LY333531 at the concentration used in the present study (1 µM) 
did not influence AMPK activity in a cell free assay of AMPK activity (either increase or 
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decrease), and did not inhibit AMPK activation by VEGF. At the highest concentration we 
have used in the present study, LY333531 is neither a direct activator nor inhibitor of 
AMPK, and as such PKC inhibition tends to increase AMPK activity only in intact cells. 
The present study also demonstrates that PKC activation using the synthetic phorbol ester 
PMA, or the diacylglycerol mimetic OAG stimulates the phosphorylation of AMPK α1 at 
Ser485, and not AMPK α2 Ser491. We have assessed the relative contribution of AMPK 
α1 and α2 containing complexes in vascular endothelial cell lysates. AMPK α1 containing 
complexes account for the vast majority of vascular AMPK activity (basal and VEGF-
/AICAR-stimulated) such that abrogation of AMPK α1 activity has the potential to 
significantly influence AMPK activity in the vascular endothelium. Specific anti-phospho-
AMPK α2 Ser491 antibodies were not widely available at the time of these studies 
although have become commercially available since. These conclusions were therefore 
reached using a phospho-specific AMPK α1/α2 Ser485/491 antibody after successful 
separation of AMPK α1 and α2 containing complexes by immunoprecipitation. It would be 
interesting to reassess these results with specific anti-phospho-AMPK α2 Ser491 
antibodies. Data to this point also indicates that in addition to VEGF, other activators of 
PKC (PMA and OAG) also preferentially stimulate AMPK α1 Ser485 phosphorylation in 
primary human vascular endothelial cells. Therefore, PKC activation, rather than a VEGF-
specific signalling event stimulates AMPK α1 Ser485 phosphorylation and inhibition of 
AMPK activity. 
5.3.4 Characterising the PKC isoform(s) responsible for PKC-mediated 
AMPK α1 Ser485 phosphorylation 
Phosphorylation of MARCKS is often used as a surrogate marker for PKC activity. In Sf9 
insect cells, a heterologously expressed human MARCKS was found to be phosphorylated 
by PKCs α, βι, βµ, γ, δ, ε and η but not PKC ζ (Cabell et al. 1996). MARCKS 
phosphorylation is therefore a surrogate marker of PKC activity, representing the activity 
of multiple PKC isoforms. 
The time course of PMA-stimulated AMPK α1 Ser485 and MARCKS Ser152/156 was 
assessed, in addition to the sensitivity of PMA- and VEGF-stimulated AMPK and 
MARCKS phosphorylation to PKC inhibition using LY333531. In response to PMA, 
MARCKS was rapidly phosphorylated with the time taken to reach half-maximal 
phosphorylation calculated as being 1 min. The time taken to reach half-maximal AMPK 
α1 Ser485 phosphorylation was calculated to be 2.6 min. LY333531 inhibited VEGF-
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stimulated MARCKS and AMPK α1 Ser485 phosphorylation with remarkably similar 
kinetics and significant inhibition of phosphorylation of both MARCKS and AMPK α1 
Ser485 at the lowest concentration tested (0.1 µM). PMA-stimulated MARCKS 
phosphorylation was however less sensitive to inhibition by low concentrations of 
LY333531 such that significant inhibition of PMA-stimulated MARKS was only measured 
at LY333531 concentrations ≥0.5 µM, whereas the inhibition of PMA-stimulated AMPK 
α1 Ser485 phosphorylation demonstrated kinetics similar to VEGF-stimulated AMPK α1 
Ser485 phosphorylation. Together, this data suggests that AMPK α1 Ser485 may be a 
substrate for only a subset of PKC isoforms, whereas MARCKS is a substrate for more 
PKC isoforms. 
Chronic stimulation of PKC activity with nanomolar concentrations of PMA has been 
shown to downregulate PKC expression by increasing its degradation via the lysosome 
machinery (Young et al. 1987). Downregulation of the PKC isoforms α, β1, γ, η, θ and μ  
by chronic PMA treatment (200 nM, overnight) inhibited both VEGF- and OAG-
stimulated AMPK α1 Ser485 phosphorylation, however siRNA-mediated PKC α 
downregulation (~90 % reduction) had no effect on VEGF-stimulated AMPK α1 Ser485 
phosphorylation. Conversely, over expression of either PKC α or β1 was sufficient to 
increase AMPK α1 Ser485 phosphorylation, even in the absence of a stimulus. Together 
these data indicate that over expression of a single PKC isoform is sufficient to increase 
AMPK α1 Ser485 phosphorylation, but alternate PKC isoforms may able to compensate 
for depletion of single PKC isoforms. 
It was interesting to observe that down regulation of PKC α stimulated a concurrent 
decrease in PKC β1 levels. Conversely, overexpression of PKC β1 caused a concurrent 
increase in PKC α expression. Data presented therefore raises the interesting concept of 
PKC isoenzyme trans-regulation. Such coordinated regulation has been described 
previously in murine hemopoietic cells (Baf3) and a murine myeloid cell line (32D), in 
which PKC α upregulated PKC δ protein levels by increasing mRNA transcription and 
stability (Romanova et al. 1998). PKC β and γ expression was not detected in these cells 
lines so the effect of PKC α overexpression on the level of these was not studied and 
cannot be compared with the present study.  
Despite previous suggestions that PKC stimulates AMPK α1 Ser485 phosphorylation, no 
data demonstrating this has been made available to date (Kodiha and Stochaj 2011). We 
have established in this study that PKC is an AMPK α1 Ser485 kinase in vitro. Purified rat-
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brain PKC consisting of mostly α, β and γ (δ and ζ to a lesser extent) phosphorylated 
isolated kinase-dead (therefore not capable of auto-phosphorylation) AMPK at least as 
well as a quantity of Akt with comparable kinase activity. This is the first demonstration to 
our knowledge of PKC acting as a direct AMPK α1 Ser485 kinase in vitro. The identity of 
the PKC isoform(s) mediating AMPK α1 Ser485 phosphorylation however is not clear. 
The calcium dependence of VEGF-stimulated AMPK α1 Ser485 phosphorylation, and the 
demonstration that purified PKC consisting of predominantly PKC α, β and γ (δ and ζ to a 
lesser extent) phosphorylate AMPK α1 Ser485 in vitro, indicates that the PKC isoform 
mediating this effect is likely to be one of the classical (Ca
2+
 regulated) isoforms. 
5.3.5 PKC inhibition as a therapeutic approach for ameliorating reduced 
AMPK activity in metabolic disease 
LY333531 is a compound also known as ruboxistaurin and has previously been reported to 
reverse vascular abnormalities in animal models of diabetes (Ishii et al. 1996), and 
normalise diabetes induced elevations in PKC activity in the retina and kidney of diabetic 
animals (Kowluru et al. 1996). Furthermore, LY333531 ameliorated abnormal 
hemodynamics in patients with diabetes and enhanced endothelium dependent vasodilation 
impaired by hyperglycaemia (Aiello et al. 1999, Beckman et al. 2002). Ruboxistaurin (64 
mg) administered as a daily oral dose was found to be well tolerated in human subjects. It 
was further shown to pass into the systemic circulation after oral administration where it is 
extensively metabolised by CYP34A (Yeo et al. 2006). The major metabolite of 
ruboxistaurin is N-desmethyl ruboxistaurin and was found to be an equally potent inhibitor 
of PKC β. The plasma concentration of ruboxistaurin and N-desmethyl ruboxistaurin in 17 
men after an oral dose of 64 mg was found to be 200 and 128 nmol/L respectively (Yeo et 
al. 2006). Later reports characterising the metabolism and excretion of [
14
C]-ruboxistaurin 
in six human subjects achieved plasma concentrations of 204 nmol/L. and 87.4 nmol/L for 
ruboxistaurin and N-desmethyl ruboxistaurin respectively (Burkey et al. 2006) consistent 
with previous reports. We have demonstrated that therapeutically achievable 
concentrations of LY333531 significantly reduce AMPK α1 Ser485 phosphorylation 
>60%. Given that ruboxistaurin and N-desmethyl ruboxistaurin are equipotent, it would be 
interesting to assess in vitro the combined inhibitory effect of ruboxistaurin and N-
desmethyl ruboxistaurin on AMPK α1 Ser485 phosphorylation, under more biologically 
relevant conditions. 
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5.3.6 AMPK α1 Ser485 phosphorylation in mouse and human models of 
metabolic disease 
The present study demonstrates that PKC-mediated AMPK α1 Ser485 phosphorylation is 
not limited to vascular endothelial cells and therefore has the potential to influence AMPK 
activity at the level of the whole organism. We have also demonstrated that AMPK α1 
Ser485 phosphorylation is associated with reduced AMPK activity (Thr172 
phosphorylation) in both human and murine derived cultured cells. In both HeLa and 
MEFs, basal Thr172 phosphorylation is reduced in the presence of PMA. Additionally, 
AICAR-stimulated ACC Ser79 phosphorylation is significantly reduced with prior PMA 
treatment, confirming previous reports of the inhibitory effect of AMPK α1 Ser485 
phosphorylation on AMPK activity. Together, these studies suggest that Ser485/491 
phosphorylation may underlie reduced AMPK activity observed under conditions where 
PKC activity is known to be elevated e.g. diabetes. After determining the greater efficiency 
of the AMPK α1/α2 Ser485/491 antibody for detecting Ser485/491 phosphorylation in 
murine tissue (not shown), the Ser485/491 phosphorylation status of wild type mice, fed 
either normal chow or HFD was investigated. Significantly elevated Akt phosphorylation 
was measured in skeletal muscle, white adipose and kidney tissue from HFD fed mice 
compared to chow, however no difference in Ser485/491 phosphorylation was measured 
between the groups. If, as suggested by previous reports (Horman et al. 2006, Soltys et al. 
2006, Berggreen et al. 2009, Ning et al. 2011), Akt activation stimulates AMPK α1 Ser485 
phosphorylation, we might have expected to observe concurrent increase in AMPK α1 
Ser485 phosphorylation, in these tissues. 
Given the striking differences observed previously between mouse models of diabetes and 
human subjects, we also assessed the AMPK α1 Ser485 phosphorylation status in muscle 
biopsies obtained from European men in a previous study in which Akt phosphorylation 
levels and insulin sensitivity index (ISI) had been determined: 10000/√[(fasting glucose x 
fasting insulin) x (mean glucose during OGTT x mean insulin during OGTT)] (Matsuda 
and DeFronzo 1999). A strong inverse correlation (r
2=0.7337) between ISI and AMPK α1 
Ser485 phosphorylation was observed, and subjects who were determined to be less 
sensitive to insulin (ISI <7) demonstrated significantly elevated AMPK α1 Ser485 
phosphorylation (p<0.05). Inhibition of AMPK α1, which is reported to contribute 50 % of 
basal AMPK activity in human vastus lateralis muscle (Deshmukh et al. 2010), therefore 
has the potential to markedly influence AMPK activity. Crucially, no relationship was 
observed between previously reported Akt phosphorylation levels (Hall et al. 2010), and 
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AMPK α1 Ser485 such that it remains possible that PKC mediates AMPK α1 Ser485 
phosphorylation in human muscle despite not being able to detect the phosphorylation of 
MARCKS in these samples. The samples used in this analysis were chosen to represent a 
range of insulin sensitivities although none of the volunteers had diabetes. Reduced AMPK 
activity due to Ser485 phosphorylation may therefore occur during metabolic dysfunction 
preceding the development of insulin resistance and diabetes thus providing a therapeutic 
window to ameliorate or slow the development of diabetes. We believe this to be the first 
report of an inverse correlation between insulin sensitivity and AMPK α1 Ser485 
phosphorylation, and propose that AMPK α1 Ser485 phosphorylation may explain some of 
the reduced AMPK activity associated with insulin resistance. Whether AMPK α1 Ser485 
phosphorylation contributes to vascular dysfunction or cardiovascular disease associated 
with insulin resistance remains to be established. 
During the preparation of this thesis, Coughlan and co-workers reported that PKD1 inhibits 
AMPK α2 through phosphorylation of Ser491 and impairs insulin signalling in skeletal 
muscle cells (Coughlan et al. 2016). The authors of this study report that PMA stimulates 
PKD1 activation which catalyses the phosphorylation of AMPK α2 at Ser491, resulting in 
the inhibition of AMPK α2 activity resulting in impaired insulin signalling. Broad-
spectrum PKC inhibition or PKD1 specific inhibition prevented PMA-stimulated AMPK 
α2 Ser491 phosphorylation. Our study reports that PKC activation, either by the addition of 
PMA, or the endogenous signalling molecule VEGF stimulates AMPK α1 Ser485 
phosphorylation, and furthermore, we see no effect of PMA on AMPK α2 Ser491 
phosphorylation. In light of this recent report, we sourced the PKD1 inhibitor 
(CRT0066101) used by Coughlan and co-workers and assessed the effect of inhibiting 
PKD1 (murine designation for human PKCμ) on VEGF-stimulated AMPK α1 Ser485 
phosphorylation in primary human vascular endothelial cells. 
VEGF stimulates significant phosphorylation of PKD (Ser916) which is prevented by prior 
incubation with the PKD1 inhibitor, CRT0066101. PKD1 inhibition has no effect on 
AMPK Thr172 phosphorylation whereas we see a (not-significant) reduction in VEGF-
stimulated AMPK α1 Ser485 phosphorylation in the presence of CRT0066101. 
Furthermore, the presence of CRT0066101 does not prevent VEGF stimulating a 
significant increase in AMPK α1 Ser485 phosphorylation. Together these suggest that 
PKD1 may contribute to VEGF-stimulated AMPK α1 Ser485 phosphorylation but PKD1 
cannot account for all the AMPK α1 Ser485 kinase activity we observe in response to 
VEGF. 
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Coughlan and co-workers also report that PMA-stimulated AMPK α2 Ser491 is 
independent of the previously reported AMPK α1 Ser485 kinases Akt and ERK1/2, in 
agreement with our findings using VEGF. The authors of this study also report that PKD1 
phosphorylates AMPK α2 in vitro. Phosphorylation of AMPK α2 Ser491 has previously 
been reported to likely be a result of AMPK auto-phosphorylation (Hawley et al. 2014). 
For our in vivo assessment of AMPK α1 Ser485 phosphorylation by PKC, we have utilised 
kinase-dead AMPK α1, excluding the possibility that the PKC-mediated AMPK α1 Ser485 
phosphorylation we measured is a result of AMPK auto-phosphorylation unlike Coughlan 
and co-workers. Furthermore, contrary to their findings, we have no evidence that PMA 
stimulates the phosphorylation of AMPK α2 in human vascular endothelial cells. While 
this article reports that PKD1 is an AMPK α2 Ser491 kinase in murine muscle cells 
stimulated by the addition of exogenous PMA via a PKC-PKD-AMPK α2 Ser491 
signalling cascade, our study was conducted in primary human vascular endothelial cells, 
and furthermore we report that the physiologically relevant stimulus VEGF stimulates 
AMPK α1 Ser485 phosphorylation, in addition to the application of synthetic PMA. 
Comparing our findings with those of this recent report generates a number of interesting 
questions. Given that we found altering the expression of specific PKC isoforms, whether 
downregulation using siRNA or transient overexpression using plasmids, caused 
concurrent alterations in the expression of other PKC isoforms, it would be interesting to 
know what concentration of siRNA was required by Coughlan and co-workers to induce 
the downregulation of phospho-PKD1 reported (total PKD1 was not reported) and whether 
any other PKC isoforms were affected. Furthermore, we report that AMPK α1 Ser485 
phosphorylation is dependent on Ca
2+
, despite not being Ca
2+
 regulated itself it would be 
interesting to assess the Ca
2+
 dependence of PKD1 activation in response to PMA, such 
that it remains possible that a Ca
2+
-regulated PKC isoform regulates PKD1 activity. We are 
also able to report that AMPK α1 Ser485 phosphorylation is inversely correlated with 
insulin sensitivity in human muscle; the findings of the current study are therefore still of 
significant relevance. 
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5.4 Conclusion 
Data presented here demonstrates for the first time that PKC activation stimulates the 
inhibitory phosphorylation of AMPK α1 at Ser485 in primary human vascular endothelial 
cells, independently of LKB1 and CaMKK, and has established that PKC is a novel AMPK 
α1 Ser485 kinase in vitro. Previous reports that Akt and ERK1/2 are AMPK α1 Ser485 
kinases may describe cell and or stimuli specific effects. Furthermore, AMPK α1 Ser485 
phosphorylation levels show a strong inverse correlation with insulin sensitivity in human 
muscle. Elevated PKC activity and reduced AMPK activity are observed in metabolic 
diseases such as diabetes, as such these findings report a novel mechanism of AMPK 
regulation by PKC, which may be of therapeutic interest in the treatment of metabolic 
disease. 
Despite recent reports that PKD1 is an AMPK α2 Ser491 kinase, we can show that 
inhibition of PKD1 does not prevent VEGF significantly inducing AMPK α1 Ser485 
phosphorylation, such that PKD1 may contribute to AMPK α1 Ser485 phosphorylation but 
PKD1 does not account for all the AMPK α1 Ser485-kinase activity seen in response to 
VEGF.
183 
Chapter 6 – Discussion 
H. R. Heathcote (2016)  Chapter 6 – Discussion 184 
6.1 Final discussion 
Our laboratory has previously reported that AMPK is activated in response to VEGF 
(Reihill et al. 2007), and that AMPK is required for VEGF-stimulated endothelial cell 
‘proliferation’ (Reihill et al. 2011), in contrast to reports that AMPK activation by other 
agents e.g. AICAR, is anti-proliferative. We therefore sought to determine the specific 
effect of VEGF on AMPK activity in order to assess whether VEGF activated a specific α 
isoform-containing complex or subcellular pool of AMPK in order to mediate this 
paradoxical effect. As reported in Chapter 3, VEGF activates AMPK complexes containing 
the same α1 catalytic subunit as AICAR; α1 account for the vast majority of both basal and 
VEGF-/AICAR-stimulated AMPK activity in agreements with previous reports that 
AMPK α1 is the predominant isoform expressed in vascular endothelial cells. It is 
however, also the predominant isoform reported to be expressed in SMC derived from rat 
aortae and porcine carotid arteries (Horman et al. 2008, Rubin et al. 2005) suggesting that 
targeting AMPK α1 in the endothelium in vivo has the potential to also influence the 
underlying VSM. It is worth nothing that most of the experiments performed in the current 
study were performed using cultured cells. Extrapolating the findings in the current study 
to the situation in vivo must be done with caution. Intact vessels in vivo are comprised of 
numerous cell populations e.g. endothelial cells, smooth muscle, pericytes etc. and 
endothelial cells in vivo are exposed to sheer stress, blood components and the influence of 
immune cells. Furthermore, at any given time, the percentage of endothelial cells 
undergoing proliferation is reported to be in the region of 0.01 %, a minute proportion of 
the estimated 2 x 10
12
 endothelial cells that line the human vasculature (Bianconi et al. 
2013). Culturing endothelial cells inadvertently selects for an enhanced proliferative 
phenotype during sequential passaging, such that cells in culture may not best represent 
native endothelial cells. 
Contrary to previous reports from our laboratory (Reihill et al. 2011), infection of HUVEC 
with Ad.AMPK-DN had no effect on cell proliferation, when it measured with the RTCA 
xCELLigence system. This was in contrast to concurrent MTS proliferation assays 
showing that AMPK is required for cell proliferation. Together, these experiments suggest 
that experiments using the MTS assay as a measure of proliferation need to be supported 
by other methods e.g. xCELLigence or BrdU incorporation, to accurately differentiate 
between effects on cell proliferation and mitochondrial activity. 
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Previous work in our laboratory also reported that VEGF activates AMPK in a CaMKK 
(Reihill et al. 2007) and extracellular Ca
2+
 dependent manner, and that this could be 
mimicked by the DAG mimetic OAG (Reihill 2009). It was therefore hypothesised that 
VEGF-stimulated AMPK activation is facilitated by one or more members of the DAG 
sensitive Ca
+2 
channel family (TRPCs 3, 6 and 7). The present study was neither able to 
confirm, nor exclude the possibility of TRPC channel expression in human vascular 
endothelial cells, contrary to numerous previous reports. We show here that the 
pharmacological and molecular analysis tools available, at the time of this study into TRPC 
channel activity are, at least in our hands, insufficiently efficacious, nor specific enough to 
enable the contribution of their targets in the mechanism of VEGF-stimulated AMPK 
activation to be resolved fully. 
Numerous reports however claim to have characterised the expression profile of TRPC 
channels in vascular tissues summarised well by Yao and Garland (2005), with widely 
varying results. As such no consensus expression profile of TRPC isoforms in endothelial 
cells has been reached. Furthermore, numerous reports claim that different individual 
TRPC isoforms are crucial in regulating vascular homeostasis and/or pathological states 
without necessarily reporting the effect of modulating the activity of other TRPC isoforms 
in the same models. TRPC channels form heteromeric in addition to homomeric 
complexes, with an ever-increasing number of combinations reported. The tetrameric 
composition of the TRPC channel complex therefore has the capacity to affect channel 
characteristics (Vazquez et al. 2004). Until such time that the subunit composition of 
TRPCs can be determined with high resolution, studies reporting that channel a or b, and 
not c are responsible for effect x, should be interpreted with caution. Furthermore, we have 
shown for the first time that hyperforin activates AMPK in vascular endothelial cells, 
consistent with recent reports (Wiechmann et al. 2015) that hyperforin disrupts 
mitochondrial processes, activating AMPK in leukemic cells. 
We report that activation of PKC stimulates AMPK α1 Ser485 phosphorylation and 
concomitantly reduces AMPK activity, whereas inhibition of PKC tends to increase 
AMPK activity; together this data suggests that PKC is a negative regulator of AMPK 
activity. We have further demonstrated that active PKC phosphorylates AMPK α1 Ser485 
in a cell free assay, indicating that at least in vitro, PKC is a direct AMPK α1 Ser485-
kinase. Furthermore, AMPK α1 Ser485 phosphorylation is inversely correlated with 
insulin sensitivity in human muscle, such that it remains possible that the elevated PKC 
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activity observed in response to over-nutrition may contribute to the reduction in AMPK 
activity observed in animal and human models of metabolic disease. 
This study demonstrates that PKC is a direct AMPK α1 Ser485 kinase, and reports for the 
first time to our knowledge that AMPK α1 Ser485 phosphorylation is inversely correlated 
with insulin sensitivity in biopsies of human muscle from volunteers who are not clinically 
classified as diabetic. Probably the most interesting finding from the current study is that 
the endogenous signalling molecule VEGF stimulates PKC activation to mediate this in 
intact primary human vascular endothelial cells. AMPK α1 Ser485 has previously been 
reported to be an inhibitory phosphorylation event, with Akt, and a MEK1/2- or ERK1/2-
dependent kinase reported to mediate this phosphorylation (Horman et al. 2006, Lopez-
Cotarelo et al. 2015). The finding that PKC activation also stimulates AMPK α1 Ser485 
phosphorylation adds to our understanding of the mechanisms by which AMPK activity is 
downregulated. 
After the completion of the experimental work for this project, and during the preparation 
of this thesis, Coughlan and co-workers reported that PKD1 inhibits AMPK α2 by 
phosphorylation of Ser491 kinase and impaired insulin signalling in murine muscle cells 
(C2C12) (Coughlan et al. 2016), results similar to what we present in the current study. 
Their findings however support those in our current study and indicate that PMA 
stimulates AMPK Ser485 phosphorylation via PKC/PKD1. We have since demonstrated 
that PKD1 does not fully account for the VEGF-stimulated activation of the kinase 
mediating AMPK α1 Ser485 phosphorylation in human vascular endothelial cells. As such 
PKC-mediated regulation of AMPK activity may still contribute to the downregulated 
AMPK activity observed in models of metabolic disease independent of PKD1-stimulated 
AMPK α1 Ser485 phosphorylation. 
6.2 Future work 
The current study presents a number of avenues warranting further investigation: 
 What is the significance of AMPK translocating to the Golgi apparatus when confluent 
and is this unique to endothelial cells? 
At this time we can only speculate as to why AMPK is localised to the Golgi body of 
confluent endothelial cells but to the ER when sub-confluent. Furthermore, we do not 
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know whether the targeting of AMPK to these different subcellular compartments affects 
its activity or interaction with substrates. We assessed the feasibility of expressing GFP 
tagged AMPK in HUVEC during the current study, in order to obtain a real-time images of 
AMPK distribution. Unfortunately, we were not able to distinguish between GFP and GFP-
tagged AMPK, which both shared a similar distribution, such that this requires further 
optimisation. Should this be better resolved, it would be of considerable interest to 
synthesise Golgi or ER-targeted AMPK in order to assess the effect of AMPK localisation 
on its activity and cell phenotype. This could be achieved using the Golgi and ER targeting 
sequences ‘GRIP-domain’ and ‘KDEL sequence’, described previously (Munro and 
Nichols 1999, Stornaiuolo et al. 2003). 
 Can mitochondrial mass and biogenesis be quantified in endothelial cells and is it 
altered by VEGF? 
Initial experiments assessing the effect of downregulating AMPK on mitochondrial oxygen 
consumption have proven inconclusive, such that we have not conclusively determined the 
mechanism by which Ad.AMPK-DN virus affects the outcome of the MTS assay, 
independently of inhibiting VEGF-stimulated cell proliferation. Given the greater 
resolution achievable, transmission electron microscopy would allow for a relative and 
absolute measurement of the area within cells occupied by mitochondria to be determined, 
rather than by confocal microscopy as we have tried. Highly sensitive qRT-PCR might also 
be used to assess the copy number of mtDNA encoded genes. Given the small volume of 
protein lysate recovered after the Seahorse XF Mito Stress Test we assessed only the 
expression of mitochondrial complexes I-V. If conditions permitted enough lysate to be 
recovered it would be interesting to assess the mRNA, or protein expression level of 
factors involved in mitochondrial biogenesis, such as PGC-1α, the nuclear respiratory 
factors NRF-1 and 2, and the mitochondrial transcription factor mtTFA. 
 What are the downstream targets of VEGF-stimulated AMPK? 
The obvious omission from the current study is the effect of VEGF downstream of AMPK 
activation. Once we have established an efficient protocol to induce siRNA-mediated 
AMPK knockdown, it would be interesting to assess this on metabolic parameters, rather 
than relying on recombinant adenoviral vector infection, a process which itself is likely to 
have effects on the cells. During the current study, the feasibility of isolating primary aortic 
endothelial cells from PRKAA1
-/-
 mice and their wild type littermates was explored. 
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Despite successfully developing a protocol for isolating murine aortic endothelial cells, the 
absolute number of isolated cells recovered was low, and expanding them in culture was 
not possible. Should this be overcome, it would be of particular interest to assess the effect 
of VEGF on potential targets in WT derived murine endothelial cells and compare this in 
cells derived from their PRKAA1
-/-
 littermates to determine their AMPK dependence.   
 Are TRPCs mediating VEGF-stimulated Ca
2+
 influx and AMPK activation? 
The development of better tools is required in order to determine if TRPCs are actually 
involved in VEGF-stimulated AMPK activation, however we report here for the first time 
that hyperforin activates AMPK in an extracellular Ca
2+
-independent manner. In addition 
to its effects on TRPC6 (Leuner et al. 2007), there are suggestions that hyperforin acts as a 
protonophore and upregulates the expression of the drug metabolising enzyme CYP34A 
(Friedland and Harteneck 2015). It would be interesting to further study the mechanism by 
which hyperforin stimulates AMPK activity and its downstream effects, in order to better 
understand the reported pleiotropic effects of hyperforin, given the over-the-counter 
availability and use of St John’s Wort preparations for the treatment of mild to moderate 
depression (Linde et al. 2008). 
 Does AMPK α1 Ser485 phosphorylation correlate with, or contribute to reduced 
insulin sensitivity in the larger population? 
The most interesting finding in the current study was that increased PKC activity such as 
that seen during over-nutrition, stimulates the inhibitory phosphorylation of AMPK α1 at 
Ser485 in primary human vascular endothelial cells. We also report that AMPK α1 Ser485 
phosphorylation is significantly, inversely correlated with insulin sensitivity in human 
muscle although we had access to only a limited number of biopsy samples. It is important 
that this be expanded in the future, including a large number of samples across a range of 
insulin sensitivities, and ideally from a range of diverse ethnic populations. Given that 
none of the biopsy volunteers in the current study were clinically classified as having 
diabetes, it remains possible that PKC-mediated inhibition of AMPK activity precedes, or 
underlies the development of insulin resistance and diabetes. Although initial clinical trials 
with the PKC inhibitor LY333531 (Ruboxistaurin) showed promising results in the 
treatment of diabetic retinopathy, the overall benefit was not deemed significant enough to 
warrant further investigation therapeutically; oral delivery of the drug was however very 
well tolerated. Furthermore, clinically achievable concentrations of ruboxistaurin 
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decreased AMPK α1 Ser485 phosphorylation by >60 %. It might therefore be interesting in 
the future to investigate whether PKC inhibitors like ruboxistaurin augment the activation 
of AMPK by drugs such as metformin and TZDs, under conditions where AMPK activity 
may have been previously impaired 
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Our current understanding of the mechanism by which VEGF regulates AMPK activity is 
summarised (Figure 6-1). VEGF binds to its cognate receptor stimulating PLCγ-mediated 
PIP2 hydrolysis. The resultant DAG stimulates Ca
2+
 influx but we cannot, at this time 
identify the channel mediating this Ca
2+
 influx. CaMKKβ is activated by this influx of 
extracellular Ca
2+
 resulting in transient activation of AMPK α1. This Ca2+ influx, also 
appears to stimulate PKC, which either directly as we have demonstrated here, or 
indirectly as suggested by others, stimulates the phosphorylation of AMPK α1 Ser485, 
thereby negatively regulating its activity. PKC can also be activated by endogenous DAG, 
or the application of DAG mimetics such as PMA, but the contribution of DAG-mediated 
PKC activation to VEGF-stimulated Ser485 phosphorylation is not clear. 
Figure 6-1: Mechanism of VEGF-stimulated phosphorylation of AMPK at Thr172 and Ser485 
VEGF binds to its receptor on the extracellular surface of endothelial cells stimulating PIP2 hydrolysis by 
PLCγ to generate IP3 and DAG. IP3 stimulates Ca
2+
 release from intracellular stores (ER; endoplasmic 
reticulum) however previous reports indicate that Ca
2+
 mobilisation from the ER is not sufficient to activate 
AMPK. DAG however stimulates the influx of extracellular Ca
2+
, potentially via DAG-sensitive TRPC 
channels. Influx of extracellular Ca
2+
 stimulates CaMKKβ which further activates AMPK. Ca2+ influx also 
stimulates PKC activity resulting in the phosphorylation of AMPK α1 Ser485 by PKC, therefore directly or 
indirectly causing AMPK activity to be inhibited. 
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